Neuroactive steroids for treatment of CNS-related disorders
A combination of compound (1) and an additional antidepressant administered for 14 days, followed by continued antidepressant treatment for 28 days, addresses the limitations of current antidepressants by providing rapid symptom relief and reducing side effects in MDD and PPD.
Patent Information
- Application Number
- CN202380033285.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-01-30
- Filing Date
- 2023-02-15
- Publication Date
- 2024-12-03
AI Technical Summary
Current antidepressants for major depressive disorder (MDD) and postpartum depression (PPD) have limited efficacy, require a latent period of 4 to 8 weeks for full effect, and cause undesirable side effects such as weight gain, GI symptoms, and sexual dysfunction, necessitating a need for faster-acting and side-effect-reducing therapies.
A combination treatment involving a therapeutically effective amount of compound (1) or its pharmaceutically acceptable salt, administered at 40-50 mg, alongside an additional antidepressant, for 14 days, followed by continued administration of the antidepressant for at least 28 days, to rapidly alleviate depressive symptoms and reduce gastrointestinal adverse events.
The combination therapy provides rapid symptom relief for MDD and PPD, reducing the latency period and minimizing side effects like nausea, vomiting, diarrhea, and other gastrointestinal issues.
Smart Images

Figure BDA0005076980960000021 
Figure BDA0005076980960000031 
Figure BDA0005076980960000041
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 310,581, filed on February 16, 2022; U.S. Provisional Application No. 63 / 337,828, filed on May 3, 2022, and U.S. Provisional Application No. 63 / 482,200, filed on January 30, 2023. The entire contents of the above applications are incorporated herein by reference in their entirety. Technical Field
[0003] The present disclosure relates to methods of treating major depressive disorder (MDD) or postpartum depression (PPD) in a subject in need thereof with compound (1) and an additional antidepressant. Background Art
[0004] The World Health Organization (WHO) has listed depression as the leading cause of disability worldwide and a major contributor to the global burden of disease (http: / / www.who.int / mediacentre / factsheets / fs369 / en / ). It is estimated that approximately 260 million people worldwide are affected by depression.
[0005] In the United States, the economic burden of depression (including workplace costs, direct costs, and suicide-related costs) was estimated at $210.5 billion in 2010. According to the WHO, more than 700,000 people die each year by suicide, and suicide is the fourth leading cause of death among people aged 15 to 29. Suicide attempts have increased among adults in the United States (from 0.62% in 2004-2005 to 0.79% in 2012-2013), with greater rates among younger adults (42% to 50%, respectively) and among those with a depressive disorder (26% to 54%, respectively).
[0006] The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5, American Psychiatric Association 2013) provides diagnostic criteria for major depressive disorder (MDD). These criteria include the presence of at least 5 of 9 depressive symptoms (depressed mood and / or loss of interest or pleasure, and other changes affecting appetite or weight, sleep, psychomotor activity, energy level, guilt, ability to concentrate, and suicidality) during the same 2-week period, which represents a change from previous functioning.
[0007] Antidepressants are the mainstay of pharmacological treatment for depressive disorders. Selective serotonin uptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs), and other compounds that affect monoaminergic neurotransmission (e.g., mirtrazapine and bupropion) represent the major classes of antidepressants. Although widely used, large-scale studies have demonstrated limited efficacy, including low remission rates and untreated symptoms. Furthermore, these agents may require 4 to 8 weeks to demonstrate full clinical efficacy, and for the most commonly prescribed SSRI and SNRI classes, common side effects include weight gain, GI symptoms, and sexual dysfunction, which can prevent titration to an adequate therapeutic range.
[0008] In the largest studies evaluating the effectiveness of depression treatments in patients with MDD, the time to remission after treatment ranged from 5.4 to 7.4 weeks; approximately half of patients who ultimately remitted did so after 6 weeks, and 40% of those who did remit took 8 or more weeks to do so. Even after remission, many patients report residual symptoms, often related to a decrease in positive affect, such as loss of interest in activities once considered enjoyable, fatigue, weakness, and sleep and appetite / weight disturbances. Thus, patients may remain symptomatic for up to 2 months while they wait for the full effect of current standard-of-care pharmacotherapy. They may also have to cope with undesirable side effects and residual symptoms. These aspects underscore the need for newer, rapidly acting therapies.
[0009] Therefore, there is a need to improve symptoms during the acute phase of a major depressive episode while awaiting the latent period of drug therapy to take effect. Summary of the invention
[0010] One aspect of the present disclosure relates to a method of treating major depressive disorder (MDD) or postpartum depression (PPD) in a subject in need thereof, comprising:
[0011] (i) providing a first treatment comprising administering a combination comprising about 40 mg to about 50 mg of compound (1) or a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound,
[0012]
[0013] and a therapeutically effective amount of an additional antidepressant; and
[0014] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant.
[0015] Another aspect of the present disclosure relates to a method of treating major depressive disorder (MDD) or postpartum depression (PPD) in a subject in need thereof, comprising:
[0016] (i) providing a first treatment comprising administering a combination comprising a therapeutically effective amount of compound (1) or a pharmaceutically acceptable salt thereof,
[0017]
[0018] and a therapeutically effective amount of an additional antidepressant; and
[0019] (ii) providing a second treatment comprising administering a therapeutically effective amount of said additional antidepressant,
[0020] None of the subjects had received treatment.
[0021] In some embodiments, the subject is treatment naive.
[0022] In some embodiments, the subject has not received any antidepressant treatment within at least 30 days before the start of the first treatment. In some embodiments, the subject has not received the additional antidepressant treatment within at least 30 days before the start of the first treatment. In some embodiments, the subject has not received the additional antidepressant treatment within at least 60 days before the start of the first treatment.
[0023] In some embodiments, the first treatment administers the combination for about 14 days. In some embodiments, the second treatment administers the additional antidepressant for at least 28 days. In some embodiments, the second treatment administers the additional antidepressant for 28 days. In some embodiments, the second treatment administers the additional antidepressant for at least 28 days.
[0024] In some embodiments, the additional antidepressant is administered at the same dose in the first and second treatments. In some embodiments, the additional antidepressant is administered at different doses in the first and second treatments.
[0025] In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof is not administered to the subject in the second treatment.
[0026] In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant are administered in separate dosage forms in the first treatment. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant are administered at the same time in the first treatment. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant are administered at different times in the first treatment.
[0027] In some embodiments, the additional antidepressant is administered at the same dose in the first treatment and the second treatment. In some embodiments, the additional antidepressant is administered at different doses in the first treatment and the second treatment.
[0028] In some embodiments, the additional antidepressant administered in the second treatment is the same as the additional antidepressant administered in the first treatment.
[0029] In some embodiments, the combination of compound (1) or a pharmaceutically acceptable salt thereof and an additional antidepressant is re-administered to the subject in response to recurrence of depressive symptoms. In some embodiments, there is an interval of at least 6 weeks between the last dose of the first treatment and the first dose of re-administration.
[0030] Another aspect of the present disclosure relates to a method of treating major depressive disorder (MDD) or postpartum depression (PPD) in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of compound (1) or a pharmaceutically acceptable salt thereof,
[0031]
[0032] and a therapeutically effective amount of another antidepressant,
[0033] None of the subjects had received treatment.
[0034] Another aspect of the present disclosure relates to a method of treating major depressive disorder (MDD) or postpartum depression (PPD) in a treatment-naive subject in need thereof, comprising co-initiating administration of a combination comprising a therapeutically effective amount of compound (1) or a pharmaceutically acceptable salt thereof,
[0035]
[0036] and a therapeutically effective amount of an additional antidepressant.
[0037] In some embodiments, the subject has not received any antidepressant treatment within at least 30 days prior to treatment. In some embodiments, the subject has not received treatment with another antidepressant within at least 30 days prior to treatment. In some embodiments, the subject has not received treatment with another antidepressant within at least 60 days prior to treatment.
[0038] In some embodiments, the combination is administered for about 14 days.
[0039] In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and another antidepressant are administered in separate dosage forms. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and another antidepressant are administered at the same time. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and another antidepressant are administered at different times.
[0040] In some embodiments, the treatment further comprises a second treatment comprising administering a therapeutically effective amount of an additional antidepressant. In some embodiments, the second treatment administers an additional antidepressant for at least 28 days. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof is not administered to the subject in the second treatment.
[0041] In some embodiments, the additional antidepressant is administered in the second treatment at the same dose as in the combination. In some embodiments, the additional antidepressant is administered in the second treatment at a different dose than that administered in the combination. In some embodiments, the additional antidepressant administered in the second treatment is the same as the additional antidepressant administered in the combination.
[0042] In some embodiments, the subject suffers from MDD. In some embodiments, the subject suffers from MDD with increased anxiety. In some embodiments, the subject is experiencing a major depressive episode. In some embodiments, the subject has increased anxiety during most days of a major depressive episode. In some embodiments, the HAM-D anxiety / somatization subscale score of the subject is at least 7 at baseline. In some embodiments, the HAM-A total score of the subject is at least 17, at least 18, at least 19 or at least 20 at baseline. In some embodiments, the HAM-A total score of the subject is at least 17 or at least 20 at baseline. In some embodiments, the HAM-A total score of the subject is at least 17 at baseline. In some embodiments, the HAM-A total score of the subject is at least 20 at baseline.
[0043] In some embodiments, the subject suffers from PPD.In some embodiments, the subject suffers from PPD with increased anxiety.In some embodiments, the subject is experiencing a major depressive episode with the beginning of the perinatal period.In some embodiments, the subject has increased anxiety during most days with the major depressive episode with the beginning of the perinatal period.In some embodiments, the HAM-D anxiety / somatization subscale score of the subject is at least 7 at baseline.In some embodiments, the HAM-A total score of the subject is at least 17, at least 18, at least 19 or at least 20 at baseline.In some embodiments, the HAM-A total score of the subject is at least 17 or at least 20 at baseline.In some embodiments, the HAM-A total score of the subject is at least 17 at baseline.In some embodiments, the HAM-A total score of the subject is at least 20 at baseline.
[0044] In some embodiments, the administration of the combination reduces adverse events that occur in gastrointestinal treatments. In some embodiments, adverse events that occur in gastrointestinal treatments include nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, increased appetite or dry mouth, or any combination thereof. In some embodiments, adverse events that occur in gastrointestinal treatments include nausea and / or diarrhea. In some embodiments, adverse events that occur in gastrointestinal treatments include nausea. In some embodiments, adverse events that occur in gastrointestinal treatments include diarrhea. In some embodiments, adverse events that occur in gastrointestinal treatments are caused by treatment with another antidepressant.
[0045] In some embodiments, the combination of compound (1) or a pharmaceutically acceptable salt thereof and another antidepressant is re-administered to the subject in response to the recurrence of depressive symptoms. In some embodiments, there is an interval of at least 6 weeks between the last dose administered and the first dose re-administered.
[0046] In some embodiments, compound (1) is administered. In some embodiments, a pharmaceutically acceptable salt of compound (1) is administered.
[0047] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) or postpartum depression (PPD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with about 40 mg to about 50 mg of compound (1):
[0048]
[0049]
[0050] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0051] Antidepressants were continued after the 14th day of treatment.
[0052] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) or postpartum depression (PPD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound:
[0053]
[0054] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0055] Antidepressants were continued after the 14th day of treatment.
[0056] In one aspect, the present disclosure relates to a method of treating major depressive disorder with elevated anxiety (MDD) or postpartum depression with elevated anxiety (PPD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with about 40 mg to about 50 mg of compound (1):
[0057]
[0058] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0059] Antidepressants were continued after the 14th day of treatment.
[0060] In one aspect, the present disclosure relates to a method of treating major depressive disorder with elevated anxiety (MDD) or postpartum depression with elevated anxiety (PPD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound:
[0061]
[0062] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0063] Antidepressants were continued after the 14th day of treatment.
[0064] In some embodiments, the subject is treatment naive.
[0065] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising:
[0066] (i) providing a first treatment comprising administering a combination comprising a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound:
[0067]
[0068] and a therapeutically effective amount of an additional antidepressant; and
[0069] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant.
[0070] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising:
[0071] (i) providing a first treatment comprising administering a combination comprising from about 40 mg to about 50 mg of compound (1):
[0072]
[0073] and a therapeutically effective amount of an additional antidepressant; and
[0074] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant.
[0075] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising:
[0076] (i) providing a first treatment comprising administering a combination comprising a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound:
[0077]
[0078] and a therapeutically effective amount of an additional antidepressant; and
[0079] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant.
[0080] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising:
[0081] (i) providing a first treatment comprising administering a combination comprising a therapeutically effective amount of compound (1):
[0082]
[0083] and a therapeutically effective amount of an additional antidepressant; and
[0084] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant,
[0085] None of the subjects had received treatment.
[0086] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising:
[0087] (i) providing a first treatment comprising administering a combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0088]
[0089] and a therapeutically effective amount of an additional antidepressant; and
[0090] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant,
[0091] None of the subjects had received treatment.
[0092] In one aspect, the present disclosure relates to a method of reducing gastrointestinal treatment-emergent adverse events in a subject in need thereof, comprising:
[0093] (i) providing a first treatment comprising administering a combination comprising a therapeutically effective amount of compound (1):
[0094]
[0095] and a therapeutically effective amount of an additional antidepressant; and
[0096] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant.
[0097] In one aspect, the present disclosure relates to a method of reducing gastrointestinal treatment-emergent adverse events in a subject in need thereof, comprising:
[0098] (i) providing a first treatment comprising administering a combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of:
[0099]
[0100] and a therapeutically effective amount of an additional antidepressant; and
[0101] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant.
[0102] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising
[0103] (i) administering a combination comprising a therapeutically effective amount of compound (1):
[0104]
[0105] and a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine, and desvenlafaxine; followed by
[0106] (ii) administering a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine for at least 28 days.
[0107] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising
[0108] (i) administering a combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1) for about 14 days:
[0109]
[0110] and a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine, and desvenlafaxine; followed by
[0111] (ii) administering a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine for at least 28 days.
[0112] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising
[0113] (i) administering a combination comprising a therapeutically effective amount of compound (1):
[0114]
[0115] and a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine, and desvenlafaxine; followed by
[0116] (ii) administering a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine for at least 28 days.
[0117] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising
[0118] (i) administering a combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1) for about 14 days:
[0119]
[0120] and a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine, and desvenlafaxine; followed by
[0121] (ii) administering a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine for at least 28 days.
[0122] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising:
[0123] (i) providing a first treatment comprising co-administering for about 14 days:
[0124] (a) about 50 mg of compound (1):
[0125]
[0126]
[0127] and
[0128] (b) a therapeutically effective amount of another antidepressant,
[0129] wherein in the first treatment compound (1) is administered once daily, and wherein compound (1) and the additional antidepressant are administered in separate dosage forms; and
[0130] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant for at least 28 days.
[0131] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising:
[0132] (i) providing a first treatment comprising co-administering for about 14 days:
[0133] (a) a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 50 mg of the free base compound:
[0134]
[0135] and
[0136] (b) a therapeutically effective amount of another antidepressant,
[0137] wherein the pharmaceutically acceptable salt of compound (1) is administered once daily, and wherein the pharmaceutically acceptable salt of compound (1) and the additional antidepressant in the first treatment are administered in separate dosage forms; and
[0138] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant for at least 28 days.
[0139] In some embodiments, the subject is experiencing a major depressive episode. In some embodiments, the subject has elevated anxiety during most days of a major depressive episode. In some embodiments, the subject's HAM-D anxiety / somatization subscale score is at least 7 at baseline. In some embodiments, the subject's HAM-A total score is at least 17 or at least 20 at baseline.
[0140] In some embodiments, administering the combination reduces adverse events arising from gastrointestinal treatments. In some embodiments, providing the first treatment reduces adverse events arising from gastrointestinal treatments.
[0141] In some embodiments, adverse events arising in gastrointestinal treatments include nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, increased appetite, or dry mouth, or any combination thereof. In some embodiments, adverse events arising in gastrointestinal treatments include nausea and / or diarrhea. In some embodiments, adverse events arising in gastrointestinal treatments are caused by treatment with another antidepressant.
[0142] In some embodiments, the subject is treatment naive. In some embodiments, the subject has not been treated with any antidepressant for at least 30 days prior to the start of the first treatment. In some embodiments, the subject has not been treated with another antidepressant for at least 30 days prior to the start of the first treatment. In some embodiments, the subject has not been treated with another antidepressant for at least 60 days prior to the start of the first treatment.
[0143] In some embodiments, the first treatment administers the combination for about 14 days. In some embodiments, the second treatment administers the additional antidepressant for at least 28 days. In some embodiments, the additional antidepressant is administered at the same dose in the first and second treatments. In some embodiments, the additional antidepressant is administered at different doses in the first and second treatments. In some embodiments, compound (1) or a pharmaceutically acceptable salt of compound (1) is not administered to the subject in the second treatment.
[0144] In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant are administered in separate dosage forms in the first treatment. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant are administered at the same time in the first treatment. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant are administered at different times in the first treatment.
[0145] In some embodiments, the additional antidepressant is administered at the same dose in (i) and (ii). In some embodiments, the additional antidepressant is administered at different doses in (i) and (ii). In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof is not administered to the subject in (ii). In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant in (i) are administered in separate dosage forms. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant in (i) are administered at the same time. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant in (i) are administered at different times. In some embodiments, the additional antidepressant administered in (ii) is the same as the additional antidepressant administered in (i).
[0146] In some embodiments, the combination of compound (1) or a pharmaceutically acceptable salt of compound (1) and an additional antidepressant is re-administered to the subject in response to recurrence of depressive symptoms. In some embodiments, there is an interval of at least 6 weeks between the last dose of the first treatment and the first dose of re-administration.
[0147] In one aspect, the disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of compound (1):
[0148]
[0149] and a therapeutically effective amount of another antidepressant,
[0150] None of the subjects had received treatment.
[0151] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0152]
[0153] and a therapeutically effective amount of another antidepressant,
[0154] None of the subjects had received treatment.
[0155] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of compound (1):
[0156]
[0157]
[0158] and a therapeutically effective amount of another antidepressant,
[0159] None of the subjects had received treatment.
[0160] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0161]
[0162] and a therapeutically effective amount of another antidepressant,
[0163] None of the subjects had received treatment.
[0164] In one aspect, the present disclosure relates to a method of reducing adverse events arising from gastrointestinal treatment with antidepressant therapy in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of compound (1):
[0165]
[0166] and a therapeutically effective amount of another antidepressant
[0167] None of the subjects had received treatment.
[0168] In one aspect, the present disclosure relates to a method for reducing adverse events arising from gastrointestinal treatment of antidepressant therapy in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0169]
[0170]
[0171] and a therapeutically effective amount of another antidepressant
[0172] None of the subjects had received treatment.
[0173] In one aspect, the disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising administering a combination for about 14 days, the combination comprising a therapeutically effective amount of compound (1):
[0174]
[0175] and a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine, and desvenlafaxine;
[0176] None of the subjects had received treatment.
[0177] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising administering a combination for about 14 days, the combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0178]
[0179] and a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine, and desvenlafaxine;
[0180] None of the subjects had received treatment.
[0181] In one aspect, the disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising administering a combination comprising about 40 mg to about 50 mg of compound (1):
[0182]
[0183]
[0184] and a therapeutically effective amount of an additional antidepressant.
[0185] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising administering a combination comprising a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound:
[0186]
[0187] and a therapeutically effective amount of an additional antidepressant.
[0188] In some embodiments, the subject is experiencing a major depressive episode. In some embodiments, the subject has elevated anxiety during most days of a major depressive episode. In some embodiments, the subject's HAM-D anxiety / somatization subscale score is at least 7 at baseline. In some embodiments, the subject's HAM-A total score is at least 17 or at least 20 at baseline.
[0189] In some embodiments, the administration of the combination reduces adverse events that occur in gastrointestinal treatments. In some embodiments, providing the combination reduces adverse events that occur in gastrointestinal treatments. In some embodiments, adverse events that occur in gastrointestinal treatments include nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, increased appetite or dry mouth, or any combination thereof. In some embodiments, adverse events that occur in gastrointestinal treatments include nausea and / or diarrhea. In some embodiments, adverse events that occur in gastrointestinal treatments are caused by treatment with another antidepressant.
[0190] In some embodiments, the subject has not been treated with any antidepressant for at least 30 days prior to the start of treatment. In some embodiments, the subject has not been treated with another antidepressant for at least 30 days prior to the start of treatment. In some embodiments, the subject has not been treated with another antidepressant for at least 60 days prior to the start of treatment.
[0191] In some embodiments, the therapeutic administration combination continues for about 14 days.
[0192] In some embodiments, the compound (1) or its pharmaceutically acceptable salt and the other antidepressant in the combination are administered in separate dosage forms. In some embodiments, the compound (1) or its pharmaceutically acceptable salt and the other antidepressant in the combination are administered at the same time. In some embodiments, the compound (1) or its pharmaceutically acceptable salt and the other antidepressant in the combination are administered at different times.
[0193] In some embodiments, the treatment further comprises a second treatment comprising administering a therapeutically effective amount of an additional antidepressant. In some embodiments, the second treatment administers an additional antidepressant for at least 28 days. In some embodiments, the additional antidepressant is administered in the second treatment at the same dose as in the combination. In some embodiments, the additional antidepressant is administered in the second treatment at a dose different from that administered in the combination. In some embodiments, compound (1) or a pharmaceutically acceptable salt of compound (1) is not administered to the subject in the second treatment. In some embodiments, the additional antidepressant administered in the second treatment is the same as the additional antidepressant administered in the combination.
[0194] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with about 40 mg to about 50 mg of compound (1):
[0195]
[0196] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0197] Antidepressants were continued after the 14th day of treatment.
[0198] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound:
[0199]
[0200] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0201] Antidepressants were continued after the 14th day of treatment.
[0202] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with about 40 mg to about 50 mg of compound (1):
[0203]
[0204] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0205] Antidepressants were continued after the 14th day of treatment.
[0206] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound:
[0207]
[0208] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0209] Antidepressants were continued after the 14th day of treatment.
[0210] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of compound (1):
[0211]
[0212] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0213] Antidepressants were continued after the 14th day of treatment.
[0214] None of the subjects had received treatment.
[0215] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0216]
[0217] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0218] Antidepressants were continued after the 14th day of treatment.
[0219] None of the subjects had received treatment.
[0220] In one aspect, the present disclosure relates to a method of reducing adverse events arising from gastrointestinal treatment with an antidepressant in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of compound (1):
[0221]
[0222] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0223] Antidepressants were continued after the 14th day of treatment.
[0224] In one aspect, the present disclosure relates to a method for reducing adverse events arising from gastrointestinal treatment with an antidepressant in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0225]
[0226] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0227] Antidepressants were continued after the 14th day of treatment.
[0228] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of compound (1):
[0229]
[0230] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0231] Antidepressants were continued after the 14th day of treatment.
[0232] The antidepressants are selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine.
[0233] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0234]
[0235] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0236] Antidepressants were continued after the 14th day of treatment.
[0237] The antidepressants are selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine.
[0238] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of compound (1):
[0239]
[0240] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0241] Antidepressants were continued after the 14th day of treatment.
[0242] The antidepressants are selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine.
[0243] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) associated with elevated anxiety in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0244]
[0245] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0246] Antidepressants were continued after the 14th day of treatment.
[0247] The antidepressants are selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine.
[0248] In some embodiments, the subject is experiencing a major depressive episode. In some embodiments, there is an increase in anxiety during most days of a major depressive episode. In some embodiments, the subject's HAM-D anxiety / somatization subscale score is at least 7 at baseline. In some embodiments, the subject's HAM-A total score is at least 17 or at least 20 at baseline.
[0249] In some embodiments, co-administration reduces adverse events that occur in gastrointestinal treatments. In some embodiments, co-administration reduces adverse events that occur in gastrointestinal treatments. In some embodiments, adverse events that occur in gastrointestinal treatments include nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, increased appetite or dry mouth, or any combination thereof. In some embodiments, adverse events that occur in gastrointestinal treatments include nausea and / or diarrhea. In some embodiments, adverse events that occur in gastrointestinal treatments are caused by treatment with antidepressants.
[0250] In some embodiments, the subject is treatment naive. In some embodiments, the subject has not been treated with any antidepressant within at least 30 days before the start of co-administration. In some embodiments, the subject has not been treated with the antidepressant within at least 30 days before the start of co-administration. In some embodiments, the subject has not been treated with the antidepressant within at least 60 days before the start of co-administration.
[0251] In some embodiments, the antidepressant is continued for at least an additional 28 days after the 14th day of treatment. In some embodiments, Compound (1) or a pharmaceutically acceptable salt of Compound (1) is not administered after the 14th day of treatment.
[0252] In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the antidepressant are administered in separate dosage forms during co-administration. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the antidepressant are administered at the same time during co-administration. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the antidepressant are administered at different times during co-administration. In some embodiments, the antidepressant is administered at the same dose from day 1 of treatment to about day 14 of treatment and after day 14 of treatment. In some embodiments, the antidepressant is administered at the same dose from day 1 of treatment to about day 14 of treatment and after day 14 of treatment.
[0253] In one aspect, the present disclosure provides a method of treating major depressive disorder (MDD) in a treatment-naive subject in need thereof, comprising co-initiating administration of a combination comprising a therapeutically effective amount of compound (1):
[0254]
[0255] and a therapeutically effective amount of an antidepressant.
[0256] In each of the embodiments described herein, the methods directed to treating MDD also directed to treating postpartum depression (PPD). BRIEF DESCRIPTION OF THE DRAWINGS
[0257] Figure 1 This is a schematic study design for the clinical study of Example 1.
[0258] Figure 2 Patient disposition for the study of Example 2 is shown.
[0259] Figure 3 is a bar graph showing the change from baseline (CFB) in HAM-D total score on Day 3. Data for the full analysis set are shown using a mixed effects model with repeated measures. *p<0.05.
[0260] Figure 4 It is a bar graph showing CFB in the HAM-D total score during the blind treatment period (treatment 14 days; using the same weights for the 3rd, 8th, 12th and 15th days). The data of the full analysis set are shown using a mixed effects model of repeated measures. The change of the HAMD-17 total score relative to baseline during the blind treatment period was estimated using the same weights of the scheduled visits on the 3rd, 8th, 12th and 15th days. *p<0.05.
[0261] Figure 5 is a line graph showing the change from baseline in HAM-D total score over time, least squares mean (LSM) (± SE). Data for the full analysis set are shown using a mixed effects model with repeated measures. Day 3 was the primary endpoint; all other time points were not adjusted for multiplicity and p values were considered nominal. *p<0.05. The dashed line indicates the end of the treatment period and the final assessment of the primary endpoint.
[0262] Figure 6 is a forest plot of treatment differences in HAMD-17 total score on Day 3. Data for the full analysis set are shown.
[0263] Fig. 7A Bar graphs of HAM-D responses (≥50% reduction from baseline in HAMD-17) at various time points are shown. Data for the full analysis set are shown. Endpoints were not adjusted for multiplicity and p values are considered nominal. *p<0.05.
[0264] Figure 7B Bar graphs of HAM-D remission (HAMD-17≤7) at different time points are shown. Data for the full analysis set are shown. Endpoints were not adjusted for multiplicity and p values were considered nominal. *p<0.05.
[0265] Figure 8 Line graphs showing the change from baseline in MADRS total score, LSM (± SE). Data for the full analysis set are shown using a mixed effects model with repeated measures. These endpoints were not adjusted for multiplicity and p values were considered nominal. *p<0.05.
[0266] Fig. 9 Bar graphs of CGI-I responses by study visit are shown. Data for the full analysis set are shown. Response was defined as "very much improved" or "very much improved" on the CGI-I score. These endpoints were not adjusted for multiplicity and p values are considered nominal. *p<0.05.
[0267] Fig. 10Ais a line graph showing the change from baseline in HAM-D total score over time in patients with MDD with elevated anxiety. Data from the full analysis set are shown. *p<0.05 for significant nominal differences. p values are not adjusted for multiplicity. The term "elevated anxiety" is used only to refer to or as a symptom of depression.
[0268] Fig. 10B Subgroup analysis of changes in HAMD-17 total scores from baseline in patients with MDD with elevated anxiety is shown. Patients with MDD with elevated anxiety were defined as having a baseline HAM-A total score ≥ 20. Data from the full analysis set are shown using a mixed effects model with repeated measures. The term "elevated anxiety" is used only to refer to or as a symptom of depression. These endpoints were not adjusted for multiplicity, and p values were considered nominal. *p<0.05.
[0269] Fig. 10C is a line graph showing the change from baseline in HAM-D total score over time in patients with MDD without elevated anxiety. Data for the full analysis set are shown. p values were not adjusted for multiplicity.
[0270] Fig.11 is a line graph showing the change from baseline in HAM-A, LSM (±SE) over time. DETAILED DESCRIPTION OF THE INVENTION
[0272] definition
[0273] As used herein, "compound (1)" refers to a compound having the following formula (or structure):
[0274]
[0275] Compound (1) is also known as zuranolone, 3α-hydroxy-3β-methyl-21-(4-cyanopyrazol-1-yl)-5β-19-norpregnane-20-one, and its IUPAC name is:
[0276] 1-(2-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethylhexahydro-1H-cyclopenta[a]phenanthrene-17-yl)-2-oxoethyl)-1H-pyrazole-4-carbonitrile (CAS Reg. No. 1632051-40-1). Methods for chemically synthesizing compound (1) are described in U.S. Pat. No. 9,512,165 and PCT Application Publication No. WO 2014 / 169833; the entire contents of the above applications are incorporated herein by reference in their entirety. Several crystalline forms of compound (1) and methods for preparing the forms are described in U.S. Pat. No. 11,236,121 and PCT Application Publication No. WO 2018 / 039378; the entire contents of the above applications are incorporated herein by reference in their entirety. Pharmaceutical compositions of compound (1) and methods for preparing the same are described in PCT Application Publication No. WO 2022 / 020363A9 and in U.S. Application No. 17 / 579,541; the entire contents of the above applications are incorporated herein by reference in their entirety. Several deuterated forms of compound (1) and methods for preparing the same are described in PCT Application Publication No. WO 2019 / 113494 and U.S. Application No. 17 / 545,290; the entire contents of the above applications are incorporated herein by reference in their entirety.
[0277] Compound (1) is a neuroactive steroid that has been shown to be a positive allosteric modulator of GABAA receptors that targets synaptic and extrasynaptic GABAA receptors. As a positive allosteric modulator of GABAA receptors, compound (1) is used as a therapeutic agent to treat CNS-related disorders (e.g., depression, postpartum depression, and major depressive disorder) and to treat nervous system disorders (e.g., essential tremor, epilepsy, and Parkinson's disease).
[0278] As used herein, "crystalline" refers to a solid phase of a given chemical entity with a well-defined 3-dimensional structural order. Atoms, ions and / or molecules are arranged in a regular, periodic manner in a repeated 3-dimensional lattice. In various embodiments, a crystalline material may comprise one or more discrete crystalline forms.
[0279] As used herein, the terms "crystalline form", "crystalline solid form", "crystal form", "solid form" and related terms herein refer to crystalline modifications comprising a given substance (e.g., Compound (1)), including single-component crystal forms and multi-component crystal forms, and include but are not limited to polymorphs, solvates, hydrates and salts.
[0280] The term "substantially crystalline" refers to a form that can be at least a specific weight percentage crystallized. The specific weight percentage may include 70%, 75%, 80%, 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% or any percentage between 70% and 100%. In certain embodiments, the specific weight percentage of crystallinity is at least 90%. In certain other embodiments, the specific weight percentage of crystallinity is at least 95%. In some embodiments, compound (1) can be any crystalline form described herein (e.g., crystalline forms A and C) and / or a substantially crystalline sample of PCT application publication number WO 2018 / 039378; the entire contents of the above application are incorporated herein by reference as a whole.
[0281] The term "substantially pure" refers to a composition of a particular crystalline form (e.g., a crystalline form of compound (1)) that is free of impurities and / or other solid forms at least in a particular weight percentage. The particular weight percentage may include 70%, 75%, 80%, 85%, 90%, 95%, 99%, or any percentage between 70% and 100%. In certain embodiments, compound (1) may be a substantially pure sample of any crystalline form described herein (e.g., crystalline forms A and C). In certain embodiments, compound (1) may be substantially pure form A. In certain embodiments, compound (1) may be substantially pure form C.
[0282] As used herein, "XRPD" refers to X-ray powder diffraction. The XRPD spectrum is an xy graph that plots 2Q (diffraction angle) on the x-axis and intensity on the y-axis. These are diffraction peaks that can be used to characterize crystalline materials. Diffraction peaks are usually represented and mentioned by their positions on the x-axis rather than the diffraction peak intensity on the y-axis, because the diffraction peak intensity may be particularly sensitive to the sample direction (see Pharmaceutical Analysis, Lee & Web, pp.255-257 (2003)). Therefore, those skilled in the art do not usually use intensity to characterize crystalline materials. As with any data measurement, there may be variability in the XRPD data. In addition to the variability in the diffraction peak intensity, there may also be variability in the position of the diffraction peak on the x-axis. However, when the position of the diffraction peak is reported for characterization purposes, this variability can usually be explained. This variability of the position of the diffraction peak along the x-axis may come from several sources. One such source can be sample preparation. Samples of the same crystalline material prepared under different conditions may produce slightly different diffraction patterns. Factors such as particle size, moisture content, solvent content, temperature and orientation may all affect how a sample diffracts X-rays. Another source of variability comes from instrument parameters. Different X-ray powder diffractometers operate using different parameters and may result in slightly different diffraction patterns from the same crystalline material. Similarly, different software packages process XRPD data differently, and this may also result in variability. These and other sources of variability are known to those of ordinary skill in the art. Due to such sources of variability, the value of each X-ray diffraction peak may be preceded by the term "about" or continue to define experimental variability with an appropriate range (e.g., ± 0.1 °, ± 0.2 °, ± 0.3 °, ± 0.4 °, ± 0.5 °, etc.).
[0283] When the term "characteristic peak" refers to a peak in the XRPD pattern of a crystalline form of a given chemical entity (e.g., a crystalline form of compound (1)), it refers to a collection of specific diffraction peaks whose values span a range of 2θ values (e.g., 0° to 40°) that are unique to that specific crystalline form as a whole.
[0284] "Pharmaceutically acceptable" means approved or approvable by a regulatory agency of the Federal or a state government or equivalent in a country outside the United States, or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly, in humans.
[0285] "Pharmaceutically acceptable salt" refers to a salt of the compound of the present invention that is pharmaceutically acceptable and has the desired pharmacological activity of the parent compound. In particular, such salts are non-toxic and may be inorganic or organic acid addition salts and base addition salts. Specifically, such salts include: (1) acid addition salts, salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; or with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4- or (2) when the acidic proton present in the parent compound is replaced by a metal ion, such as an alkali metal ion, an alkaline earth ion or an aluminum ion; or coordinated with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, etc. Salts also include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, etc. salts; when the compound contains a basic functional group, non-toxic organic or inorganic acid salts such as hydrochloride, hydrobromide, tartrate, methanesulfonate, acetate, maleate, oxalate, etc. The term "pharmaceutically acceptable cation" refers to an acceptable cationic counter ion of an acidic functional group. Examples of such cations are sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium cations, etc. See, for example, Berge, et al., J. Pharm. Sci. (1977) 66(1): 1-79.
[0286] Chemical elements are identified according to the Periodic Table of the Elements (CAS version, Handbook of Chemistry and Physics, 75ili Edition, inside cover), and specific functional groups are generally defined as described therein. In addition, general principles of organic chemistry as well as specific functional moieties and reactivity are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Smith and March, March's Advanced Organic Chemistry, 5ili Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3rd Edition, Cambridge University Press, Cambridge, 1987.
[0287] As used herein, the term "about" when referring to a value or range allows for a certain degree of variation in the value or range, for example, within 10% or within 5% of the stated value or limit of the stated range.
[0288] As used herein, the term "modulates" refers to GABA A Inhibition or enhancement of receptor function. "Modulators" (e.g., modulators of GABA A The compound that can function as a receptor or a pharmaceutically acceptable salt thereof) can be, for example, GABA A Agonist, partial agonist, antagonist or partial antagonist of a receptor.
[0289] As used herein, and unless otherwise indicated, the terms "treat," "treating," and "treatment" contemplate actions that occur while a subject has a particular disease, disorder or condition that reduces the severity of the disease, disorder or condition (or any symptom thereof), or that arrests or slows the progression of the disease, disorder or condition ("therapeutic treatment"), and also contemplate preventive actions that occur before a subject begins to suffer from a particular disease, disorder or condition.
[0290] The terms "disease," "disorder," and "condition" are used interchangeably herein.
[0291] As used herein, “not treated "Treatment naive" refers to a subject who has not been previously treated with another antidepressant in the current depressive episode. "Treatment naive" also refers to a subject who has not taken any antidepressant for at least 30 days before the start of treatment (i.e., Day 1). In some embodiments, the subject has not taken any antidepressant for at least 60 days before the start of treatment (i.e., Day 1).
[0292] Hamilton Depression Rating Scale, sometimes abbreviated as "HRSD", "HDRS", "HAMD" or "HAM-D", is a multi-item questionnaire for providing indications of depression. In 1960, the original scale / version published by Max Hamilton (Max Hamilton) included 17 rating items, and other available versions included up to 29 items. As used herein, "HAMD-17" or "17-HAM-D" refers to 17 Hamilton Depression Rating Scales. In some embodiments, "HAM-D total score" and "HAMD-17 total score" are used interchangeably, and refer to the total score obtained using 17 Hamilton Depression Rating Scales. In some embodiments, the subscale or individual score followed by "HAM-D", such as the HAM-D anxiety / somatization subscale, refers to the subscale or individual score using 17 Hamilton Depression Rating Scales.
[0293] The term "anxiety elevation" is used to refer to or as a symptom of depression. "MDD with anxiety elevation" or "MDD with anxiety pain" are used interchangeably and refer to subjects with MDD who exhibit anxiety elevation as a symptom of depression. In some embodiments, the MDD with anxiety elevation is characterized by a HAM-D anxiety / somatization subscale score of at least 7 at baseline. In some embodiments, the MDD with anxiety elevation is characterized by a HAM-D anxiety / somatization subscale standardized or normalized score of at least 39 at baseline. In some embodiments, a HAM-D anxiety / somatization subscale standardized or normalized score of at least 39 is equivalent to a HAM-D anxiety / somatization subscale (raw) score of at least 7. In some embodiments, the MDD with anxiety elevation is characterized by a HAM-A total score of at least 17 at baseline (i.e., before administering compound (1) or a pharmaceutically acceptable salt thereof). In some embodiments, the MDD with anxiety elevation is characterized by a HAM-A total score of at least 18 at baseline. In some embodiments, MDD with increased anxiety is characterized by a HAM-A total score at baseline of at least 20. In some embodiments, the definition of MDD with increased anxiety is consistent with the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), which is MDD with an anxious distress specifier.
[0294] In other embodiments, "anxiety rises" is characterized by a HAM-A score based on a HAM-A anxiety item and a somatic item. In some embodiments, "anxiety rises" is characterized by a HAM-A score based on a HAM-A anxiety item. In some embodiments, "anxiety rises" is characterized by a HAM-D score based on the following HAM-D items: mental anxiety, somatic anxiety, GI somatic symptoms and / or general somatic symptoms. In some embodiments, "anxiety rises" is characterized by a HAM-D score based on the following HAM-D items: mental anxiety. In some embodiments, "anxiety rises" is characterized by a HAM-D score based primarily on an item assessing somatic symptoms of depression. In some embodiments, "anxiety rises" is characterized by a HAM-D score based primarily on an item assessing anxiety symptoms of depression. In some embodiments, "anxiety rises" is characterized by a HAM-D anxiety / somatization subscale score based primarily on an item assessing somatic symptoms of depression. In some embodiments, "anxiety rises" is characterized by a HAM-D anxiety / somatization subscale score based primarily on an item assessing somatic symptoms of depression. In some embodiments, "anxiety rises" is characterized by a HAM-D anxiety / somatization subscale score based primarily on an item assessing anxiety symptoms of depression. In some embodiments, "elevated anxiety" is characterized by a MADRS score based primarily on items assessing somatic symptoms of depression. In some embodiments, "elevated anxiety" is characterized by a MADRS score based primarily on items assessing anxiety symptoms of depression.
[0295] "PPD with increased anxiety," "PPD with anxious distress," or "MDD with peripartum onset, anxious distress" are used interchangeably and refer to subjects with PPD who exhibit increased anxiety as a symptom of their depression. In some embodiments, the definition of PPD with increased anxiety is consistent with the definition of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), which is MDD with a peripartum onset marker and an anxious distress marker. In some embodiments, PPD with increased anxiety is characterized by the HAM-D anxiety / somatization subscale score, HAM-A total score, and / or MADRS score described herein.
[0296] As used herein, an "effective amount" of a compound (or a pharmaceutically acceptable salt thereof) refers to an amount sufficient to elicit a desired biological response (e.g., to treat sexual dysfunction, e.g., to treat sexual dysfunction caused by treatment). As will be appreciated by those skilled in the art, the effective amount of a compound of the invention (or a pharmaceutically acceptable salt thereof) may vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age, weight, health, and condition of the subject. An effective amount includes both therapeutic and prophylactic treatments.
[0297] As used herein, and unless otherwise indicated, a "therapeutically effective amount" of a compound (or a pharmaceutically acceptable salt thereof) is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder, or condition, or to delay or minimize one or more symptoms associated with the disease, disorder, or condition. A therapeutically effective amount of a compound (or a pharmaceutically acceptable salt thereof) refers to an amount of a therapeutic agent, alone or in combination with other therapies, that provides a therapeutic benefit in the treatment of a disease, disorder, or condition. The term "therapeutically effective amount" may include an amount that improves overall treatment, reduces or avoids symptoms or causes of a disease or condition, or enhances the therapeutic efficacy of another therapeutic agent.
[0298] In alternative embodiments, the present invention contemplates the use of a compound of the present invention or its pharmaceutically acceptable salt or pharmaceutically acceptable composition as prevention before a subject begins to suffer from a particular disease, disorder or condition. As used herein and unless otherwise indicated, the "preventive effective amount" of a compound is an amount sufficient to prevent disease, disorder or condition, or one or more symptoms associated with a disease, disorder or condition, or to prevent its recurrence. The preventive effective amount of a compound refers to the amount of a therapeutic agent alone or in combination with other agents, which provides preventive benefits in preventing disease, disorder or condition. The term "preventive effective amount" may include an amount that improves overall prevention or enhances the preventive efficacy of another preventive agent.
[0299] A "subject" or "patient" is a human (eg, a male or female of any age group, such as a pediatric subject (eg, an infant, child, adolescent) or an adult subject (eg, a young adult, middle-aged adult, or elderly)).
[0300] As used herein, the term "dose equivalent" refers to a bioequivalent dose. For example, for a 50 mg dose of compound (1), the dose equivalent of a pharmaceutically acceptable salt of compound (1) is the amount (by weight) of the pharmaceutically acceptable salt required to provide a bioequivalent dose of the free base of compound (1) equivalent to a 50 mg dose.
[0301] As used herein, the term "unit dosage form" is defined as a form involving administration of compound (1) to a patient. Specifically, the unit dosage form can be, for example, a pill, capsule, or tablet. In some embodiments, the unit dosage form is a capsule. In some embodiments, the unit dosage form is a tablet.
[0302] As used herein, "solid dosage form" refers to a pharmaceutical dosage form in solid form, such as tablets, capsules, granules, powders, sachets, reconstitutable powders, dry powder inhalers, and chewables.
[0303] As used herein, the terms "administer," "administering," or "administration" refer to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing a compound described herein, or a composition thereof, into or onto the body of a subject.
[0304] As used herein, "co-administration" or administration "in combination" refers to the administration of selected therapeutic agents to a single patient, and includes treatment regimens in which the agents are administered by the same or different routes or at the same or different times. In some embodiments, the agents are a fixed dose combination. In some embodiments, the agents are not a fixed dose. In some embodiments, the agents are administered simultaneously. In some embodiments, the agents are administered sequentially. In some embodiments, the agents are not a fixed dose and are administered at the same or different times.
[0305] Treatment
[0306] The present disclosure relates to methods of treating major depressive disorder (MDD) or postpartum depression. The diagnosis and severity of MDD or PPD treated by the methods described herein can be characterized as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
[0307] Depressive disorders
[0308] Depressive disorders include disruptive mood dysregulation disorder, major depressive disorder (including major depressive episode), persistent depressive disorder (dysthymia), premenstrual dysphoric disorder, substance / medication-induced depressive disorder, depressive disorder due to another medical condition, other specified depressive disorder, and unspecified depressive disorder. All of these disorders share the common feature of sad, empty, or irritable moods accompanied by physical and cognitive changes that significantly affect the individual's ability to function. They differ in duration, timing, or presumed etiology.
[0309] Major depressive disorder represents the classic condition in this group of disorders. It is characterized by discrete episodes of at least two weeks' duration (although most episodes last considerably longer) involving marked changes in affect, cognition, and autonomic function, and remissions between episodes. Discrete episodes of major depressive disorder may be referred to as "major depressive episodes" or "depressive episodes."
[0310] Major depressive disorder
[0311] Major depressive disorder is well known in the art.
[0312] In some embodiments, MDD is also known as depression or clinical depression, and it is a mood disorder that causes persistent feelings of sadness and loss of interest. MDD affects how a subject may feel, think, and behave, and can lead to a variety of emotional and physical problems.
[0313] In some embodiments, MDD is defined and diagnosed according to DSM-5, for example, MDD is diagnosed according to Criterion A, as described below.
[0314] Criterion A. Five (or more) of the following symptoms are present within the same 2-week period and represent a change from previous functioning; at least one symptom is (1) depressed mood or (2) loss of interest or pleasure.
[0315] 1. Depressed mood most of the day, nearly every day, as indicated by subjective report (e.g., feeling sad, empty, hopeless) or observation by others (e.g., looking tearful) (Note: in children and adolescents, this may be dysphoric mood).
[0316] 2. Markedly diminished interest or pleasure in all or nearly all activities (as described subjectively or observed) most of the day, nearly every day.
[0317] 3. Significant weight loss or weight gain when not dieting (e.g., greater than 5% change in body weight in a month), or decreased or increased appetite on a nearly daily basis (Note: In children, consider failure to achieve expected weight gain.)
[0318] 4. Insomnia or hypersomnia almost every day.
[0319] 5. Psychomotor agitation or retardation nearly every day (observable by others and not just a subjective feeling of restlessness or slowness).
[0320] 6. Feeling tired or weak almost every day.
[0321] 7. Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) occur nearly every day (not just self-blame or guilt about being ill).
[0322] 8. Decreased ability to think or concentrate, or indecisiveness, nearly every day (either subjectively described or observed by others).
[0323] 9. Recurrent thoughts of death (not just fear of death), recurrent suicidal ideation without a specific plan, suicide attempts, or specific suicide plans.
[0324] The standard BE described below is an additional description of MDD and may be considered for describing or diagnosing MDD, but is not required.
[0325] Criterion B. The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
[0326] Criterion C. The episode is not attributable to the physiological effects of a substance or to another medical condition.
[0327] Criteria A–C represent a major depressive episode.
[0328] Criterion D. The occurrence of a major depressive episode is not better explained by schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other specified and unspecified schizophrenia spectrum and other psychotic disorders.
[0329] Criterion E. Never had a manic or hypomanic episode.
[0330] In some embodiments, a major depressive episode (MDE) is a period characterized by symptoms of MDD as described above.
[0331] In some embodiments, MDD is a clinical course characterized by one or more major depressive episodes (MDE) in a subject.
[0332] In some embodiments, MDD is diagnosed according to criteria AC as described above. In some embodiments, MDD is diagnosed according to criteria AE as described above.
[0333] Diagnostic features
[0334] The standard symptoms of major depressive disorder must be present nearly every day to be considered present, with the exception of weight change and suicidal ideation. In addition to being present nearly every day, the depressed mood must be present for most of the day. Often insomnia or fatigue is the presenting complaint, and failure to detect concomitant depressive symptoms results in underdiagnosis. Sadness may be initially denied but may be elicited by interview or inferred from facial expressions and demeanor. For individuals who are preoccupied with somatic complaints, the clinician should determine whether the distress caused by the complaint is related to specific depressive symptoms. Fatigue and sleep disturbances are present in the majority of cases; psychomotor disturbances are less common but indicate a greater overall severity, as is the presence of delusional or near-delusional guilt.
[0335] The essential feature of a major depressive episode is a period lasting at least two weeks during which the mood is either depressed or there is a loss of interest or pleasure in almost all activities (Criterion A above). In children and adolescents, the mood may be irritable rather than sad. The individual must also experience at least four additional symptoms from changes in appetite or weight, sleep, and psychomotor activity; decreased energy; feelings of worthlessness or guilt; difficulty thinking, concentrating, or making decisions; or recurrent thoughts of death or suicidal ideation or plans or attempts. To count as a major depressive episode, the symptoms must be new or significantly worse than the patient's state before the episode. The symptoms must persist for most of the day, nearly every day, for at least two consecutive weeks. The episode must be associated with clinically significant distress or impairment in social, occupational, or other important areas of functioning. For some individuals with a mild episode, functioning may appear normal but require a marked increase in effort.
[0336] Sleep disorders may manifest as difficulty sleeping or excessive sleep (criterion A4). When insomnia is present, it is usually manifested as mid-term insomnia (i.e., waking up at night and then having difficulty falling asleep again) or terminal insomnia (i.e., waking up too early and unable to fall asleep again). Initial insomnia (i.e., difficulty falling asleep) may also occur. Individuals with excessive sleep (hypersomnia) may experience prolonged episodes of nocturnal sleep or increased daytime sleep. Sometimes, the reason for individuals seeking treatment is that sleep is disturbed.
[0337] In some embodiments, MDD may have a designation as defined by DSM-5, such as "anxiety distress" or "elevated anxiety."
[0338] Major depressive disorder with anxiety and distress
[0339] As defined by DSM-5, the "anxiety distress" identifier for MDD indicates the presence of at least two of the following symptoms during most days of a major depressive episode or persistent depressive disorder (dysthymia):
[0340] 1. To feel keyed up or tense.
[0341] 2. Feeling unusually restless.
[0342] 3. Having trouble concentrating because of worry.
[0343] 4. Fear that something terrible will happen.
[0344] 5. Feeling that the individual may lose control of himself or herself.
[0345] Severity is defined as:
[0346] Mild: Two symptoms.
[0347] Moderate: Three symptoms.
[0348] Moderate to severe: Four to five symptoms.
[0349] Severe: Four or five symptoms plus motor agitation.
[0350] “Anxiety distress” and “elevated anxiety” are used interchangeably in this article.
[0351] Anxiety and distress are recognized as prominent features of bipolar and major depressive disorders in both primary care and specialty mental health settings. High levels of anxiety are associated with a higher risk of suicide, longer illness duration, and a greater likelihood of nonresponse to treatment.
[0352] Gastrointestinal treatment-emergent adverse events (TEAEs) are frequently observed in patients with major depressive disorder (MDD) taking antidepressants and can lead to treatment discontinuation. For example, one study (Oliva V. et al., Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13; 109: 110266) found that escitalopram and sertraline were the most gastrointestinal-intolerant antidepressants, associated with all considered TEAEs (nausea / vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, increased appetite, and dry mouth), except constipation and increased appetite.
[0353] Postpartum depression
[0354] In some embodiments, each of the methods described herein also relates to treating postpartum depression (PPD).
[0355] Postpartum depression (PPD), also known as postnatal depression, is a mood disorder associated with childbirth. Postpartum depression (PPD) is well known in the art.
[0356] PPD is considered the most common psychiatric disorder occurring during the postpartum period (O'Hara MW, Wisner KL. Best Pract Res Clin Obstet Gynaecol. 2014; 28(1): 3-12); and it may occur during the third trimester or after delivery. If not treated, PPD may have devastating consequences for women and their families. In some embodiments, PPD is characterized by significant functional impairment in the mother due to sadness and depression, loss of interest in daily activities, changes in eating and sleeping habits, fatigue and decreased energy, inability to concentrate, and feelings of worthlessness, shame, or guilt. Postpartum depression also increases the risk of suicide, which is the leading cause of maternal death after childbirth in developed countries.
[0357] Professional health organizations differ in their definitions of the onset of PPD. For example, the American Psychiatric Association describes PPD as beginning during pregnancy or within 4 weeks of delivery (DSM-5). The American College of Obstetricians and Gynecologists describes PPD as beginning during pregnancy or within 12 months postpartum (ACOG updated in December 2021). The World Health Organization describes PPD as beginning within 12 months postpartum (International Classification of Diseases, 10th Edition (ICD-10)). Therefore, in some embodiments, the diagnosis of PPD treated by the methods described herein can be characterized as defined in DSM-5. In some embodiments, the diagnosis of PPD treated by the methods described herein can be characterized as defined in ACOG. In some embodiments, the diagnosis of PPD treated by the methods described herein can be characterized as defined in ICD-10.
[0358] In some embodiments, the diagnosis of PPD and / or PPD with elevated anxiety treated by the methods described herein can be characterized as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), i.e., as MDD with perinatal onset and MDD with perinatal onset with anxious distress markers. MDD and anxious distress markers as defined in DSM-5 are described above.
[0359] With perinatal onset (as specified for DSM-5 depressive disorder)
[0360] This designation may apply to the current episode or, if full criteria for a major depressive episode are not currently met, to the most recent major depressive episode if the onset of mood symptoms occurred during pregnancy or within 4 weeks of delivery.
[0361] Mood episodes may begin during pregnancy or postpartum. Although estimates vary depending on the period of postpartum follow-up, 3% to 6% of women experience the beginning of a major depressive episode during pregnancy or in the weeks or months after delivery. Fifty percent of "postpartum" major depressive disorder actually begins before delivery. Therefore, these episodes are collectively referred to as peripartum episodes. Women who have a peripartum major depressive episode often have severe anxiety and even panic attacks. Prospective studies have shown that mood and anxiety symptoms during pregnancy and "baby blues" increase the risk of postpartum major depressive disorder. Mood episodes that begin peripartum can be with or without psychotic features. Infanticide is most commonly associated with postpartum psychotic episodes, characterized by hallucinations of commands to kill the infant or delusions that the infant is possessed, but psychotic symptoms can also occur in severe postpartum mood episodes without such specific delusions or hallucinations.
[0362] Treatment
[0363] One aspect of the present disclosure relates to a method of treating major depressive disorder (MDD) or postpartum depression (PPD) in a subject in need thereof, comprising:
[0364] (i) providing a first treatment comprising administering a combination comprising about 40 mg to about 50 mg of compound (1) or a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound,
[0365]
[0366] and a therapeutically effective amount of an additional antidepressant; and
[0367] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant.
[0368] Another aspect of the present disclosure relates to a method of treating major depressive disorder (MDD) or postpartum depression (PPD) in a subject in need thereof, comprising:
[0369] (i) providing a first treatment comprising administering a combination comprising a therapeutically effective amount of compound (1) or a pharmaceutically acceptable salt thereof,
[0370]
[0371] and a therapeutically effective amount of an additional antidepressant; and
[0372] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant,
[0373] None of the subjects had received treatment.
[0374] In some embodiments, the subject is treatment naive.
[0375] In some embodiments, the subject has not been treated with any antidepressant for at least 30 days prior to the start of the first treatment. In some embodiments, the subject has not been treated with another antidepressant for at least 30 days prior to the start of the first treatment. In some embodiments, the subject has not been treated with another antidepressant for at least 60 days prior to the start of the first treatment.
[0376] In some embodiments, the first treatment administers the combination for about 14 days. In some embodiments, the second treatment administers the additional antidepressant for at least 28 days. In some embodiments, the second treatment administers the additional antidepressant for 28 days. In some embodiments, the second treatment administers the additional antidepressant for at least 28 days.
[0377] In some embodiments, the additional antidepressant is administered at the same dose in the first and second treatments. In some embodiments, the additional antidepressant is administered at different doses in the first and second treatments.
[0378] In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof is not administered to the subject in the second treatment.
[0379] In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant are administered in separate dosage forms in the first treatment. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant are administered at the same time in the first treatment. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant are administered at different times in the first treatment.
[0380] In some embodiments, the additional antidepressant is administered at the same dose in the first treatment and the second treatment. In some embodiments, the additional antidepressant is administered at different doses in the first treatment and the second treatment.
[0381] In some embodiments, the additional antidepressant administered in the second treatment is the same as the additional antidepressant administered in the first treatment.
[0382] In some embodiments, the combination of compound (1) or a pharmaceutically acceptable salt thereof and an additional antidepressant is re-administered to the subject in response to recurrence of depressive symptoms. In some embodiments, there is an interval of at least 6 weeks between the last dose of the first treatment and the first dose of re-administration.
[0383] Another aspect of the present disclosure relates to a method of treating major depressive disorder (MDD) or postpartum depression (PPD) in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of compound (1) or a pharmaceutically acceptable salt thereof,
[0384]
[0385] and a therapeutically effective amount of another antidepressant,
[0386] None of the subjects had received treatment.
[0387] Another aspect of the present disclosure relates to a method of treating major depressive disorder (MDD) or postpartum depression (PPD) in a treatment-naive subject in need thereof, comprising co-initiating administration of a combination comprising a therapeutically effective amount of compound (1) or a pharmaceutically acceptable salt thereof,
[0388]
[0389] and a therapeutically effective amount of an additional antidepressant.
[0390] In some embodiments, the subject has not been treated with any antidepressant within at least 30 days prior to treatment. In some embodiments, the subject has not been treated with the additional antidepressant within at least 30 days prior to treatment. In some embodiments, the subject has not been treated with the additional antidepressant within at least 60 days prior to treatment. In some embodiments, the subject has not been treated with any antidepressant within at least 30 days prior to the start of treatment. In some embodiments, the subject has not been treated with the additional antidepressant within at least 30 days prior to the start of treatment. In some embodiments, the subject has not been treated with the additional antidepressant within at least 60 days prior to the start of treatment.
[0391] In some embodiments, the combination is administered for about 14 days.
[0392] In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and another antidepressant are administered in separate dosage forms. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and another antidepressant are administered at the same time. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and another antidepressant are administered at different times.
[0393] In some embodiments, the treatment further comprises a second treatment comprising administering a therapeutically effective amount of an additional antidepressant. In some embodiments, the second treatment administers an additional antidepressant for at least 28 days. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof is not administered to the subject in the second treatment.
[0394] In some embodiments, the additional antidepressant is administered in the second treatment at the same dose as in the combination. In some embodiments, the additional antidepressant is administered in the second treatment at a different dose than that administered in the combination. In some embodiments, the additional antidepressant administered in the second treatment is the same as the additional antidepressant administered in the combination.
[0395] In some embodiments, the subject suffers from MDD. In some embodiments, the subject suffers from MDD with increased anxiety. In some embodiments, the subject is experiencing a major depressive episode. In some embodiments, the subject has increased anxiety during most days of a major depressive episode. In some embodiments, the subject has at least 7 HAM-D anxiety / somatization subscale scores at baseline. In some embodiments, the subject has at least 17, at least 18, at least 19 or at least 20 HAM-A total scores at baseline. In some embodiments, the subject has at least 17 or is at least 20 HAM-A total scores at baseline. In some embodiments, the subject has at least 17 or is at least 20 HAM-A total scores at baseline. In some embodiments, the subject has at least 17 HAM-A total scores at baseline. In some embodiments, the subject has at least 17 HAM-A total scores at baseline. In some embodiments, the subject has at least 20 HAM-A total scores at baseline.
[0396] In some embodiments, the subject suffers from PPD.In some embodiments, the subject suffers from PPD with increased anxiety.In some embodiments, the subject is experiencing a major depressive episode with the beginning of the perinatal period.In some embodiments, the subject has increased anxiety during most days with the major depressive episode with the beginning of the perinatal period.In some embodiments, the HAM-D anxiety / somatization subscale score of the subject is at least 7 at baseline.In some embodiments, the HAM-A total score of the subject is at least 17, at least 18, at least 19 or at least 20 at baseline.In some embodiments, the HAM-A total score of the subject is at least 17 or at least 20 at baseline.In some embodiments, the HAM-A total score of the subject is at least 17 at baseline.In some embodiments, the HAM-A total score of the subject is at least 20 at baseline.
[0397] In some embodiments, the administration of the combination reduces adverse events that occur in gastrointestinal treatments. In some embodiments, adverse events that occur in gastrointestinal treatments include nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, increased appetite or dry mouth, or any combination thereof. In some embodiments, adverse events that occur in gastrointestinal treatments include nausea and / or diarrhea. In some embodiments, adverse events that occur in gastrointestinal treatments include nausea. In some embodiments, adverse events that occur in gastrointestinal treatments include diarrhea. In some embodiments, adverse events that occur in gastrointestinal treatments are caused by treatment with another antidepressant.
[0398] In some embodiments, the combination of compound (1) or a pharmaceutically acceptable salt thereof and another antidepressant is re-administered to the subject in response to the recurrence of depressive symptoms. In some embodiments, there is an interval of at least 6 weeks between the last dose administered and the first dose re-administered.
[0399] In some embodiments, compound (1) is administered. In some embodiments, a pharmaceutically acceptable salt of compound (1) is administered.
[0400] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) or postpartum depression (PPD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with about 40 mg to about 50 mg of compound (1):
[0401]
[0402] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0403] Antidepressants were continued after the 14th day of treatment.
[0404] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) or postpartum depression (PPD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound:
[0405]
[0406] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0407] Antidepressants were continued after the 14th day of treatment.
[0408] In one aspect, the present disclosure relates to a method of treating major depressive disorder with elevated anxiety (MDD) or postpartum depression with elevated anxiety (PPD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with about 40 mg to about 50 mg of compound (1):
[0409]
[0410] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0411] Antidepressants were continued after the 14th day of treatment.
[0412] In one aspect, the present disclosure relates to a method of treating major depressive disorder with elevated anxiety (MDD) or postpartum depression with elevated anxiety (PPD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound:
[0413]
[0414] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0415] Antidepressants were continued after the 14th day of treatment.
[0416] In some embodiments, the subject is treatment naive.
[0417] In another aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising:
[0418] (i) providing a first treatment comprising administering a combination comprising from about 40 mg to about 50 mg of compound (1):
[0419]
[0420] and a therapeutically effective amount of an additional antidepressant; and
[0421] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant.
[0422] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising:
[0423] (i) providing a first treatment comprising administering a combination comprising a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound:
[0424]
[0425] and a therapeutically effective amount of an additional antidepressant; and
[0426] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant.
[0427] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising:
[0428] (i) providing a first treatment comprising administering a combination comprising from about 40 mg to about 50 mg of compound (1):
[0429]
[0430] and a therapeutically effective amount of an additional antidepressant; and
[0431] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant.
[0432] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising:
[0433] (i) providing a first treatment comprising administering a combination comprising a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound:
[0434]
[0435] and a therapeutically effective amount of an additional antidepressant; and
[0436] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant.
[0437] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising:
[0438] (i) providing a first treatment comprising administering a combination comprising a therapeutically effective amount of compound (1):
[0439]
[0440] and a therapeutically effective amount of an additional antidepressant; and
[0441] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant,
[0442] None of the subjects had received treatment.
[0443] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising:
[0444] (i) providing a first treatment comprising administering a combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0445]
[0446] and a therapeutically effective amount of an additional antidepressant; and
[0447] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant,
[0448] None of the subjects had received treatment.
[0449] In one aspect, the present disclosure relates to a method of reducing gastrointestinal treatment-emergent adverse events in a subject in need thereof, comprising:
[0450] (i) providing a first treatment comprising administering a combination comprising a therapeutically effective amount of compound (1):
[0451]
[0452] and a therapeutically effective amount of an additional antidepressant; and
[0453] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant.
[0454] In one aspect, the present disclosure relates to a method of reducing gastrointestinal treatment-emergent adverse events in a subject in need thereof, comprising:
[0455] (i) providing a first treatment comprising administering a combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of:
[0456]
[0457] and a therapeutically effective amount of an additional antidepressant; and
[0458] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant.
[0459] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising
[0460] (i) administering a combination comprising a therapeutically effective amount of compound (1):
[0461]
[0462] and a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine, and desvenlafaxine; followed by
[0463] (ii) administering a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine for at least 28 days.
[0464] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising
[0465] (i) administering a combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1) for about 14 days:
[0466]
[0467] and a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine, and desvenlafaxine; followed by
[0468] (ii) administering a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine for at least 28 days.
[0469] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising
[0470] (i) administering a combination comprising a therapeutically effective amount of compound (1):
[0471]
[0472] and a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine, and desvenlafaxine; followed by
[0473] (ii) administering a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine for at least 28 days.
[0474] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising
[0475] (i) administering a combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1) for about 14 days:
[0476]
[0477] and a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine, and desvenlafaxine; followed by
[0478] (ii) administering a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine for at least 28 days.
[0479] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising:
[0480] (i) providing a first treatment comprising co-administering the following for about 14 days
[0481] (a) about 50 mg of compound (1):
[0482]
[0483] and
[0484] (b) a therapeutically effective amount of another antidepressant,
[0485] wherein compound (1) is administered once daily, and wherein in the first treatment compound (1) and the additional antidepressant are administered in separate dosage forms; and
[0486] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant for at least 28 days.
[0487] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising:
[0488] (i) providing a first treatment comprising co-administering the following for about 14 days
[0489] (a) a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 50 mg of the free base compound:
[0490]
[0491] and
[0492] (b) a therapeutically effective amount of another antidepressant,
[0493] wherein the pharmaceutically acceptable salt of compound (1) is administered once daily, and wherein in the first treatment the pharmaceutically acceptable salt of compound (1) and the additional antidepressant are administered in separate dosage forms; and
[0494] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant for at least 28 days.
[0495] In some embodiments, the subject is experiencing a major depressive episode. In some embodiments, the subject has anxiety rising during most days of a major depressive episode. In some embodiments, the subject has a HAM-D anxiety / somatization subscale score of at least 7 at baseline. In some embodiments, the subject has a HAM-A total score of at least 17 at baseline. In some embodiments, the subject has a HAM-A total score of at least 18 at baseline. In some embodiments, the subject has a HAM-A total score of at least 20 at baseline.
[0496] In some embodiments, the subject has a HAM-D total score of at least 24 and a HAM-A total score of at least 17 at baseline. In some embodiments, the subject has a HAM-D total score of at least 24 and a HAM-A total score of at least 18 at baseline. In some embodiments, the subject has a HAM-D total score of at least 24 and a HAM-A total score of at least 19 at baseline. In some embodiments, the subject has a HAM-D total score of at least 24 and a HAM-D total score of at least 20 at baseline. In some embodiments, the subject has a HAM-D total score of at least 24 and a HAM-D anxiety / somatization subscale score of at least 7 at baseline.
[0497] In some embodiments, administering the combination reduces adverse events arising from gastrointestinal treatments. In some embodiments, providing the first treatment reduces adverse events arising from gastrointestinal treatments.
[0498] In some embodiments, adverse events arising in gastrointestinal treatments include nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, increased appetite, or dry mouth, or any combination thereof. In some embodiments, adverse events arising in gastrointestinal treatments include nausea and / or diarrhea. In some embodiments, adverse events arising in gastrointestinal treatments are caused by treatment with another antidepressant.
[0499] In some embodiments, the subject is treatment naive. In some embodiments, the subject has not been treated with any antidepressant for at least 30 days prior to the start of the first treatment. In some embodiments, the subject has not been treated with another antidepressant for at least 30 days prior to the start of the first treatment. In some embodiments, the subject has not been treated with another antidepressant for at least 60 days prior to the start of the first treatment.
[0500] In some embodiments, the first treatment administers the combination for about 14 days. In some embodiments, the second treatment administers the additional antidepressant for at least 28 days. In some embodiments, the additional antidepressant is administered at the same dose in the first and second treatments. In some embodiments, the additional antidepressant is administered at different doses in the first and second treatments. In some embodiments, compound (1) or a pharmaceutically acceptable salt of compound (1) is not administered to the subject in the second treatment.
[0501] In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant are administered in separate dosage forms in the first treatment. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant are administered at the same time in the first treatment. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant are administered at different times in the first treatment.
[0502] In some embodiments, the additional antidepressant in (i) and (ii) is administered at the same dose. In some embodiments, the additional antidepressant in (i) and (ii) is administered at different doses. In some embodiments, compound (1) or a pharmaceutically acceptable salt of compound (1) is not administered to the subject in (ii). In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant in (i) are administered in separate dosage forms. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant in (i) are administered at the same time. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant in (i) are administered at different times. In some embodiments, the additional antidepressant administered in (ii) is the same as the additional antidepressant administered in (i).
[0503] In some embodiments, the combination of compound (1) or a pharmaceutically acceptable salt of compound (1) and another antidepressant is re-administered to the subject in response to the recurrence of depressive symptoms. In some embodiments, there is an interval of at least 6 weeks between the last dose of the first treatment and the first dose of re-administration.
[0504] In each of the embodiments described herein, the methods directed to treating MDD also directed to treating postpartum depression (PPD).
[0505] In one aspect, the disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of compound (1):
[0506]
[0507] and a therapeutically effective amount of another antidepressant,
[0508] None of the subjects had received treatment.
[0509] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0510]
[0511] and a therapeutically effective amount of another antidepressant,
[0512] None of the subjects had received treatment.
[0513] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of compound (1):
[0514]
[0515] and a therapeutically effective amount of another antidepressant,
[0516] None of the subjects had received treatment.
[0517] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0518]
[0519] and a therapeutically effective amount of another antidepressant,
[0520] None of the subjects had received treatment.
[0521] In one aspect, the present disclosure relates to a method of reducing adverse events arising from gastrointestinal treatment with antidepressant therapy in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of compound (1):
[0522]
[0523] and a therapeutically effective amount of another antidepressant
[0524] None of the subjects had received treatment.
[0525] In one aspect, the present disclosure relates to a method for reducing adverse events arising from gastrointestinal treatment of antidepressant therapy in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0526]
[0527] and a therapeutically effective amount of another antidepressant
[0528] None of the subjects had received treatment.
[0529] In one aspect, the disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising administering a combination for about 14 days, the combination comprising a therapeutically effective amount of compound (1):
[0530]
[0531] and a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine, and desvenlafaxine;
[0532] None of the subjects had received treatment.
[0533] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising administering a combination for about 14 days, the combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0534]
[0535] and a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine, and desvenlafaxine;
[0536] None of the subjects had received treatment.
[0537] In one aspect, the disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising administering a combination comprising about 40 mg to about 50 mg of compound (1):
[0538]
[0539] and a therapeutically effective amount of an additional antidepressant.
[0540] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising administering a combination comprising a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound:
[0541]
[0542] and a therapeutically effective amount of an additional antidepressant.
[0543] In some embodiments, the subject is experiencing a major depressive episode. In some embodiments, the subject has anxiety rising during most days of a major depressive episode. In some embodiments, the subject has a HAM-D anxiety / somatization subscale score of at least 7 at baseline. In some embodiments, the subject has a HAM-A total score of at least 17 at baseline. In some embodiments, the subject has a HAM-A total score of at least 18 at baseline. In some embodiments, the subject has a HAM-A total score of at least 20 at baseline.
[0544] In some embodiments, the subject has a HAM-D total score of at least 24 and a HAM-A total score of at least 17 at baseline. In some embodiments, the subject has a HAM-D total score of at least 24 and a HAM-A total score of at least 18 at baseline. In some embodiments, the subject has a HAM-D total score of at least 24 and a HAM-A total score of at least 19 at baseline. In some embodiments, the subject has a HAM-D total score of at least 24 and a HAM-A total score of at least 20 at baseline. In some embodiments, the subject has a HAM-D total score of at least 24 and a HAM-D Anxiety / Somatization subscale score of at least 7 at baseline.
[0545] In some embodiments, the administration of the combination reduces adverse events that occur in gastrointestinal treatments. In some embodiments, providing the combination reduces adverse events that occur in gastrointestinal treatments. In some embodiments, adverse events that occur in gastrointestinal treatments include nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, increased appetite or dry mouth, or any combination thereof. In some embodiments, adverse events that occur in gastrointestinal treatments include nausea and / or diarrhea. In some embodiments, adverse events that occur in gastrointestinal treatments are caused by treatment with another antidepressant.
[0546] In some embodiments, the subject has not been treated with any antidepressant for at least 30 days prior to the start of treatment. In some embodiments, the subject has not been treated with another antidepressant for at least 30 days prior to the start of treatment. In some embodiments, the subject has not been treated with another antidepressant for at least 60 days prior to the start of treatment.
[0547] In some embodiments, the therapeutic administration combination continues for about 14 days.
[0548] In some embodiments, the compound (1) or its pharmaceutically acceptable salt and the other antidepressant in the combination are administered in separate dosage forms. In some embodiments, the compound (1) or its pharmaceutically acceptable salt and the other antidepressant in the combination are administered at the same time. In some embodiments, the compound (1) or its pharmaceutically acceptable salt and the other antidepressant in the combination are administered at different times.
[0549] In some embodiments, the treatment further comprises a second treatment comprising administering a therapeutically effective amount of an additional antidepressant. In some embodiments, the second treatment administers an additional antidepressant for at least 28 days. In some embodiments, the additional antidepressant is administered in the second treatment at the same dose as in the combination. In some embodiments, the additional antidepressant is administered in the second treatment at a dose different from that administered in the combination. In some embodiments, compound (1) or a pharmaceutically acceptable salt of compound (1) is not administered to the subject in the second treatment. In some embodiments, the additional antidepressant administered in the second treatment is the same as the additional antidepressant administered in the combination.
[0550] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with about 40 mg to about 50 mg of compound (1):
[0551]
[0552] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0553] Antidepressants were continued after the 14th day of treatment.
[0554] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound:
[0555]
[0556] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0557] Antidepressants were continued after the 14th day of treatment.
[0558] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with about 40 mg to about 50 mg of compound (1):
[0559]
[0560] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0561] Antidepressants were continued after the 14th day of treatment.
[0562] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound:
[0563]
[0564] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0565] Antidepressants were continued after the 14th day of treatment.
[0566] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of compound (1):
[0567]
[0568] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0569] Antidepressants were continued after the 14th day of treatment.
[0570] None of the subjects had received treatment.
[0571] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0572]
[0573] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0574] Antidepressants were continued after the 14th day of treatment.
[0575] None of the subjects had received treatment.
[0576] In one aspect, the present disclosure relates to a method of reducing adverse events arising from gastrointestinal treatment with an antidepressant in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of compound (1):
[0577]
[0578] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0579] Antidepressants were continued after the 14th day of treatment.
[0580] In one aspect, the present disclosure relates to a method for reducing adverse events arising from gastrointestinal treatment with an antidepressant in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0581]
[0582] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0583] Antidepressants were continued after the 14th day of treatment.
[0584] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of compound (1):
[0585]
[0586] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0587] Antidepressants were continued after the 14th day of treatment.
[0588] The antidepressants are selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine.
[0589] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0590]
[0591] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0592] Antidepressants were continued after the 14th day of treatment.
[0593] The antidepressants are selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine.
[0594] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of compound (1):
[0595]
[0596] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0597] Antidepressants were continued after the 14th day of treatment.
[0598] The antidepressants are selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine.
[0599] In one aspect, the present disclosure relates to a method of treating major depressive disorder (MDD) associated with elevated anxiety in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0600]
[0601] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0602] Antidepressants were continued after the 14th day of treatment.
[0603] The antidepressants are selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine.
[0604] In some embodiments, the subject is experiencing a major depressive episode. In some embodiments, there is an anxiety rise during most days of a major depressive episode. In some embodiments, the HAM-D anxiety / somatization subscale score of the subject is at least 7 at baseline. In some embodiments, the HAM-A total score of the subject is at least 17 at baseline. In some embodiments, the HAM-A total score of the subject is at least 18 at baseline. In some embodiments, the HAM-A total score of the subject is at least 20 at baseline.
[0605] In some embodiments, the subject has a HAM-D total score of at least 24 and a HAM-A total score of at least 17 at baseline. In some embodiments, the subject has a HAM-D total score of at least 24 and a HAM-A total score of at least 18 at baseline. In some embodiments, the subject has a HAM-D total score of at least 24 and a HAM-A total score of at least 19 at baseline. In some embodiments, the subject has a HAM-D total score of at least 24 and a HAM-A total score of at least 20 at baseline. In some embodiments, the subject has a HAM-D total score of at least 24 and a HAM-D Anxiety / Somatization subscale score of at least 7 at baseline.
[0606] In some embodiments, co-administration reduces adverse events that occur in gastrointestinal treatments. In some embodiments, co-administration reduces adverse events that occur in gastrointestinal treatments. In some embodiments, adverse events that occur in gastrointestinal treatments include nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, increased appetite or dry mouth, or any combination thereof. In some embodiments, adverse events that occur in gastrointestinal treatments include nausea and / or diarrhea. In some embodiments, adverse events that occur in gastrointestinal treatments are caused by treatment with antidepressants.
[0607] In some embodiments, the subject is treatment naive. In some embodiments, the subject has not received any antidepressant treatment within at least 30 days before the start of co-administration. In some embodiments, the subject has not received treatment with an antidepressant within at least 30 days before the start of co-administration. In some embodiments, the subject has not received treatment with an antidepressant within at least 60 days before the start of co-administration.
[0608] In some embodiments, the antidepressant is continued for at least an additional 28 days after the 14th day of treatment. In some embodiments, compound (1) or a pharmaceutically acceptable salt of compound (1) is no longer administered after the 14th day of treatment.
[0609] In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the antidepressant are administered in separate dosage forms during co-administration. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the antidepressant are administered at the same time during co-administration. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the antidepressant are administered at different times during co-administration. In some embodiments, the antidepressant is administered at the same dose from day 1 of treatment to about day 14 of treatment and after day 14 of treatment. In some embodiments, the antidepressant is administered at the same dose from day 1 of treatment to about day 14 of treatment and after day 14 of treatment.
[0610] In one aspect, the present disclosure provides a method of treating major depressive disorder (MDD) in a treatment-naive subject in need thereof, comprising co-initiating administration of a combination comprising a therapeutically effective amount of compound (1):
[0611]
[0612] and a therapeutically effective amount of an antidepressant.
[0613] In each of the embodiments described herein, the methods directed to treating MDD also directed to treating postpartum depression (PPD).
[0614] The severity of the disorder treated by the methods described herein can be characterized by methods known to those skilled in the art, such as moderate or severe. These methods may include, but are not limited to, the following scales / assessments: Hamilton Depression Score (HAM-D), Hamilton Anxiety Score (HAM-A), Montgomery-Osberg Depression Rating Scale (MADRS), Clinical Global Impression (CGI) Scale, Clinical Global Impression-Improvement Scale (CGI-I), Clinical Global Impression-Severity of Disease (CGI-S), Clinical Global Impression-Change (CGI-C), Sheehan Disability Scale (SDS), 9-item Patient Health Questionnaire (PHQ-9) and Short Form 36 Health Survey Version 2 (SF-36v2). The score of each of the above scales / assessments is based on each assessment measurement, and the result can be reported as a total score, a subscale score and / or a single score.
[0615] The safety and tolerability of compound (1) can be assessed by methods known to those skilled in the art. These methods include, but are not limited to, collecting and summarizing adverse events (AEs), clinical laboratory measurements, vital signs, and 12-lead electrocardiograms. The Columbia Suicide Severity Rating Scale (C-SSRS) can be used to assess sudden suicidal thoughts and behaviors. The Stanford Sleepiness Scale (SSS) can be used to assess sedation / sleepiness. The Physician Withdrawal Checklist-20 Total Score (PWC-20) can be used to monitor the presence of potential withdrawal symptoms after discontinuation of treatment with compound (1).
[0616] In some embodiments, the method provides a therapeutic effect. In some embodiments, a therapeutic effect is observed, such as measured by reducing the HAM-D total score in about 42 (± 3) days, about 35 (± 3) days, about 28 (± 3) days, about 21 (± 1) days, about 18 (± 1) days, about 15 (± 1) days, about 12 (± 1) days, about 8 (± 1), about 3 (± 1) days or about 1 day. In some embodiments, the therapeutic effect is that the HAM-D total score is reduced relative to baseline at the end of the first treatment period or when the combination of compound (1) and other antidepressants is applied (that is, when compound (1) and other antidepressants are applied for 14 days). In some embodiments, the therapeutic effect is that the HAM-D total score is reduced relative to baseline at the end of the second treatment period. In some embodiments, the HAM-D total score is reduced relative to baseline from severe (for example, HAM-D total score is 24 or higher; or score is 26 or higher) to asymptomatic relative to baseline, i.e., depression is relieved (for example, HAM-D total score is 7 or lower). In some embodiments, the reduction in HAM-D total score relative to baseline is from severe (e.g., a HAM-D total score of 24 or more; or a total score of 26 or more) to normal or mild depression (e.g., a HAM-D total score of 7 or less; or a HAM-D total score of 18-13). In some embodiments, the change (LS mean) in the HAM-D total score relative to baseline on Day 3 is at least about 8-10. In some embodiments, the change (LS mean) in the HAM-D total score relative to baseline on Day 3 is at least about 8. In some embodiments, the change (LS mean) in the HAM-D total score relative to baseline on Day 3 is at least about 9. In some embodiments, the change (LS mean) in the HAM-D total score relative to baseline for the treatment period (i.e., the first treatment or combination or co-administration) is at least about 11. In some embodiments, the change (LS mean) in the HAM-D total score relative to baseline for the treatment period (i.e., the first treatment or combination or co-administration) is at least about 11.5. In some embodiments, the change from baseline in HAM-D total score (LS mean) during the treatment period (ie, first treatment or combination or co-administration) is at least about 12.
[0617] In some embodiments, the method provides a therapeutic effect, such as measured by a reduction in the total score of the Montgomery-Osberg Depression Rating Scale (MADRS) within about 42 (± 3) days, about 35 (± 3) days, about 28 (± 3) days, about 21 (± 1) days, about 18 (± 1) days, about 15 (± 1) days, about 12 (± 1) days, about 8 (± 1), about 3 (± 1) days, or about 1 day. The Montgomery-Osberg Depression Rating Scale (MADRS) is a ten-item diagnostic questionnaire (about obvious sadness, reported sadness, inner tension, reduced sleep, loss of appetite, difficulty concentrating, fatigue, inability to feel, pessimistic thoughts, and suicidal thoughts) that psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. 0-6 represents normal / no symptoms; 7-19 represents mild depression; 20-34 represents moderate depression; and >34 represents severe depression. In some embodiments, the therapeutic effect is a decrease in the MADRS total score relative to baseline at the end of the first treatment period or at the end of the combined administration of compound (1) and another antidepressant (i.e., at the end of 14 days of administration of compound (1) and another antidepressant). In some embodiments, the therapeutic effect is a decrease in the MADRS total score relative to baseline at the end of the second treatment period. In some embodiments, the decrease in the MADRS score relative to baseline is from severe (e.g., a MADRS score of 30 or more) to asymptomatic (e.g., a MADRS score of 20 or less). In some embodiments, the change in the MADRS total score relative to baseline on day 8 (LS mean) is at least about 12-14. In some embodiments, the change in the MADRS total score relative to baseline on day 15 (LS mean) is at least about 16-18.
[0618] In some embodiments, the method provides a therapeutic effect as measured by a reduction in the Hamilton Anxiety Score (HAM-A) within about 42 (±3) days, about 35 (±3) days, about 28 (±3) days, about 21 (±1) days, about 18 (±1) days, about 15 (±1) days, about 12 (±1) days, about 8 (±1), about 3 (±1) days, or about 1 day. A HAM-A score of <17 indicates mild severity, 18-24 indicates mild to moderate severity, and 25-30 indicates moderate to severe. In some embodiments, the therapeutic effect is a decrease in the HAM-A score relative to baseline at the end of the first treatment period or at the end of the combined administration of compound (1) and the additional antidepressant (i.e., at the end of 14 days of administration of compound (1) and the additional antidepressant). In some embodiments, the therapeutic effect is a decrease in the HAM-A score relative to baseline at the end of the second treatment period. In some embodiments, the decrease in HAM-A score relative to baseline is from severe (e.g., a HAM-A score of 25 or more) to asymptomatic (e.g., a HAM-A score of 17 or less). In some embodiments, the decrease in HAM-A score relative to baseline is from severe (e.g., a HAM-A score of 25 or more) to mild (e.g., a HAM-A score of 24 or less). In some embodiments, the change (LS mean) in the HAM-A total score relative to baseline on Day 3 is at least about 9. In some embodiments, the change (LS mean) in the HAM-A total score relative to baseline on Day 8 is at least about 11. In some embodiments, the change (LS mean) in the HAM-A total score relative to baseline on Day 15 is at least about 14.
[0619] Other antidepressants
[0620] In some embodiments, the antidepressant in the first and second treatments or combination or co-administration is a selective serotonin reuptake inhibitor (SSRI), a serotonin norepinephrine reuptake inhibitor (SNRI), a serotonin modulator and stimulant (SMS), a serotonin antagonist and reuptake inhibitor (SARI), a norepinephrine reuptake inhibitor (NRI), a norepinephrine dopamine reuptake inhibitor (NDRI), a tricyclic antidepressant (TCA), a tetracyclic antidepressant (TeCA), a monoamine oxidase inhibitor (MAOI) , atypical antipsychotics, agomelatine, esketamine, tianeptine, ketamine, alpha-methyltryptamine, etryptamine, ethyltryptamine, indolozine, medixamine, oxaflophen, pitavagine, adenosine methionine, hypericum perforatum, hydroxytryptophan, tryptophan, trifluoperazine, buspirone, lithium, thyroxine, triiodothyronine, amitriptyline and chlordiazepoxide, amitriptyline and perphenazine, flupentixol and melitracen, olanzapine and fluoxetine, or tranylcypromine and trifluoperazine.
[0621] In some embodiments, the antidepressant in the first and second treatments or combination or co-administration is 4-chlorokynurenine (AV-101), Apimostinel (NRX-1074), Arketamine (PCN-101, HR-071603), Dextromethadone (REL-1017), MIJ-821, Rislenemdaz (CERC-301, MK-0657), TAK-653 (NBI-1065845), OPC- 64005, PDC-1421 (BLI-1005), Toludesvenlafaxinem, Hypidone (YL-0919), TGBA01AD (FKB01MD), Vortioxetine, Lysoxetine Dimesylate, Midomafetamine, (R)-Aramisulpride / (S)-esamisulpride (85 :15 ratio) (SEP-4199), Gepiron, Pramipexole, Psilocybin, Brilaroxazine, Cariprazine, Lumateperone, Lurasidone, Pimavanserin, Adenosine Methionine, 3β-Methoxypregnenolone (MAP-4343), PH-10–vomeropherine, Aticaprant, BTRX-335140 (BTRX-140), Buprenorphine / samidorphan, BTRX-246040 (LY-2940 094), scopolamine (DPI-386), JNJ-39393406, botulinum toxin type A (OnabotulinumtoxinA), JNJ-61393215, Seltorexant, BI-1358894, Crisdesalazine, Erteberel, JNJ-54175446, NSI-189, NV-5138, SNG-12, TS-121, WIP-DF17, tramadol, bupropion / dextromethorphan (AXS-05; Auvelity TM ), carbidopa / hydroxytryptophan (EVX-101), cycloserine / lurasidone (NRX-101; Cyclurad), or deudextromethorphan / quinidine (AVP-786, CTP-786).
[0622] In some embodiments, the antidepressant in the first or second treatment or combination or co-administration is an SSRI. In some embodiments, the SSRI is sertraline, escitalopram, citalopram, fluvoxamine, paroxetine, fluoxetine, indalpine, or zolmadin. In some embodiments, the SSRI is sertraline. In some embodiments, the SSRI is escitalopram. In some embodiments, the SSRI is citalopram.
[0623] In some embodiments, the antidepressant in the first or second treatment or combination or co-administration is a SNRI. In some embodiments, the SNRI is duloxetine, desvenlafaxine, levomilnacipran, milnacipran, or venlafaxine. In some embodiments, the SNRI is duloxetine. In some embodiments, the SNRI is desvenlafaxine.
[0624] In some embodiments, the antidepressant in the first or second treatment or combination or co-administration is SMS. In some embodiments, the SMS is vilazodone or vortioxetine.
[0625] In some embodiments, the antidepressant in the first or second treatment or combination or co-administration is a SARI. In some embodiments, the SARI is nefazodone, trazodone, or etoperidone.
[0626] In some embodiments, the antidepressant in the first or second treatment or combination or co-administration is an NRI. In some embodiments, the NRI is reboxetine, tenisazine, viloxazine, or atomoxetine.
[0627] In some embodiments, the antidepressant in the first or second treatment or combination or co-administration is an NDRI. In some embodiments, the NDRI is bupropion, amphetamine, methylphenidate, modafinil, amineptine, or nomifensine.
[0628] In some embodiments, the antidepressant in the first or second treatment or combination or co-administration is a TCA. In some embodiments, the TCA is amitriptyline, amitriptyline oxy, clomipramine, desipramine, diebnzepin, dimethaline, dosluepin, doxepin, imipramine, lofepramine, melitracen, nitroxazepine, nortriptyline, noxetine, opipramol, pipofilazine, protriptyline, trimipramine, buttriptyline, demetriptyline, fluocinol, oxymipramine, iprindol, metapramine, propazepine, quinupramine, thiozepine or tolfenacin.
[0629] In some embodiments, the antidepressant in the first or second treatment or combination or co-administration is a TeCA. In some embodiments, the TeCA is amoxapine, maprotiline, mianserin, mirtazapine, or setiptiline.
[0630] In some embodiments, the antidepressant in the first or second treatment or combination or co-administration is a MAOI. In some embodiments, the MAOI is isocarboxazid, phenelzine, tranylcypromine, benmoxin, iproclorazepam, iproniazid, mebanazine, nyalamid, octamoxin, pheniprazine, phenoxyprorazine, pivalazine, safrazine, selegiline, caroxadone, metrindol, moclobemide, pyrindole, iprembamide, bendamorph, toloxatone, or difemelane.
[0631] In some embodiments, the antidepressant in the first or second treatment or combination or co-administration is an atypical antipsychotic. In some embodiments, the atypical antipsychotic is amisulpride, lumepirone, lurasidone, quetiapine, aripiprazole, epiriprazole, lumepirone, lurasidone, olanzapine, quetiapine, or risperidone.
[0632] In some embodiments, the antidepressant in the first or second treatment or combination or co-administration is agomelatine, esketamine, tianeptine, ketamine, alpha-methyltryptamine, ethyltryptamine, ethyltryptamine, indolozine, medixamine, oxafluxane, pitavagine, adenosine methionine, hypericum perforatum, hydroxytryptophan, tryptophan, trifluoperazine, buspirone, lithium, thyroxine, triiodothyronine, amitriptyline and chlordiazepoxide, amitriptyline and perphenazine, flupentixol and melitracen, olanzapine and fluoxetine, or tranylcypromine and trifluoperazine.
[0633] In some embodiments, the antidepressant drug in the first or second treatment or combination or co-administration is administered according to the prescribing information of its label.
[0634] In some embodiments, the co-administration is co-initiating administration of the compound (1) or a pharmaceutically acceptable salt thereof; and the antidepressant.
[0635] In some embodiments, the SSRI is sertraline, and the dosage thereof is about 50 mg to about 200 mg, or about 50 mg to about 100 mg, or about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, or about 200 mg. In some embodiments, the dosage of sertraline is increased by about 25 to about 50 mg per day. In some embodiments, the dosage of sertraline is about 50 mg. In some embodiments, the dosage of sertraline is about 100 mg. In some embodiments, the dosage of sertraline is about 150 mg. In some embodiments, the dosage of sertraline is about 200 mg.
[0636] In some embodiments, the SSRI is citalopram and is administered at a dose of about 10 mg to about 40 mg, or about 15 mg to about 30 mg, or about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, or about 40 mg. In some embodiments, the dose of citalopram administered is about 20 mg. In some embodiments, the dose of citalopram administered is about 30 mg. In some embodiments, the dose of citalopram administered is about 40 mg.
[0637] In some embodiments, the SSRI is escitalopram and is administered at a dose of about 10 mg to about 40 mg, or about 15 mg to about 30 mg, or about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, or about 40 mg. In some embodiments, escitalopram is administered at a dose of about 10 mg. In some embodiments, escitalopram is administered at a dose of about 15 mg. In some embodiments, escitalopram is administered at a dose of about 20 mg.
[0638] In some embodiments, the SNRI is duloxetine and is administered at a dose of about 40 mg to about 120 mg, or about 60 mg to about 100 mg, or about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, or about 120 mg. In some embodiments, duloxetine is administered at a dose of about 40 mg. In some embodiments, duloxetine is administered at a dose of about 60 mg.
[0639] In some embodiments, the SNRI is desvenlafaxine and is administered at a dose of about 10 mg to about 100 mg, or about 20 mg to about 50 mg, or about 10 mg, about 20 mg, about 30 mg, about 40 mg, or about 50 mg. In some embodiments, desvenlafaxine is administered at a dose of about 50 mg.
[0640] dose
[0641] In some embodiments, compound (1) is administered. In some embodiments, a pharmaceutically acceptable salt of compound (1) is administered. In some embodiments, compound (1) exists in a non-deuterated form. In some embodiments, compound (1) exists in a deuterated form. In some embodiments, the deuterated form of compound (1) is those disclosed and described in PCT Application Publication No. WO2019 / 113494 and in U.S. Application No. 17 / 545,290; the entire contents of the above applications are incorporated herein by reference in their entirety.
[0642] In some embodiments, compound (1) is administered at a dose of about 10 mg to about 100 mg. In some embodiments, compound (1) is administered at a dose of about 15 mg to about 75 mg. In some embodiments, compound (1) is administered at a dose of about 20 mg to about 60 mg. In some embodiments, compound (1) is administered at a dose of about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, or about 60 mg. In some embodiments, compound (1) is administered at a dose of about 50 mg. In some embodiments, compound (1) is administered at a dose of about 40 mg.
[0643] In some embodiments, compound (1) is administered at a dose of about 10 mg to about 100 mg, once a day. In some embodiments, compound (1) is administered at a dose of about 20 mg to about 60 mg, once a day. In some embodiments, compound (1) is administered at a dose of about 50 mg, once a day. In some embodiments, compound (1) is administered at a dose of about 40 mg, once a day.
[0644] In some embodiments, compound (1) is administered at a dose of about 50 mg, once a day, for less than 2 weeks. In some embodiments, compound (1) is administered at a dose of about 50 mg, once a day, for about 14 days. In some embodiments, compound (1) is administered at a dose of about 40 mg, once a day, for less than 2 weeks. In some embodiments, compound (1) is administered at a dose of about 40 mg, once a day, for about 14 days.
[0645] In some embodiments, the patient is administered compound (1) at night. In some embodiments, the patient is administered compound (1) no more than 1 hour before the patient falls asleep. In some embodiments, the patient is administered compound (1) no more than 15 minutes before the patient falls asleep.
[0646] In some embodiments, compound (1) is administered with food. In some embodiments, compound (1) is administered with a fat-containing food. Examples of fat-containing foods include nuts, peanut butter, avocados, eggs, and cheese. In some embodiments, compound (1) is administered in the evening with a fat-containing food (e.g., within 1 hour after a fat-containing dinner, or with a fat-containing snack).
[0647] In some embodiments, compound (1) is administered orally, parenterally, intradermally, intrathecally, intramuscularly, subcutaneously, vaginally, buccally, sublingually, rectally, topically, as an inhalant, intranasally, or transdermally. In some embodiments, compound (1) is administered orally.
[0648] In some embodiments, compound (1) is administered in one or more capsules. In some embodiments, the therapeutically effective amount is administered by two capsules. In some embodiments, the therapeutically effective amount is administered by three capsules. In some embodiments, the therapeutically effective amount is administered by two capsules, wherein at least one capsule contains about 20 mg of compound (1). In some embodiments, the therapeutically effective amount is administered by two capsules, wherein at least one capsule contains about 25 mg of compound (1). In some embodiments, the therapeutically effective amount is administered by two capsules, wherein at least one capsule contains about 30 mg of compound (1). In some embodiments, the therapeutically effective amount is administered by two capsules, wherein each capsule contains about 20 mg of compound (1). In some embodiments, the therapeutically effective amount is administered by two capsules, wherein each capsule contains about 25 mg of compound (1). In some embodiments, the therapeutically effective amount is administered by two capsules, wherein one capsule contains about 30 mg of compound (1), and the other capsule contains about 20 mg of compound (1).
[0649] In some embodiments, the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent of about 10 mg to about 100 mg of the free base compound. In some embodiments, the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent of about 15 mg to about 75 mg of the free base compound. In some embodiments, the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent of about 20 mg to about 60 mg of the free base compound. In some embodiments, the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent of about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, or about 60 mg of the free base compound. In some embodiments, the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent of about 50 mg of the free base compound. In some embodiments, the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent of about 40 mg of the free base compound.
[0650] In some embodiments, the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent of about 10 mg to about 100 mg of the free base compound, once a day. In some embodiments, the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent of about 20 mg to about 60 mg of the free base compound, once a day. In some embodiments, the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent of about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, or about 60 mg of the free base compound, once a day. In some embodiments, the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent of about 50 mg of the free base compound, once a day. In some embodiments, the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent of about 40 mg of the free base compound, once a day.
[0651] In some embodiments, the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent of about 50 mg of the free base compound, once a day for less than 2 weeks. In some embodiments, the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent of about 50 mg of the free base compound, once a day for about 14 days. In some embodiments, the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent of about 40 mg of the free base compound, once a day for less than 2 weeks. In some embodiments, the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent of about 40 mg of the free base compound, once a day for about 14 days.
[0652] In some embodiments, the pharmaceutically acceptable salt of compound (1) is administered at night. In some embodiments, the pharmaceutically acceptable salt of compound (1) is administered no more than 1 hour before the subject falls asleep. In some embodiments, the pharmaceutically acceptable salt of compound (1) is administered no more than 15 minutes before the subject falls asleep.
[0653] In some embodiments, a pharmaceutically acceptable salt of compound (1) is administered with food. In some embodiments, a pharmaceutically acceptable salt of compound (1) is administered with a fat-containing food. Examples of fat-containing foods include nuts, peanut butter, avocados, eggs, and cheese. In some embodiments, compound (1) is administered in the evening with a fat-containing food (e.g., within 1 hour after a fat-containing dinner, or with a fat-containing snack).
[0654] In some embodiments, the pharmaceutically acceptable salt of compound (1) is administered orally, parenterally, intradermally, intrathecally, intramuscularly, subcutaneously, vaginally, buccally, sublingually, rectally, topically, as an inhalant, intranasally or transdermally. In some embodiments, the pharmaceutically acceptable salt of compound (1) is administered orally.
[0655] In some embodiments, the pharmaceutically acceptable salt of compound (1) is administered chronically.
[0656] In some embodiments, the first treatment administers a combination of Compound (1) or a pharmaceutically acceptable salt thereof and an additional antidepressant for about 14 days.
[0657] In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant are administered in separate dosage forms in the first treatment. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant are administered at the same time in the first treatment. In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant are administered at different times in the first treatment.
[0658] In some embodiments, the second treatment administers the additional antidepressant for at least 28 days.
[0659] In some embodiments, the additional antidepressant is administered at the same dose in the first and second treatments. In some embodiments, the additional antidepressant is administered at different doses in the first and second treatments.
[0660] In some embodiments, Compound (1) or a pharmaceutically acceptable salt of Compound (1) is not administered to the subject in the second treatment.
[0661] In some embodiments, the combination of compound (1) or a pharmaceutically acceptable salt of compound (1) and an additional antidepressant is re-administered to the subject in response to recurrence of depressive symptoms. In some embodiments, there is an interval of at least 6 weeks between the last dose of the first treatment and the first dose of re-administration.
[0662] In some embodiments, the combination of compound (1) or a pharmaceutically acceptable salt thereof and another antidepressant can be administered in combination with another agent. Administration in combination with another agent can be performed by any technique apparent to those skilled in the art, including, for example, separate, sequential, simultaneous, and alternating administration.
[0663] In some embodiments, in the second treatment, the additional antidepressant may be administered in combination with another agent. Administration in combination with another agent may be performed by any technique apparent to those skilled in the art, such as separate, sequential, simultaneous, and alternating administration.
[0664] Crystalline form of compound (1)
[0665] In some embodiments, compound (1) is in crystalline form. In some embodiments, the crystalline form of compound (1) is any crystalline form disclosed in PCT application publication number WO 2018 / 039378; the entire contents of the above application are incorporated herein by reference in their entirety.
[0666] In some embodiments, compound (1) is in a crystalline form having an XRPD pattern comprising peaks between 9.7 and 10.1 °2θ, inclusive, between 11.6 and 12.0 °2θ, inclusive, between 13.2 and 13.6 °2θ, inclusive, between 14.2 and 14.6 °2θ, inclusive, between 14.6 and 15.0 °2θ, inclusive, between 16.8 and 17.2 °2θ, inclusive, between 20.5 and 20.9 °2θ, inclusive, between 21.3 and 21.7 °2θ, inclusive, between 21.4 and 21.8 °2θ, and inclusive, and between 22.4 and 22.8 °2θ. In some embodiments, compound (1) is in a crystalline form having an XRPD pattern comprising peaks between 9.7 and 10.1 °2θ, inclusive, between 14.6 and 15.0 °2θ, inclusive, between 16.8 and 17.2 °2θ, inclusive, between 20.5 and 20.9 °2θ, inclusive, and between 21.3 and 21.7 °2θ, inclusive.
[0667] In some embodiments, compound (1) is in a crystalline form having an XRPD pattern comprising peaks between 9.3 and 9.7 °2θ, inclusive, between 10.6 and 11.0 °2θ, inclusive, between 13.0 and 13.4 °2θ, inclusive, between 14.7 and 15.1 °2θ, inclusive, between 15.8 and 16.2 °2θ, inclusive, between 18.1 and 18.5 °2θ, inclusive, between 18.7 and 19.1 °2θ, inclusive, between 20.9 and 21.3 °2θ, inclusive, between 21.4 and 21.8 °2θ, and inclusive, and between 23.3 and 23.7 °2θ. In some embodiments, compound (1) is in a crystalline form having an XRPD pattern comprising peaks between 9.3 and 9.7 °2θ, inclusive, between 10.6 and 11.0 °2θ, inclusive, between 13.0 and 13.4 °2θ, inclusive, between 18.7 and 19.1 °2θ, inclusive, and between 21.4 and 21.8 °2θ, inclusive.
[0668] In some embodiments, the crystalline form of Compound (1) comprises a mixture of two or more crystalline forms.
[0669] Pharmaceutical composition
[0670] Another aspect of the present disclosure provides a pharmaceutical composition for the combinations and methods described herein, comprising compound (1) (also referred to as "active ingredient") and a pharmaceutically acceptable excipient. On the other hand, the present disclosure provides a pharmaceutical composition for the combinations and methods described herein, comprising a pharmaceutically acceptable salt of the active ingredient and a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition comprises an effective amount of the active ingredient or a pharmaceutically acceptable salt of the active ingredient. In certain embodiments, the pharmaceutical composition comprises a therapeutically effective amount of the active ingredient or a pharmaceutically acceptable salt of the active ingredient. In some embodiments, the pharmaceutical composition of compound (1) is any pharmaceutical composition disclosed in PCT Application Publication No. WO2022 / 020363A9; the entire contents of the above application are incorporated herein by reference in their entirety.
[0671] The pharmaceutical compositions provided herein can be administered by a variety of routes, including but not limited to oral (enteral) administration, parenteral (by injection) administration, rectal administration, transdermal administration, intradermal administration, intrathecal administration, subcutaneous (SC) administration, intravenous (IV) administration, intramuscular (IM) administration, and intranasal administration. In some embodiments, the pharmaceutical composition is administered orally.
[0672] The pharmaceutical composition of the present invention can be further delivered using a variety of administration methods. For example, in certain embodiments, the pharmaceutical composition can be given as a bolus, for example, in order to increase the concentration of the compound in the blood to an effective level. The location of the bolus dose depends on the required systemic level of the active ingredient throughout the body, for example, intramuscular or subcutaneous bolus doses allow the active ingredient to be slowly released, and direct bolus delivery to the vein (for example, by IV drip) allows faster delivery, thereby quickly increasing the concentration of the active ingredient in the blood to an effective level. In other embodiments, the pharmaceutical composition can be used as a continuous infusion, for example, by IV drip, to provide maintenance of the steady-state concentration of the active ingredient in the subject. In addition, in some other embodiments, the pharmaceutical composition can be first administered as a bolus dose, and then continuously infused.
[0673] Compositions for oral administration can be in the form of bulk liquid solutions or suspensions or bulk powders. However, more commonly, compositions are presented in unit dosage form to facilitate accurate administration. The term "unit dosage form" refers to physically discrete units suitable as single doses for human subjects and other mammals, each unit containing a predetermined amount of active material calculated to produce the desired therapeutic effect, and combined with a suitable pharmaceutical excipient. Typical unit dosage forms include pre-filled, pre-measured ampoules or syringes of liquid compositions, or for solid compositions, pills, tablets, capsules, and the like. In such compositions, the compound is usually a minor component (about 0.1 to about 50% by weight or preferably about 1 to about 40% by weight), and the remainder is various vehicles or excipients and processing aids that help form the desired dosage form.
[0674] The above-mentioned components for oral administration, injection or topical administration are representative only. Other materials and processing techniques, etc., are described in Part 8 of Remington's Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania, which is incorporated herein by reference.
[0675] The compositions of the present disclosure may also be administered in sustained release form or by a sustained release drug delivery system. Descriptions of representative sustained release materials can be found in Remington's Pharmaceutical Sciences.
[0676] Although the description of the pharmaceutical compositions provided herein is primarily directed to pharmaceutical compositions suitable for administration to humans, it will be appreciated by those skilled in the art that such compositions are generally suitable for administration to a variety of animals. It is readily understood that pharmaceutical compositions suitable for administration to humans may be modified in order to make the compositions suitable for administration to a variety of animals, and generally skilled veterinary pharmacologists may design and / or perform such modifications using ordinary experiments. General considerations in the preparation and / or manufacture of pharmaceutical compositions may be found in, for example, Remington: The Science and Practice of Pharmacy 21st ed., Lippincott Williams & Wilkins, 2005.
[0677] Reagent test kit
[0678] Another aspect of the present disclosure provides a kit comprising a pharmaceutical composition comprising compound (1), an additional antidepressant, and an instruction set describing the methods as described herein for treating major depressive episode (MDD) or postpartum depression (PPD).
[0679] In one aspect, the present disclosure provides a kit comprising a pharmaceutical composition containing about 40 mg to about 50 mg of compound (1), an additional antidepressant, and an instruction set describing a method for treating major depressive episode (MDD) or postpartum depression (PPD), wherein the method provides (i) a first treatment comprising administering a combination of a pharmaceutical composition containing compound (1) and an additional antidepressant; and (ii) a second treatment comprising administering the additional antidepressant.
[0680] In one aspect, the disclosure provides a kit comprising a combination of a pharmaceutical composition comprising compound (1) and an additional antidepressant, and an instruction set describing methods of using the combination to treat major depressive episode (MDD) or postpartum depression (PPD) in a treatment-naive subject.
[0681] Another aspect of the present disclosure includes a kit comprising multiple therapeutically effective doses of compound (1), multiple therapeutically effective doses of an additional antidepressant, and an instruction set describing a method of administering the doses to treat major depressive episode (MDD) or postpartum depression (PPD) in a subject who has not received treatment. In some embodiments, the method of administering the doses is any of the methods described herein.
[0682] In some embodiments, the dose of compound (1) is a single dose unit of compound (1). In some embodiments, a single dose unit contains about 20 mg to about 30 mg of compound (1). In some embodiments, a single dose unit contains about 20 mg of compound (1). In some embodiments, a single dose unit contains about 25 mg of compound (1). In some embodiments, a single dose unit contains about 30 mg of compound (1). In some embodiments, a single dose unit of compound (1) is a capsule or tablet. In some embodiments, a single dose unit of compound (1) is a capsule. In some embodiments, a single dose unit of compound (1) is a capsule of size 1, 2, 3 or 4. In some embodiments, the capsule is size 1. In some embodiments, the capsule is a hard gelatin capsule. In some embodiments, in addition to a specified amount of compound (1) (e.g., 20 mg, 25 mg or 30 mg), the capsule further contains cross-linked sodium carboxymethyl cellulose, mannitol, silicified microcrystalline cellulose, colloidal silicon dioxide and sodium stearyl fumarate. In some embodiments, multiple therapeutically effective doses of compound (1) include two capsules. In some embodiments, the plurality of therapeutically effective doses of compound (1) comprises three capsules.
[0683] In some embodiments, the dose of the additional antidepressant is a single dosage unit of the additional antidepressant. In some embodiments, the additional antidepressant is selected from sertraline, escitalopram, citalopram, duloxetine, and desvenlafaxine. In some embodiments, the single dosage unit of the additional antidepressant is packaged and labeled by a commercial manufacturer.
[0684] In some embodiments, the additional antidepressant is sertraline. In some embodiments, the dose of the additional antidepressant is a single dose unit of sertraline. In some embodiments, the single dose unit of sertraline is a tablet. In some embodiments, the single dose unit of sertraline contains about 25 mg, 50 mg, or 100 mg of sertraline. In some embodiments, the single dose unit of sertraline is a container containing a liquid concentrate, wherein each mL of concentrate is equivalent to 20 mg of sertraline. In some embodiments, the additional antidepressant is escitalopram. In some embodiments, the dose of the additional antidepressant is a single dose unit of escitalopram. In some embodiments, the single dose unit of escitalopram is a tablet. In some embodiments, the single dose unit of escitalopram contains about 5 mg, 10 mg, or 20 mg of escitalopram. In some embodiments, the additional antidepressant is citalopram. In some embodiments, the dose of the additional antidepressant is a single dose unit of citalopram. In some embodiments, the single dose unit of citalopram is a tablet. In some embodiments, a single dosage unit of citalopram contains about 10 mg, 20 mg, or 40 mg of citalopram. In some embodiments, the additional antidepressant is duloxetine. In some embodiments, the dose of the additional antidepressant is a single dosage unit of duloxetine. In some embodiments, the single dosage unit of duloxetine is a capsule. In some embodiments, a single dosage unit of duloxetine contains about 20 mg, 30 mg, or 60 mg of duloxetine. In some embodiments, the additional antidepressant is desvenlafaxine. In some embodiments, the dose of the additional antidepressant is a single dosage unit of desvenlafaxine. In some embodiments, a single dosage unit of desvenlafaxine is a tablet. In some embodiments, a single dosage unit of desvenlafaxine contains about 25 mg, 50 mg, or 100 mg of desvenlafaxine.
[0685] In some embodiments, the instruction set is printed on a suitable material.
[0686] Other Implementations
[0687] The embodiments of the present subject matter disclosed herein may be beneficial alone or in combination with one or more other embodiments. Without limiting the foregoing description, certain non-limiting embodiments of the present disclosure are provided below, numbered 1-258. It will be understood by those skilled in the art after reading this disclosure that each individually numbered embodiment can be used or combined with any preceding or following individually numbered embodiment. This is intended to provide support for the combination of all such embodiments, without being limited to the combination of the embodiments explicitly provided below.
[0688] Embodiments of the present disclosure:
[0689] Embodiment 1. A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising:
[0690] (i) providing a first treatment comprising administering a combination comprising from about 40 mg to about 50 mg of compound (1):
[0691]
[0692] and a therapeutically effective amount of an additional antidepressant; and
[0693] (ii) providing a second treatment comprising administering a therapeutically effective amount of said additional antidepressant.
[0694] Embodiment 2. A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising:
[0695] (i) providing a first treatment comprising administering a combination comprising a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound:
[0696]
[0697] and a therapeutically effective amount of an additional antidepressant; and
[0698] (ii) providing a second treatment comprising administering a therapeutically effective amount of an additional antidepressant.
[0699] Embodiment 3. A method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising:
[0700] (i) providing a first treatment comprising administering a combination comprising from about 40 mg to about 50 mg of compound (1):
[0701]
[0702] and a therapeutically effective amount of an additional antidepressant; and
[0703] (ii) providing a second treatment comprising administering a therapeutically effective amount of said additional antidepressant.
[0704] Embodiment 4. A method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising:
[0705] (i) providing a first treatment comprising administering a combination comprising a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound:
[0706]
[0707] and a therapeutically effective amount of an additional antidepressant; and
[0708] (ii) providing a second treatment comprising administering a therapeutically effective amount of said additional antidepressant.
[0709] Embodiment 5. A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising:
[0710] (i) providing a first treatment comprising administering a combination comprising a therapeutically effective amount of compound (1):
[0711]
[0712] and a therapeutically effective amount of an additional antidepressant; and
[0713] (ii) providing a second treatment comprising administering a therapeutically effective amount of said additional antidepressant,
[0714] None of the subjects had received treatment.
[0715] Embodiment 6. A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising:
[0716] (i) providing a first treatment comprising administering a combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0717]
[0718] and a therapeutically effective amount of an additional antidepressant; and
[0719] (ii) providing a second treatment comprising administering a therapeutically effective amount of said additional antidepressant,
[0720] None of the subjects had received treatment.
[0721] Embodiment 7. A method for reducing gastrointestinal treatment-emergent adverse events during antidepressant therapy in a subject in need thereof, comprising:
[0722] (i) providing a first treatment comprising administering a combination comprising a therapeutically effective amount of compound (1):
[0723]
[0724]
[0725] and a therapeutically effective amount of an additional antidepressant; and
[0726] (ii) providing a second treatment comprising administering a therapeutically effective amount of said additional antidepressant.
[0727] Embodiment 8. A method for reducing gastrointestinal treatment-emergent adverse events during antidepressant therapy in a subject in need thereof, comprising:
[0728] (i) providing a first treatment comprising administering a combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of:
[0729]
[0730] and a therapeutically effective amount of an additional antidepressant; and
[0731] (ii) providing a second treatment comprising administering a therapeutically effective amount of said additional antidepressant.
[0732] Embodiment 9. A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising
[0733] (i) administering a combination comprising a therapeutically effective amount of compound (1):
[0734]
[0735] and a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine, and desvenlafaxine; followed by
[0736] (ii) administering a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine for at least 28 days.
[0737] Embodiment 10. A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising
[0738] (i) administering a combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1) for about 14 days:
[0739]
[0740] and a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine, and desvenlafaxine; followed by
[0741] (ii) administering a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine for at least 28 days.
[0742] Embodiment 11. A method for treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising:
[0743] (i) administering a combination comprising a therapeutically effective amount of compound (1):
[0744]
[0745] and a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine, and desvenlafaxine; followed by
[0746] (ii) administering a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine for at least 28 days.
[0747] Embodiment 12. A method for treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising:
[0748] (i) administering a combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1) for about 14 days:
[0749]
[0750] and a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine, and desvenlafaxine; followed by
[0751] (ii) administering a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine for at least 28 days.
[0752] Embodiment 13. A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising:
[0753] (i) providing a first treatment comprising co-administering the following for about 14 days
[0754] (a) about 50 mg of compound (1):
[0755]
[0756] and
[0757] (b) a therapeutically effective amount of another antidepressant,
[0758] wherein compound (1) is administered once daily, and wherein compound (1) and the additional antidepressant in the first treatment are administered in separate dosage forms; and
[0759] (ii) providing a second treatment comprising administering a therapeutically effective amount of said additional antidepressant for at least 28 days.
[0760] Embodiment 14. A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising:
[0761] (i) providing a first treatment comprising co-administering the following for about 14 days;
[0762] (a) a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 50 mg of the free base compound:
[0763]
[0764] and
[0765] (b) a therapeutically effective amount of another antidepressant,
[0766] wherein the pharmaceutically acceptable salt of compound (1) is administered once daily, and wherein the pharmaceutically acceptable salt of compound (1) and the additional antidepressant in the first treatment are administered in separate dosage forms; and
[0767] (ii) providing a second treatment comprising administering a therapeutically effective amount of said additional antidepressant for at least 28 days.
[0768] Embodiment 15. The method of any one of embodiments 1, 2, 9 or 10, wherein the subject is experiencing a major depressive episode.
[0769] Embodiment 16. The method of embodiment 15, wherein the subject has elevated anxiety during most days of the major depressive episode.
[0770] Embodiment 17. The method of any one of embodiments 3, 4, 11 or 12, wherein the subject has a HAM-D Anxiety / Somatization subscale score of at least 7 at baseline.
[0771] Embodiment 18. The method of any one of embodiments 3, 4, 11 or 12, wherein the subject has a HAM-A total score of at least 17 or at least 20 at baseline.
[0772] Embodiment 19. The method of any one of embodiments 1-6 or 9-12, wherein administration of the combination reduces adverse events arising from gastrointestinal treatment.
[0773] Embodiment 20. The method of embodiment 13 or 14, wherein providing said first treatment reduces adverse events arising from gastrointestinal treatment.
[0774] Embodiment 21. The method of any one of embodiments 7, 8, 19 or 20, wherein adverse events arising from gastrointestinal treatment include nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, increased appetite or dry mouth, or any combination thereof.
[0775] Embodiment 22. The method of embodiment 21, wherein the adverse events arising from gastrointestinal treatment include nausea and / or diarrhea.
[0776] Embodiment 23. The method of any one of embodiments 7, 8, or 19-22, wherein the gastrointestinal treatment-emergent adverse event is caused by treatment with the additional antidepressant.
[0777] Embodiment 24. The method of any one of embodiments 1-4 or 7-23, wherein the subject is treatment naive.
[0778] Embodiment 25. The method of any one of embodiments 1-4 or 7-23, wherein the subject has not been receiving any antidepressant treatment for at least 30 days prior to the start of said first treatment.
[0779] Embodiment 26. The method of any one of embodiments 1-4 or 7-23, wherein the subject has not been receiving treatment with said additional antidepressant within at least 30 days prior to the start of said first treatment.
[0780] Embodiment 27. The method of any one of embodiments 1-4 or 7-23, wherein the subject has not been receiving treatment with said additional antidepressant within at least 60 days prior to the start of said first treatment.
[0781] Embodiment 28. The method of any one of embodiments 1-8, wherein the first treatment administers the combination for about 14 days.
[0782] Embodiment 29. The method of any one of embodiments 1-8, wherein the second treatment administers the additional antidepressant for at least 28 days.
[0783] Embodiment 30. The method of any one of embodiments 1-8, wherein the additional antidepressant is administered at the same dose in the first treatment and the second treatment.
[0784] Embodiment 31. The method of any one of embodiments 1-8, wherein the additional antidepressant is administered at different doses in the first treatment and the second treatment.
[0785] Embodiment 32. The method of any one of Embodiments 1-8, wherein Compound (1) or a pharmaceutically acceptable salt of Compound (1) is not administered to the subject in the second treatment.
[0786] Embodiment 33. The method of any one of embodiments 1-8, wherein in the first treatment compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant are administered in separate dosage forms.
[0787] Embodiment 34. The method of embodiment 33, wherein in said first treatment compound (1) or a pharmaceutically acceptable salt thereof and said additional antidepressant are administered at the same time.
[0788] Embodiment 35. The method of embodiment 33, wherein in said first treatment compound (1) or a pharmaceutically acceptable salt thereof and said additional antidepressant are administered at different times.
[0789] Embodiment 36. The method of any one of embodiments 9-14, wherein the additional antidepressant in (i) and (ii) is administered at the same dose.
[0790] Embodiment 37. The method of any one of embodiments 9-14, wherein the additional antidepressant in (i) and (ii) is administered at different doses.
[0791] Embodiment 38. The method of any one of Embodiments 9-14, wherein compound (1) or a pharmaceutically acceptable salt of compound (1) is not administered to the subject in (ii).
[0792] Embodiment 39. The method of any one of embodiments 9-14, wherein the compound (1) or a pharmaceutically acceptable salt thereof in (i) and the additional antidepressant are administered in separate dosage forms.
[0793] Embodiment 40. The method of embodiment 39, wherein the compound (1) or a pharmaceutically acceptable salt thereof in (i) and the additional antidepressant are administered at the same time.
[0794] Embodiment 41. The method of embodiment 39, wherein the compound (1) or a pharmaceutically acceptable salt thereof in (i) and the additional antidepressant are administered at different times.
[0795] Embodiment 42. The method of any one of embodiments 1-41, wherein the additional antidepressant administered in (ii) is the same as the additional antidepressant administered in (i).
[0796] Embodiment 43. The method of any one of embodiments 1-12, wherein compound (1) or a pharmaceutically acceptable salt thereof is administered once a day.
[0797] Embodiment 44. The method of any one of embodiments 5, 7, 9 or 11, wherein compound (1) is administered at a dose of about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg or about 50 mg.
[0798] Embodiment 45. The method of embodiment 1, 3 or 44, wherein compound (1) is administered at a dose of about 50 mg.
[0799] Embodiment 46. The method of embodiment 1, 3 or 44, wherein compound (1) is administered at a dose of about 40 mg.
[0800] Embodiment 47. The method of embodiment 45, wherein compound (1) is administered at a dose of about 50 mg once a day.
[0801] Embodiment 48. The method of embodiment 46, wherein compound (1) is administered at a dose of about 40 mg once a day.
[0802] Embodiment 49. The method of any one of embodiments 6, 8, 10, 12, wherein the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent to about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg or about 50 mg of the free base compound.
[0803] Embodiment 50. The method of embodiment 2, 4 or 49, wherein the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent to about 50 mg of the free base compound.
[0804] Embodiment 51. The method of embodiment 2, 4 or 49, wherein the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent to about 40 mg of the free base compound.
[0805] Embodiment 52. The method of Embodiment 50, wherein the pharmaceutically acceptable salt of compound (1) is administered once daily at a dose equivalent to about 50 mg of the free base compound.
[0806] Embodiment 53. The method of Embodiment 51, wherein the pharmaceutically acceptable salt of compound (1) is administered once daily in a dose equivalent to about 40 mg of the free base compound.
[0807] Embodiment 54. The method of any one of Embodiments 1-53, wherein compound (1) or a pharmaceutically acceptable salt of compound (1) is administered orally, parenterally, intradermally, intrathecally, intramuscularly, subcutaneously, vaginally, buccally, sublingually, rectally, topically, as an inhalant, intranasally, or transdermally.
[0808] Embodiment 55. The method of Embodiment 54, wherein compound (1) or a pharmaceutically acceptable salt of compound (1) is administered orally.
[0809] Embodiment 56. The method of any one of Embodiments 1-55, wherein compound (1) or a pharmaceutically acceptable salt of compound (1) is administered with food.
[0810] Embodiment 57. The method of any one of Embodiments 1-56, wherein compound (1) or a pharmaceutically acceptable salt of compound (1) is administered once a day in the evening.
[0811] Embodiment 58. The method of any one of Embodiments 1-57, wherein the subject is re-administered with a combination of Compound (1) or a pharmaceutically acceptable salt of Compound (1) and an additional antidepressant in response to a recurrence of depressive symptoms.
[0812] Embodiment 59. The method of embodiment 58, wherein there is an interval of at least 6 weeks between the last dose of the first treatment and the first dose of the re-administration.
[0813] Embodiment 60. The method of any one of Embodiments 1, 3, 5, 7, 9, 11 or 13, wherein compound (1) is in a crystalline form having an XRPD pattern comprising peaks between 9.7 and 10.1 °2θ, inclusive, between 11.6 and 12.0 °2θ, inclusive, between 13.2 and 13.6 °2θ, inclusive, between 14.2 and 14.6 °2θ, inclusive, between 14.6 and 15.0 °2θ, inclusive, between 16.8 and 17.2 °2θ, inclusive, between 20.5 and 20.9 °2θ, inclusive, between 21.3 and 21.7 °2θ, inclusive, between 21.4 and 21.8 °2θ, and inclusive, and between 22.4 and 22.8 °2θ.
[0814] Embodiment 61. The method of any one of Embodiments 1, 3, 5, 7, 9, 11 or 13, wherein compound (1) is in a crystalline form having an XRPD pattern comprising peaks between 9.3 and 9.7 °2θ, inclusive, between 10.6 and 11.0 °2θ, inclusive, between 13.0 and 13.4 °2θ, inclusive, between 14.7 and 15.1 °2θ, inclusive, between 15.8 and 16.2 °2θ, inclusive, between 18.1 and 18.5 °2θ, inclusive, between 18.7 and 19.1 °2θ, inclusive, between 20.9 and 21.3 °2θ, inclusive, between 21.4 and 21.8 °2θ, and between 23.3 and 23.7 °2θ.
[0815] Embodiment 62. The method of any one of Embodiments 1, 3, 5, 7, 9, 11 or 13, wherein compound (1) is in a crystalline form having an XRPD pattern comprising peaks between 9.7 and 10.1 °2θ, inclusive, between 14.6 and 15.0 °2θ, inclusive, between 16.8 and 17.2 °2θ, inclusive, between 20.5 and 20.9 °2θ, inclusive, and between 21.3 and 21.7 °2θ, inclusive.
[0816] Embodiment 63. The method of any one of Embodiments 1, 3, 5, 7, 9, 11 or 13, wherein compound (1) is in a crystalline form having an XRPD pattern comprising peaks between 9.3 and 9.7 °2θ, inclusive, between 10.6 and 11.0 °2θ, inclusive, between 13.0 and 13.4 °2θ, inclusive, between 18.7 and 19.1 °2θ, inclusive, and between 21.4 and 21.8 °2θ, inclusive.
[0817] Embodiment 64. The method of any one of embodiments 1-63, wherein the additional antidepressant described in (i) and (ii) is a selective serotonin reuptake inhibitor (SSRI), a serotonin norepinephrine reuptake inhibitor (SNRI), a serotonin modulator and stimulator (SMS), a serotonin antagonist and reuptake inhibitor (SARI), a norepinephrine reuptake inhibitor (NRI), a norepinephrine dopamine reuptake inhibitor (NDRI), a tricyclic antidepressant (TCA), a tetracyclic antidepressant antipsychotic drugs (TeCA), monoamine oxidase inhibitors (MAOIs), atypical antipsychotics, agomelatine, esketamine, tianeptine, ketamine, alpha-methyltryptamine, ethyltryptamine, ethyltryptamine, indolozine, medixamine, oxaflophen, pitavagine, adenosine methionine, hypericum perforatum, hydroxytryptophan, tryptophan, trifluoperazine, buspirone, lithium, thyroxine, triiodothyronine, amitriptyline and chlordiazepoxide, amitriptyline and perphenazine, flupentixol and melitracen, olanzapine and fluoxetine, or tranylcypromine and trifluoperazine.
[0818] Embodiment 65. The method of embodiment 64, wherein the additional antidepressant in (i) or (ii) is an SSRI.
[0819] Embodiment 66. The method of embodiment 65, wherein the SSRI is sertraline, escitalopram, citalopram, fluvoxamine, paroxetine, fluoxetine, indalpine, or zolpidem.
[0820] Embodiment 67. The method of embodiment 66, wherein the SSRI is sertraline.
[0821] Embodiment 68. The method of embodiment 66, wherein the SSRI is escitalopram.
[0822] Embodiment 69. The method of Embodiment 66, wherein the SSRI is citalopram.
[0823] Embodiment 70. The method of embodiment 64, wherein the additional antidepressant agent described in (i) or (ii) is a SNRI.
[0824] Embodiment 71. The method of embodiment 70, wherein the SNRI is duloxetine, desvenlafaxine, levomilnacipran, milnacipran, or venlafaxine.
[0825] Embodiment 72. The method of Embodiment 71, wherein the SNRI is duloxetine.
[0826] Embodiment 73. The method of Embodiment 71, wherein the SNRI is desvenlafaxine.
[0827] Embodiment 74. The method of embodiment 64, wherein the additional antidepressant in (i) or (ii) is SMS.
[0828] Embodiment 75. The method of Embodiment 74, wherein the SMS is vilazodone or vortioxetine.
[0829] Embodiment 76. The method of embodiment 64, wherein the additional antidepressant agent described in (i) or (ii) is a SARI.
[0830] Embodiment 77. The method of Embodiment 76, wherein the SARI is nefazodone, trazodone, or etoperidone.
[0831] Embodiment 78. The method of embodiment 64, wherein the additional antidepressant agent described in (i) or (ii) is an NRI.
[0832] Embodiment 79. The method of embodiment 78, wherein the NRI is reboxetine, tenisazine, viloxazine, or atomoxetine.
[0833] Embodiment 80. The method of embodiment 64, wherein the additional antidepressant agent described in (i) or (ii) is an NDRI.
[0834] Embodiment 81. The method of embodiment 80, wherein the NDRI is bupropion, amphetamine, methylphenidate, modafinil, amineptine, or nomifensine.
[0835] Embodiment 82. The method of embodiment 64, wherein the additional antidepressant agent described in (i) or (ii) is a TCA.
[0836] Embodiment 83. The method of embodiment 82, wherein the TCA is amitriptyline, amitriptyline oxy, clomipramine, desipramine, dibenzepine, dimetholine, dosluepin, doxepin, imipramine, lofepramine, melitracen, nitrazepam, nortriptyline, noxetyl, opipramol, pipofilazine, protriptyline, trimipramine, butriptyline, demetriptyline, fluoxetine, oxymipramine, iprindol, metapramine, propazepine, quinupramine, thiozepine, or tolfenacin
[0837] Embodiment 84. The method of embodiment 64, wherein the additional antidepressant in (i) or (ii) is TeCA.
[0838] Embodiment 85. The method of embodiment 84, wherein TeCA is amoxapine, maprotiline, mianserin, mirtazapine, or setiptiline.
[0839] Embodiment 86. The method of embodiment 64, wherein the additional antidepressant in (i) or (ii) is a MAOI.
[0840] Embodiment 87. The method of embodiment 86, wherein the MAOI is isocarboxazid, phenelzine, tranylcypromine, phenmosin, iproclorazepam, iproniazid, mebanazine, nyalamide, octamoxin, pheniprozine, phenoxyprozine, pivalazine, safrazine, selegiline, caroxadone, metrindol, moclobemide, pyrindole, eprobemide, bendamorph, toloxatone, or difemelane.
[0841] Embodiment 88. The method of embodiment 64, wherein the additional antidepressant in (i) or (ii) is an atypical antipsychotic.
[0842] Embodiment 89. The method of embodiment 88, wherein the atypical antipsychotic is amisulpride, lumepirone, lurasidone, quetiapine, aripiprazole, epiriprazole, lumepirone, lurasidone, olanzapine, quetiapine, or risperidone.
[0843] Embodiment 90. The method of embodiment 64, wherein the additional antidepressant in (i) or (ii) is agomelatine, esketamine, tianeptine, ketamine, alpha-methyltryptamine, ethyltryptamine, ethyltryptamine, indolozine, medixamine, oxafluxane, pitavagine, adenosine methionine, hypericum perforatum, hydroxytryptophan, tryptophan, trifluoperazine, buspirone, lithium, thyroxine, triiodothyronine, amitriptyline and chlordiazepoxide, amitriptyline and perphenazine, flupentixol and melitracen, olanzapine and fluoxetine, or tranylcypromine and trifluoperazine.
[0844] Embodiment 91. The method of any one of embodiments 1-63, wherein the additional antidepressant in (i) or (ii) is 4-chlorokynurenine (AV-101), Apimostinel (NRX-1074), Levo-ketamine (PCN-101, HR-071603), Dextromethadone (REL-1017), MIJ-821, Rislenemdaz (CERC-301, MK-0657), TAK-653 (NBI-1065845) , OPC-64005, PDC-1421 (BLI-1005), torudivenlafaxine, hydroxypiperidone (YL-0919), TGBA01AD (FKB01MD), vortioxetine, lisdexamfetamine dimesylate, methylenedioxymethamphetamine, (R)-amisulpride / (S)-amisulpride (85:15 ratio) (SEP-4199), gepirone, pramipexole, psilocybin, brilaroxazine, cariprazine, lumepirone, lurasidone, pimavanserin , adenosine methionine, 3β-methoxypregnenolone (MAP-4343), PH-10–vomeropherine, Aticaprant, BTRX-335140 (BTRX-140), buprenorphine / samidorphine, BTRX-246040 (LY-2940094), scopolamine (DPI-386), JNJ-39393406, botulinum toxin type A, JNJ-61393215, Seltorexant, BI-135 8894, Crisdesalazine, Erteberel, JNJ-54175446, NSI-189, NV-5138, SNG-12, TS-121, WIP-DF17, tramadol, bupropion / dextromethorphan (AXS-05), carbidopa / hydroxytryptophan (EVX-101), cycloserine / lurasidone (NRX-101; Cyclurad), or deuterated dextromethorphan / quinidine (AVP-786, CTP-786).
[0845] Embodiment 92. The method of any one of embodiments 1-91, wherein the additional antidepressant is administered according to the prescribing information of its label.
[0846] Embodiment 93. A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of compound (1):
[0847]
[0848] and a therapeutically effective amount of another antidepressant,
[0849] None of the subjects had received treatment.
[0850] Embodiment 94. A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0851]
[0852] and a therapeutically effective amount of another antidepressant,
[0853] None of the subjects had received treatment.
[0854] Embodiment 95. A method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of compound (1):
[0855]
[0856] and a therapeutically effective amount of another antidepressant,
[0857] None of the subjects had received treatment.
[0858] Embodiment 96. A method for treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0859]
[0860] and a therapeutically effective amount of another antidepressant,
[0861] None of the subjects had received treatment.
[0862] Embodiment 97. A method for reducing adverse events arising from gastrointestinal treatment with antidepressant therapy in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of compound (1):
[0863]
[0864] and a therapeutically effective amount of another antidepressant
[0865] None of the subjects had received treatment.
[0866] Embodiment 98. A method for reducing adverse events in the gastrointestinal tract during antidepressant therapy in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0867]
[0868] and a therapeutically effective amount of another antidepressant
[0869] None of the subjects had received treatment.
[0870] Embodiment 99. A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising administering a combination for about 14 days, the combination comprising a therapeutically effective amount of compound (1):
[0871]
[0872] and a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine, and desvenlafaxine;
[0873] None of the subjects had received treatment.
[0874] Embodiment 100. A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising administering a combination for about 14 days, the combination comprising a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[0875]
[0876] and a therapeutically effective amount of an additional antidepressant selected from sertraline, escitalopram, citalopram, duloxetine, and desvenlafaxine;
[0877] None of the subjects had received treatment.
[0878] Embodiment 101. A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising administering a combination comprising about 40 mg to about 50 mg of compound (1):
[0879]
[0880] and a therapeutically effective amount of an additional antidepressant.
[0881] Embodiment 102. A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising administering a combination comprising a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound:
[0882]
[0883] and a therapeutically effective amount of an additional antidepressant.
[0884] Embodiment 103. The method of any one of embodiments 93, 94, or 99-102, wherein the subject is experiencing a major depressive episode.
[0885] Embodiment 104. The method of embodiment 103, wherein the subject has elevated anxiety during most days of the major depressive episode.
[0886] Embodiment 105. The method of any one of Embodiments 95, 96 or 104, wherein the subject has a HAM-D Anxiety / Somatization subscale score of at least 7 at baseline.
[0887] Embodiment 106. The method of any one of embodiments 95, 96 or 104, wherein the subject has a HAM-A total score of at least 17 or at least 20 at baseline.
[0888] Embodiment 107. The method of any one of embodiments 93-96 or 99-102, wherein administration of the combination reduces adverse events arising from gastrointestinal treatment.
[0889] Embodiment 108. The method of embodiment 97 or 98, wherein providing the combination reduces adverse events occurring during gastrointestinal treatment.
[0890] Embodiment 109. The method of any one of embodiments 97, 98, 107 or 108, wherein adverse events arising from gastrointestinal treatment include nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, increased appetite or dry mouth, or any combination thereof.
[0891] Embodiment 110. The method of embodiment 109, wherein the adverse events arising from gastrointestinal treatment include nausea and / or diarrhea.
[0892] Embodiment 111. The method of any one of embodiments 97, 98, or 107-110, wherein the gastrointestinal treatment-emergent adverse event results from treatment with an additional antidepressant.
[0893] Embodiment 112. The method of any one of Embodiments 93-111, wherein the subject has not been receiving any antidepressant treatment for at least 30 days prior to the start of treatment.
[0894] Embodiment 113. The method of any one of Embodiments 93-111, wherein the subject has not been receiving treatment with the additional antidepressant within at least 30 days prior to initiating treatment.
[0895] Embodiment 114. The method of any one of Embodiments 93-111, wherein the subject has not been receiving treatment with the additional antidepressant within at least 60 days prior to initiating treatment.
[0896] Embodiment 115. The method of any one of embodiments 93-98 or 101-102, wherein the treatment administers the combination for about 14 days.
[0897] Embodiment 116. The method of any one of embodiments 93-102, wherein compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant in the combination are administered in separate dosage forms.
[0898] Embodiment 117. The method of embodiment 116, wherein compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant in the combination are administered at the same time.
[0899] Embodiment 118. The method of embodiment 116, wherein compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant in the combination are administered at different times.
[0900] Embodiment 119. The method of any one of Embodiments 93-118, wherein the treatment further comprises a second treatment comprising administering a therapeutically effective amount of an additional antidepressant.
[0901] Embodiment 120. The method of embodiment 119, wherein the second treatment administers the additional antidepressant for at least 28 days.
[0902] Embodiment 121. The method of embodiment 119, wherein the additional antidepressant is administered in the second treatment at the same dose as in the combination.
[0903] Embodiment 122. The method of embodiment 119, wherein the additional antidepressant is administered in a different dose in the second treatment compared to the dose administered in the combination.
[0904] Embodiment 123. The method of Embodiment 119, wherein Compound (1) or a pharmaceutically acceptable salt of Compound (1) is not administered to the subject in the second treatment.
[0905] Embodiment 124. The method of any one of embodiments 119-123, wherein the additional antidepressant administered in the second treatment is the same as the additional antidepressant administered in the combination.
[0906] Embodiment 125. The method of any one of embodiments 93-102, wherein compound (1) or a pharmaceutically acceptable salt thereof is administered once a day.
[0907] Embodiment 126. The method of any one of embodiments 93, 95, 97 or 99, wherein compound (1) is administered at a dose of about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg or about 50 mg.
[0908] Embodiment 127. The method of embodiment 101 or 126, wherein compound (1) is administered at a dose of about 50 mg.
[0909] Embodiment 128. The method of embodiment 101 or 126, wherein compound (1) is administered at a dose of about 40 mg.
[0910] Embodiment 129. The method of embodiment 127, wherein compound (1) is administered at a dose of about 50 mg once a day.
[0911] Embodiment 130. The method of embodiment 128, wherein compound (1) is administered at a dose of about 40 mg once a day.
[0912] Embodiment 131. The method of any one of embodiments 94, 96, 98 or 100, wherein the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent to about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg or about 50 mg of the free base compound.
[0913] Embodiment 132. The method of embodiment 102 or 131, wherein the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent to about 50 mg of the free base compound.
[0914] Embodiment 133. The method of embodiment 102 or 131, wherein the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent to about 40 mg of the free base compound.
[0915] Embodiment 134. The method of Embodiment 132, wherein the pharmaceutically acceptable salt of compound (1) is administered once daily at a dose equivalent to about 50 mg of the free base compound.
[0916] Embodiment 135. The method of Embodiment 133, wherein the pharmaceutically acceptable salt of compound (1) is administered once daily at a dose equivalent to about 40 mg of the free base compound.
[0917] Embodiment 136. The method of any one of Embodiments 93-135, wherein compound (1) or a pharmaceutically acceptable salt of compound (1) is administered orally, parenterally, intradermally, intrathecally, intramuscularly, subcutaneously, vaginally, buccally, sublingually, rectally, topically, as an inhalant, intranasally, or transdermally.
[0918] Embodiment 137. The method of Embodiment 136, wherein compound (1) or a pharmaceutically acceptable salt of compound (1) is administered orally.
[0919] Embodiment 138. The method of any one of Embodiments 93-137, wherein compound (1) or a pharmaceutically acceptable salt of compound (1) is administered with food.
[0920] Embodiment 139. The method of any one of Embodiments 93-138, wherein compound (1) or a pharmaceutically acceptable salt of compound (1) is administered once a day in the evening.
[0921] Embodiment 140. The method of any one of Embodiments 93-139, wherein the subject is re-administered with a combination of Compound (1) or a pharmaceutically acceptable salt of Compound (1) and an additional antidepressant in response to a recurrence of depressive symptoms.
[0922] Embodiment 141. The method of embodiment 140, wherein there is an interval of at least 6 weeks between the last dose of the first treatment and the first dose of the re-administration.
[0923] Embodiment 142. The method of any one of Embodiments 93, 95, 97, 99 or 101, wherein compound (1) is in a crystalline form having an XRPD pattern comprising peaks between 9.7 and 10.1 °2θ, inclusive, between 11.6 and 12.0 °2θ, inclusive, between 13.2 and 13.6 °2θ, inclusive, between 14.2 and 14.6 °2θ, inclusive, between 14.6 and 15.0 °2θ, inclusive, between 16.8 and 17.2 °2θ, inclusive, between 20.5 and 20.9 °2θ, inclusive, between 21.3 and 21.7 °2θ, inclusive, between 21.4 and 21.8 °2θ, and inclusive, and between 22.4 and 22.8 °2θ.
[0924] Embodiment 143. The method of any one of Embodiments 93, 95, 97, 99 or 101, wherein compound (1) is in a crystalline form having an XRPD pattern comprising peaks between 9.3 and 9.7 °2θ, inclusive, between 10.6 and 11.0 °2θ, inclusive, between 13.0 and 13.4 °2θ, inclusive, between 14.7 and 15.1 °2θ, inclusive, between 15.8 and 16.2 °2θ, inclusive, between 18.1 and 18.5 °2θ, inclusive, between 18.7 and 19.1 °2θ, inclusive, between 20.9 and 21.3 °2θ, inclusive, between 21.4 and 21.8 °2θ, and between 23.3 and 23.7 °2θ.
[0925] Embodiment 144. The method of any one of Embodiments 93, 95, 97, 99 or 101, wherein compound (1) is in a crystalline form having an XRPD pattern comprising peaks between 9.7 and 10.1 °2θ, inclusive, between 14.6 and 15.0 °2θ, inclusive, between 16.8 and 17.2 °2θ, inclusive, between 20.5 and 20.9 °2θ, inclusive, and between 21.3 and 21.7 °2θ, inclusive.
[0926] Embodiment 145. The method of any one of Embodiments 93, 95, 97, 99 or 101, wherein compound (1) is in a crystalline form having an XRPD pattern comprising peaks between 9.3 and 9.7 °2θ, inclusive, between 10.6 and 11.0 °2θ, inclusive, between 13.0 and 13.4 °2θ, inclusive, between 18.7 and 19.1 °2θ, inclusive, and between 21.4 and 21.8 °2θ, inclusive.
[0927] Embodiment 146. The method of any one of embodiments 93-145, wherein the additional antidepressant in the combination and the second treatment is a selective serotonin reuptake inhibitor (SSRI), a serotonin norepinephrine reuptake inhibitor (SNRI), a serotonin modulator and stimulator (SMS), a serotonin antagonist and reuptake inhibitor (SARI), a norepinephrine reuptake inhibitor (NRI), a norepinephrine dopamine reuptake inhibitor (NDRI), a tricyclic antidepressant (TCA), a tetracyclic antidepressant (TCA), a Depressants (TeCA), monoamine oxidase inhibitors (MAOIs), atypical antipsychotics, agomelatine, esketamine, tianeptine, ketamine, alpha-methyltryptamine, ethyltryptamine, ethyltryptamine, indolozine, medixamine, oxaflophen, pitavagine, adenosine methionine, hypericum perforatum, hydroxytryptophan, tryptophan, trifluoperazine, buspirone, lithium, thyroxine, triiodothyronine, amitriptyline and chlordiazepoxide, amitriptyline and perphenazine, flupentixol and melitracen, olanzapine and fluoxetine, or tranylcypromine and trifluoperazine.
[0928] Embodiment 147. The method of embodiment 146, wherein the additional antidepressant in the combination and the second treatment is an SSRI.
[0929] Embodiment 148. The method of embodiment 147, wherein the SSRI is sertraline, escitalopram, citalopram, fluvoxamine, paroxetine, fluoxetine, indalpine, or zolpidem.
[0930] Embodiment 149. The method of embodiment 148, wherein the SSRI is sertraline.
[0931] Embodiment 150. The method of Embodiment 148, wherein the SSRI is escitalopram.
[0932] Embodiment 151. The method of Embodiment 148, wherein the SSRI is citalopram.
[0933] Embodiment 152. The method of Embodiment 146, wherein the additional antidepressant in the combination and the second treatment is a SNRI.
[0934] Embodiment 153. The method of embodiment 152, wherein the SNRI is duloxetine, desvenlafaxine, levomilnacipran, milnacipran, or venlafaxine.
[0935] Embodiment 154. The method of Embodiment 153, wherein the SNRI is duloxetine.
[0936] Embodiment 155. The method of Embodiment 153, wherein the SNRI is desvenlafaxine.
[0937] Embodiment 156. The method of Embodiment 146, wherein the additional antidepressant in the combination and the second treatment is SMS.
[0938] Embodiment 157. The method of Embodiment 156, wherein the SMS is vilazodone or vortioxetine.
[0939] Embodiment 158. The method of Embodiment 146, wherein the additional antidepressant in the combination and the second treatment is a SARI.
[0940] Embodiment 159. The method of Embodiment 158, wherein the SARI is nefazodone, trazodone, or etoperidone.
[0941] Embodiment 160. The method of Embodiment 146, wherein the additional antidepressant in the combination and the second treatment is an NRI.
[0942] Embodiment 161. The method of Embodiment 160, wherein the NRI is reboxetine, tenisazine, viloxazine, or atomoxetine.
[0943] Embodiment 162. The method of Embodiment 146, wherein the additional antidepressant in the combination and the second treatment is an NDRI.
[0944] Embodiment 163. The method of embodiment 162, wherein the NDRI is bupropion, amphetamine, methylphenidate, modafinil, amineptine, or nomifensine.
[0945] Embodiment 164. The method of Embodiment 146, wherein the additional antidepressant in the combination and the second treatment is a TCA.
[0946] Embodiment 165. The method of embodiment 164, wherein the TCA is amitriptyline, amitriptyline oxy, clomipramine, desipramine, dibenzepine, dimetholine, dosluepin, doxepin, imipramine, lofepramine, melitracen, nitrazepam, nortriptyline, noxetylline, opipramol, pipofiazine, protriptyline, trimipramine, butriptyline, demetriptyline, fluocinol, oxymipramine, iprapindol, metapramine, propipepine, quinupramine, thiozepine, or tolfenacin.
[0947] Embodiment 166. The method of Embodiment 146, wherein the additional antidepressant in the combination and the second treatment is TeCA.
[0948] Embodiment 167. The method of Embodiment 166, wherein the TeCA is amoxapine, maprotiline, mianserin, mirtazapine, or setiptiline.
[0949] Embodiment 168. The method of Embodiment 146, wherein the additional antidepressant in the combination and the second treatment is a MAOI.
[0950] Embodiment 169. The method of embodiment 168, wherein the MAOI is isocarboxazid, phenelzine, tranylcypromine, phenmosin, iproclorazepam, iproniazid, mebanazine, nyalamide, octamoxin, pheniprozine, phenoxyprozine, pivalazine, safrazine, selegiline, caroxadone, metrindol, moclobemide, pyrindol, eprobemide, bendamorph, toloxatone, or difemelane.
[0951] Embodiment 170. The method of Embodiment 146, wherein the additional antidepressant in the combination and the second treatment is an atypical antipsychotic.
[0952] Embodiment 171. The method of embodiment 170, wherein the atypical antipsychotic is amisulpride, lumepirone, lurasidone, quetiapine, aripiprazole, epiriprazole, lumepirone, lurasidone, olanzapine, quetiapine, or risperidone.
[0953] Embodiment 172. The method of embodiment 146, wherein the additional antidepressant in the combination and the second treatment is agomelatine, esketamine, tianeptine, ketamine, alpha-methyltryptamine, ethyltryptamine, ethyltryptamine, indolazine, medixamine, oxafluxane, pitavagine, adenosine methionine, hypericum perforatum, hydroxytryptophan, tryptophan, trifluoperazine, buspirone, lithium, thyroxine, triiodothyronine, amitriptyline and chlordiazepoxide, amitriptyline and perphenazine, flupentixol and melitracen, olanzapine and fluoxetine, or tranylcypromine and trifluoperazine.
[0954] Embodiment 173. The method of any one of embodiments 93-145, wherein the additional antidepressant in the combination and the second treatment is 4-chlorokynurenine (AV-101), Apimostinel (NRX-1074), Levo-ketamine (PCN-101, HR-071603), Dextromethadone (REL-1017), MIJ-821, Rislenemdaz (CERC-301, MK-0657), TAK-653 (NBI-106 5845), OPC-64005, PDC-1421 (BLI-1005), torudivenlafaxine, hydroxypiperidone (YL-0919), TGBA01AD (FKB01MD), vortioxetine, lisdexamfetamine dimesylate, methylenedioxymethamphetamine, (R)-amisulpride / (S)-amisulpride (85:15 ratio) (SEP-4199), gepirone, pramipexole, psilocybin, brilaroxazine, cariprazine, lumepirone, lurasidone, pimoxetine Vanserin, adenosine methionine, 3β-methoxypregnenolone (MAP-4343), PH-10–vomeropherine, Aticaprant, BTRX-335140 (BTRX-140), buprenorphine / samidorphen, BTRX-246040 (LY-2940094), scopolamine (DPI-386), JNJ-39393406, botulinum toxin type A, JNJ-61393215, Seltorexant, BI-1 358894, Crisdesalazine, Erteberel, JNJ-54175446, NSI-189, NV-5138, SNG-12, TS-121, WIP-DF17, tramadol, bupropion / dextromethorphan (AXS-05), carbidopa / hydroxytryptophan (EVX-101), cycloserine / lurasidone (NRX-101; Cyclurad), or deuterated dextromethorphan / quinidine (AVP-786, CTP-786).
[0955] Embodiment 174. The method of any one of Embodiments 93-173, wherein the additional antidepressant is administered according to the prescribing information of its label.
[0956] Embodiment 175. A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with about 40 mg to about 50 mg of compound (1):
[0957]
[0958] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0959] The antidepressant is continued to be administered after the 14th day of treatment.
[0960] Embodiment 176. A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound:
[0961]
[0962] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0963] The antidepressant is continued to be administered after the 14th day of treatment.
[0964] Embodiment 177. A method of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with about 40 mg to about 50 mg of compound (1):
[0965]
[0966] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0967] The antidepressant is continued to be administered after the 14th day of treatment.
[0968] Embodiment 178. A method for treating major depressive disorder (MDD) associated with elevated anxiety in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound:
[0969]
[0970] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0971] The antidepressant is continued to be administered after the 14th day of treatment.
[0972] Embodiment 179. A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of compound (1):
[0973]
[0974] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0975] wherein the antidepressant is continued to be administered after the 14th day of treatment,
[0976] None of the subjects had received treatment.
[0977] Embodiment 180. A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of a pharmaceutically acceptable salt of Compound (1):
[0978]
[0979] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0980] Antidepressants were continued after the 14th day of treatment.
[0981] None of the subjects had received treatment.
[0982] Embodiment 181. A method for reducing gastrointestinal treatment-emergent adverse events in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of compound (1):
[0983]
[0984] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0985] The antidepressant is continued to be administered after the 14th day of treatment.
[0986] Embodiment 182. A method for reducing gastrointestinal treatment-emergent adverse events in a subject in need thereof treated with an antidepressant, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of a pharmaceutically acceptable salt of Compound (1):
[0987]
[0988] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0989] Antidepressants were continued after the 14th day of treatment.
[0990] Embodiment 183. A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of compound (1):
[0991]
[0992] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0993] Antidepressants were continued after the 14th day of treatment.
[0994] The antidepressants are selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine.
[0995] Embodiment 184. A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of a pharmaceutically acceptable salt of Compound (1):
[0996]
[0997] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[0998] Antidepressants were continued after the 14th day of treatment.
[0999] The antidepressants are selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine.
[1000] Embodiment 185. A method of treating major depressive disorder (MDD) associated with elevated anxiety in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of compound (1):
[1001]
[1002] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[1003] Antidepressants were continued after the 14th day of treatment.
[1004] The antidepressants are selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine.
[1005] Embodiment 186. A method for treating major depressive disorder (MDD) associated with elevated anxiety in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a therapeutically effective amount of a pharmaceutically acceptable salt of compound (1):
[1006]
[1007] wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment,
[1008] Antidepressants were continued after the 14th day of treatment.
[1009] The antidepressants are selected from sertraline, escitalopram, citalopram, duloxetine and desvenlafaxine.
[1010] Embodiment 187. The method of any one of embodiments 175-176, 179-180, or 183-184, wherein the subject is experiencing a major depressive episode.
[1011] Embodiment 188. The method of Embodiment 187, wherein the subject has elevated anxiety during most days of the major depressive episode.
[1012] Embodiment 189. The method of any one of Embodiments 177-178, 185-186, or 188, wherein the subject has a HAM-D Anxiety / Somatization subscale score of at least 7 at baseline.
[1013] Embodiment 190. The method of any one of embodiments 177-178, 185-186 or 188, wherein the subject has a HAM-A total score of at least 17 or at least 20 at baseline.
[1014] Embodiment 191. The method of any one of embodiments 175-180 or 183-186, wherein co-administration reduces adverse events arising from gastrointestinal treatment.
[1015] Embodiment 192. The method of embodiment 181 or 182, wherein providing co-administration reduces adverse events arising from gastrointestinal treatment.
[1016] Embodiment 193. The method of any one of embodiments 181, 182, 191 or 192, wherein adverse events arising from gastrointestinal treatment comprise nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, increased appetite or dry mouth, or any combination thereof.
[1017] Embodiment 194. The method of embodiment 193, wherein the adverse events arising from gastrointestinal treatment include nausea and / or diarrhea.
[1018] Embodiment 195. The method of any one of embodiments 181, 182, or 192-194, wherein the gastrointestinal treatment-emergent adverse event is caused by treatment with an antidepressant.
[1019] Embodiment 196. The method of any one of embodiments 175-178 or 181-195, wherein the subject is treatment naive.
[1020] Embodiment 197. The method of any one of embodiments 175-178 or 181-195, wherein the subject has not been receiving any antidepressant treatment for at least 30 days prior to the start of co-administration.
[1021] Embodiment 198. The method of any one of embodiments 175-178 or 181-195, wherein the subject has not been receiving treatment with the antidepressant within at least 30 days prior to the start of co-administration.
[1022] Embodiment 199. The method of any one of embodiments 175-178 or 181-195, wherein the subject has not been receiving treatment with the antidepressant for at least 60 days prior to the start of co-administration.
[1023] Embodiment 200. The method of any one of Embodiments 175-199, wherein administration of the antidepressant is continued for at least an additional 28 days after the 14th day of treatment.
[1024] Embodiment 201. The method of any one of Embodiments 175-199, wherein Compound (1) or a pharmaceutically acceptable salt of Compound (1) is not administered after the 14th day of treatment.
[1025] Embodiment 202. The method of any one of embodiments 175-201, wherein the compound (1) or a pharmaceutically acceptable salt thereof and the antidepressant in the co-administration are administered in separate dosage forms.
[1026] Embodiment 203. The method of embodiment 203, wherein the compound (1) or a pharmaceutically acceptable salt thereof and the antidepressant in the co-administration are administered at the same time.
[1027] Embodiment 204. The method of embodiment 203, wherein the compound (1) or a pharmaceutically acceptable salt thereof and the antidepressant in the co-administration are administered at different times.
[1028] Embodiment 205. The method of any one of Embodiments 175-204, wherein the antidepressant is administered at the same dose from day 1 of treatment to about day 14 of treatment and after day 14 of treatment.
[1029] Embodiment 206. The method of any one of Embodiments 175-204, wherein the antidepressant is administered at the same dose from day 1 of treatment to about day 14 of treatment and thereafter.
[1030] Embodiment 207. The method of any one of Embodiments 175-206, wherein compound (1) or a pharmaceutically acceptable salt thereof is administered once a day.
[1031] Embodiment 208. The method of any one of embodiments 179, 181, 183 and 185, wherein compound (1) is administered at a dose of about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg or about 50 mg.
[1032] Embodiment 209. The method of embodiment 175, 177 or 208, wherein compound (1) is administered at a dose of about 50 mg.
[1033] Embodiment 210. The method of embodiment 175, 177 or 208, wherein compound (1) is administered at a dose of about 40 mg.
[1034] Embodiment 211. The method of Embodiment 209, wherein compound (1) is administered at a dose of about 50 mg once a day.
[1035] Embodiment 212. The method of embodiment 210, wherein compound (1) is administered at a dose of about 40 mg once a day.
[1036] Embodiment 213. The method of any one of Embodiments 180, 182, 184 and 186, wherein the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent to about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg or about 50 mg of the free base compound.
[1037] Embodiment 214. The method of Embodiment 176, 178 or 213, wherein the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent to about 50 mg of the free base compound.
[1038] Embodiment 215. The method of Embodiment 176, 178 or 213, wherein the pharmaceutically acceptable salt of compound (1) is administered at a dose equivalent to about 40 mg of the free base compound.
[1039] Embodiment 216. The method of Embodiment 214, wherein the pharmaceutically acceptable salt of compound (1) is administered once daily in a dose equivalent to about 50 mg of the free base compound.
[1040] Embodiment 217. The method of Embodiment 215, wherein the pharmaceutically acceptable salt of compound (1) is administered once daily at a dose equivalent to about 40 mg of the free base compound.
[1041] Embodiment 218. The method of any one of Embodiments 175-217, wherein compound (1) or a pharmaceutically acceptable salt of compound (1) is administered orally, parenterally, intradermally, intrathecally, intramuscularly, subcutaneously, vaginally, buccally, sublingually, rectally, topically, as an inhalant, intranasally, or transdermally.
[1042] Embodiment 219. The method of Embodiment 218, wherein compound (1) or a pharmaceutically acceptable salt of compound (1) is administered orally.
[1043] Embodiment 220. The method of any one of Embodiments 175-219, wherein compound (1) or a pharmaceutically acceptable salt of compound (1) is administered with food.
[1044] Embodiment 221. The method of any one of Embodiments 175-220, wherein compound (1) or a pharmaceutically acceptable salt of compound (1) is administered once daily in the evening.
[1045] Embodiment 222. The method of any one of Embodiments 175-222, wherein co-administration of Compound (1) or a pharmaceutically acceptable salt of Compound (1) and the antidepressant is re-administered to the subject in response to recurrence of depressive symptoms.
[1046] Embodiment 223. The method of embodiment 222, wherein there is an interval of at least 6 weeks between the last dose of the first treatment and the first dose of the re-administration.
[1047] Embodiment 224. The method of any one of Embodiments 175, 177, 179, 181, 183 or 185, wherein compound (1) is in a crystalline form having an XRPD pattern comprising peaks between 9.7 and 10.1 °2θ, inclusive, between 11.6 and 12.0 °2θ, inclusive, between 13.2 and 13.6 °2θ, inclusive, between 14.2 and 14.6 °2θ, inclusive, between 14.6 and 15.0 °2θ, inclusive, between 16.8 and 17.2 °2θ, inclusive, between 20.5 and 20.9 °2θ, inclusive, between 21.3 and 21.7 °2θ, inclusive, between 21.4 and 21.8 °2θ, and inclusive, and between 22.4 and 22.8 °2θ.
[1048] Embodiment 225. The method of any one of Embodiments 175, 177, 179, 181, 183 or 185, wherein compound (1) is in a crystalline form having an XRPD pattern comprising peaks between 9.3 and 9.7 °2θ, inclusive, between 10.6 and 11.0 °2θ, inclusive, between 13.0 and 13.4 °2θ, inclusive, between 14.7 and 15.1 °2θ, inclusive, between 15.8 and 16.2 °2θ, inclusive, between 18.1 and 18.5 °2θ, inclusive, between 18.7 and 19.1 °2θ, inclusive, between 20.9 and 21.3 °2θ, inclusive, between 21.4 and 21.8 °2θ, and between 23.3 and 23.7 °2θ.
[1049] Embodiment 226. The method of any one of Embodiments 175, 177, 179, 181, 183 or 185, wherein compound (1) is in a crystalline form having an XRPD pattern comprising peaks between 9.7 and 10.1 °2θ, inclusive, between 14.6 and 15.0 °2θ, inclusive, between 16.8 and 17.2 °2θ, inclusive, between 20.5 and 20.9 °2θ, inclusive, and between 21.3 and 21.7 °2θ, inclusive.
[1050] Embodiment 227. The method of any one of Embodiments 175, 177, 179, 181, 183 or 185, wherein compound (1) is in a crystalline form having an XRPD pattern comprising peaks between 9.3 and 9.7 °2θ, inclusive, between 10.6 and 11.0 °2θ, inclusive, between 13.0 and 13.4 °2θ, inclusive, between 18.7 and 19.1 °2θ, inclusive, and between 21.4 and 21.8 °2θ, inclusive.
[1051] Embodiment 228. The method of any one of embodiments 175-227, wherein the antidepressant is a selective serotonin reuptake inhibitor (SSRI), a serotonin norepinephrine reuptake inhibitor (SNRI), a serotonin modulator and stimulator (SMS), a serotonin antagonist and reuptake inhibitor (SARI), a norepinephrine reuptake inhibitor (NRI), a norepinephrine dopamine reuptake inhibitor (NDRI), a tricyclic antidepressant (TCA), a tetracyclic antidepressant (TCA), or a tetracyclic antidepressant (TCA). ), monoamine oxidase inhibitors (MAOIs), atypical antipsychotics, agomelatine, esketamine, tianeptine, ketamine, alpha-methyltryptamine, ethyltryptamine, ethyltryptamine, indolozine, medixamine, oxaflophen, pitavagine, adenosine methionine, hypericum perforatum, hydroxytryptophan, tryptophan, trifluoperazine, buspirone, lithium, thyroxine, triiodothyronine, amitriptyline and chlordiazepoxide, amitriptyline and perphenazine, flupentixol and melitracen, olanzapine and fluoxetine, or tranylcypromine and trifluoperazine.
[1052] Embodiment 229. The method of embodiment 228, wherein the antidepressant is an SSRI.
[1053] Embodiment 230. The method of embodiment 229, wherein the SSRI is sertraline, escitalopram, citalopram, fluvoxamine, paroxetine, fluoxetine, indalpine, or zolpidem.
[1054] Embodiment 231. The method of Embodiment 230, wherein the SSRI is sertraline.
[1055] Embodiment 232. The method of Embodiment 230, wherein the SSRI is escitalopram.
[1056] Embodiment 233. The method of Embodiment 230, wherein the SSRI is citalopram.
[1057] Embodiment 234. The method of embodiment 228, wherein the antidepressant is a SNRI.
[1058] Embodiment 235. The method of embodiment 234, wherein the SNRI is duloxetine, desvenlafaxine, levomilnacipran, milnacipran, or venlafaxine
[1059] Embodiment 236. The method of Embodiment 235, wherein the SNRI is duloxetine.
[1060] Embodiment 237. The method of Embodiment 235, wherein the SNRI is desvenlafaxine.
[1061] Embodiment 238. The method of embodiment 228, wherein the antidepressant is SMS.
[1062] Embodiment 239. The method of Embodiment 238, wherein the SMS is vilazodone or vortioxetine.
[1063] Embodiment 240. The method of embodiment 228, wherein the antidepressant is a SARI.
[1064] Embodiment 241. The method of Embodiment 240, wherein the SARI is nefazodone, trazodone, or etoperidone.
[1065] Embodiment 242. The method of embodiment 228, wherein the antidepressant is an NRI.
[1066] Embodiment 243. The method of Embodiment 242, wherein the NRI is reboxetine, tenisazine, viloxazine, or atomoxetine.
[1067] Embodiment 244. The method of embodiment 228, wherein the antidepressant is an NDRI.
[1068] Embodiment 245. The method of embodiment 244, wherein the NDRI is bupropion, amphetamine, methylphenidate, modafinil, amineptine, or nomifensine.
[1069] Embodiment 246. The method of embodiment 228, wherein the antidepressant is a TCA.
[1070] Embodiment 247. The method of embodiment 246, wherein the TCA is amitriptyline, amitriptyline oxy, clomipramine, desipramine, dibenzepine, dimetholine, dosluepin, doxepin, imipramine, lofepramine, melitracen, nitrazepam, nortriptyline, noxetylline, opipramol, pipofilazine, protriptyline, trimipramine, butriptyline, demetriptyline, fluocinol, oxymipramine, iprapindol, metapramine, propazepine, quinupramine, thiozepine, or tolfenacin.
[1071] Embodiment 248. The method of embodiment 228, wherein the antidepressant is TeCA.
[1072] Embodiment 249. The method of Embodiment 248, wherein the TeCA is amoxapine, maprotiline, mianserin, mirtazapine, or setiptiline.
[1073] Embodiment 250. The method of embodiment 228, wherein the antidepressant is a MAOI.
[1074] Embodiment 251. The method of embodiment 250, wherein the MAOI is isocarboxazid, phenelzine, tranylcypromine, benmosin, iproclorazepam, iproniazid, mebanazine, nyalamide, octamoxin, pheniprozine, phenoxyprozine, pivalazine, safrazine, selegiline, caroxadone, metrindole, moclobemide, pyrindole, eprobemide, bendamorph, toloxatone, or difemelane.
[1075] Embodiment 252. The method of embodiment 228, wherein the antidepressant is an atypical antipsychotic.
[1076] Embodiment 253. The method of embodiment 252, wherein the atypical antipsychotic is amisulpride, lumepirone, lurasidone, quetiapine, aripiprazole, epiriprazole, lumepirone, lurasidone, olanzapine, quetiapine, or risperidone.
[1077] Embodiment 254. The method of embodiment 228, wherein the antidepressant is agomelatine, esketamine, tianeptine, ketamine, alpha-methyltryptamine, ethyltryptamine, ethyltryptamine, indolozine, medixamine, oxafluxane, pitavagine, adenosine methionine, hypericum perforatum, hydroxytryptophan, tryptophan, trifluoperazine, buspirone, lithium, thyroxine, triiodothyronine, amitriptyline and chlordiazepoxide, amitriptyline and perphenazine, flupentixol and melitracen, olanzapine and fluoxetine, or tranylcypromine and trifluoperazine.
[1078] Embodiment 255. The method of any one of embodiments 175-227, wherein the antidepressant is 4-chlorokynurenine (AV-101), Apimostinel (NRX-1074), Levo-ketamine (PCN-101, HR-071603), Dextromethadone (REL-1017), MIJ-821, Rislenemdaz (CERC-301, MK-0657), TAK-653 (NBI-1065845), OPC-6 4005, PDC-1421 (BLI-1005), torudivenlafaxine, hydroxypiperidone (YL-0919), TGBA01AD (FKB01MD), vortioxetine, lisdexamfetamine dimesylate, methylenedioxymethamphetamine, (R)-amisulpride / (S)-amisulpride (85:15 ratio) (SEP-4199), gepirone, pramipexole, psilocybin, brilaroxazine, cariprazine, lumepirone, lurasidone, pimavanserin, adenosine Amine, 3β-methoxypregnenolone (MAP-4343), PH-10–vomeropherine, Aticaprant, BTRX-335140 (BTRX-140), buprenorphine / samidorphine, BTRX-246040 (LY-2940094), scopolamine (DPI-386), JNJ-39393406, botulinum toxin type A, JNJ-61393215, Seltorexant, BI-13588 94, Crisdesalazine, Erteberel, JNJ-54175446, NSI-189, NV-5138, SNG-12, TS-121, WIP-DF17, tramadol, bupropion / dextromethorphan (AXS-05), carbidopa / hydroxytryptophan (EVX-101), cycloserine / lurasidone (NRX-101; Cyclurad), or deuterated dextromethorphan / quinidine (AVP-786, CTP-786).
[1079] Embodiment 256. The method of any one of Embodiments 175-255, wherein the antidepressant is administered according to the prescribing information of its label.
[1080] Embodiment 257. The method of any one of embodiments 13, 14, and 175-255, wherein the co-administration is co-initiation of administration of said compound (1) or a pharmaceutically acceptable salt thereof; and said antidepressant.
[1081] Embodiment 258. A method of treating major depressive disorder (MDD) in a treatment-naive subject in need thereof, comprising co-initiating administration of a combination comprising a therapeutically effective amount of compound (1):
[1082]
[1083] and a therapeutically effective amount of an antidepressant. Example
[1084] In order to more fully understand the invention herein, the following examples are presented.The examples described in this application are used to illustrate the methods provided herein and should not be interpreted in any way as limiting the scope thereof.
[1085] Example 1: Study protocol for a phase 3, randomized, double-blind study comparing the efficacy and safety of compound (1) plus an antidepressant versus placebo plus an antidepressant in adults with major depressive disorder (CORAL).
[1086] List of abbreviations and definitions
[1087]
[1088]
[1089] introduce
[1090] Major depressive disorder (MDD) is a mental health disorder associated with significant mortality, severe functional impairment, and decreased quality of life (QoL). The global prevalence of MDD, often a recurrent condition, has increased worldwide in recent decades, even more so during the COVID-19 pandemic. Many patients with MDD do not receive treatment or are often undertreated. In fact, less than one-third of patients with depression in the United States receive adequate treatment.
[1091] Standard of care (SOC) antidepressant therapies (ADT), such as selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs), are effective but often require weeks or months to improve depressive symptoms, which can lead to an increased risk of suicide and treatment discontinuation.
[1092] In the Sequential Treatment Alternatives for Remission of Depression study, the mean time to remission for patients with MDD receiving SOC ADT ranged from 5.4 to 7.4 weeks. Furthermore, the likelihood of remission after acute treatment decreases, and the relapse rate increases with each acute ADT treatment step. Existing SOC ADT may also be inappropriate for some patients with MDD because commonly reported adverse events (AEs) may lead to nonadherence and decreased QoL. Therefore, given the limitations of currently available treatments for some patients with MDD, new treatment options that provide rapid responses with tolerable AE profiles are needed.
[1093] In the search for new treatments, different mechanisms of depression are being investigated, particularly the disruption of the balance between excitatory glutamate and inhibitory gamma-aminobutyric acid (GABA) signaling. Existing agents exert their effects through GABAergic / glutamatergic balance, helping to restore brain networks. It is hypothesized that by binding to GABAA receptors, neuroactive steroids (NAS) can rapidly restore network balance in brain regions that are dysregulated in depression. Compound (1) is a positive allosteric modulator of synaptic and extrasynaptic GABAA receptors and is a NAS in clinical development (as monotherapy or adjunctive therapy) as an oral, once-daily, 14-day course of treatment for adults with MDD and PPD in the LANDSCAPE and NEST clinical development programs, respectively. As part of the LANDSCAPE program, the ongoing SHORELINE study (NCT03864614) is designed to evaluate the safety and tolerability of a 14-day course of treatment with compound (1) at 30 or 50 mg, and the need for up to 5 courses over 1 year or less. Interim results from the SHORELINE study showed that approximately 80% of patients who responded to the first course of compound (1) 50 mg and continued to respond beyond day 28 received a total of 1 or 2 courses during treatment follow-up up to 1 year. Other completed studies have shown that compound (1) 50 mg resulted in improvements in depressive symptoms at day 15 relative to placebo, and began to have an effect as early as day 2 or 3 in patients with MDD or PPD, regardless of whether they were on stable SOC ADT. However, the efficacy and safety of compound (1) co-started with SOC ADT was not investigated in the above studies.
[1094] Understanding the potential of compound (1) to rapidly improve depressive symptoms, including when co-started with ADT, is important because prior literature suggests that individuals with MDD who achieve an early treatment response may achieve better outcomes than those who do not achieve an early response or those with persistent or unresolved symptoms. In addition, the potential for a 14-day course of compound (1) may lead to better compliance. Co-starting compound (1) with SOC ADT may also result in improved efficacy because the mechanism of action of NAS is different from that of other ADTs.
[1095] There is an unmet need for new therapies that have minimal adverse effects typically associated with ADT and do not require long-term therapy.
[1096] Given the prevalence of SSRI and SNRI ADT, this study provides clinical context for the potential to achieve a more rapid response by switching from ADT therapy with a slow onset, long-term administration to co-initiation of compound (1) with SOC ADT therapy, which is effective.
[1097] Goals and End Points
[1098] The primary objective of this study was to evaluate the efficacy of compound (1) plus an antidepressant compared with placebo plus an antidepressant in the treatment of MDD. Secondary objectives were to evaluate patient-reported outcome (PRO) measures as they relate to depressive symptoms and to assess the safety and tolerability of compound (1) plus an antidepressant. Other objectives were to evaluate PRO measures as they relate to health-related quality of life and to assess the PK of compound (1) using a population PK approach.
[1099] end
[1100] The primary endpoint was the change from baseline in the total score of the 17-item Hamilton Rating Scale for Depression (HAM-D) at day 3.
[1101] The key secondary endpoint was the change from baseline in HAM-D total score during the blinded treatment period (using equal weights for scheduled visits - Day 3, Day 8, Day 12, Day 15) (CFB). Other secondary endpoints included change from baseline in HAM-D total score at Day 15 and Day 42, change from baseline in HAM-D total score at the end of blinded treatment (using equal weights for scheduled visits - Day 12, Day 15, Day 18), HAM-D response at Day 15 and Day 42, HAM-D remission at Day 15 and Day 42, change from baseline in Clinical Global Impression - Severity (CGI-S) at Day 15, CGI-I response (defined as “very much improved” at Day 3 and Day 15) and remission at Day 15. or “very much improved”), change from baseline in MADRS total score at Day 15, MADRS response at Day 15 (reduction in MADRS total score by ≥50% from baseline), MADRS remission at Day 15 (MADRS total score ≤10), change from baseline in HAM-A total score at Day 15, time to first HAM-D response, change from baseline in depressive symptoms at Day 15 (as assessed by PHQ-9), and the incidence and severity of treatment-emergent adverse events (TEAEs).
[1102] Other endpoints included change from baseline to day 15 in PRO measures of health-related quality of life assessed by response to the SF-36v2, change from baseline to day 15 in PRO measures assessed by the Sheehan Disability Scale (SDS) (when they were related to function), change from baseline in clinical laboratory measures, vital signs, and electrocardiogram (ECG), suicidal ideation and behavior assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS), potential withdrawal symptoms assessed using the 20-item Physician Withdrawal Checklist (PWC-20), and pharmacokinetic (PK) parameters (e.g., clearance) and exposure estimates (e.g., area under the curve over the dosing interval, maximum plasma concentration) assessed by population PK methods.
[1103] Overall study design
[1104] This was a randomized, double-blind, parallel-group, placebo-controlled study in adults with MDD. The diagnosis of MDD was made based on the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), Clinical Trial Version (SCID5-CT) administered by a qualified healthcare professional.
[1105] The study consisted of a 28-day screening period, a 14-day double-blind treatment period, and a 28-day ADT continuation period. The screening period began with the signing of the informed consent form (ICF) at the screening visit. The initial screening procedure to determine eligibility included completion of the MGH-ATRQ and HAM-D.
[1106] Participants were randomized to receive blinded compound (1) 50 mg or placebo, administered nightly from day 1 to day 14. In addition, all participants received 1 of two classes of ADT in an open-label fashion from day 1 to the end of the study: a selective serotonin reuptake inhibitor (SSRI; sertraline, escitalopram, citalopram) or a serotonin-norepinephrine reuptake inhibitor (SNRI; duloxetine or desvenlafaxine). ADT was administered according to label prescribing information. Investigators assigned 1 of 5 ADTs according to clinical standard of care; participants must not have been previously treated with the assigned ADT during the current depressive episode and must not have taken any ADT in the 30 days prior to day 1 (or fluoxetine in the 60 days prior to day 1). Randomization was stratified by ADT class (SSRI or SNRI).
[1107] After the double-blind treatment period, ADT continued every night for the remainder of the study (ADT continuation period). During this period (weeks 3 to 6), the ADT dose could be adjusted based on individual response, investigator judgment, and in accordance with the label prescribing information.
[1108] No initiation of additional antidepressants or any other medications that could affect efficacy or safety endpoints was permitted between Screening and completion of the Day 42 / end of study visit assessment.
[1109] Participants self-administered blinded study product (IP) once daily for 14 days at approximately 8 PM in the clinic with a fat-containing meal (e.g., within 1 hour after a fat-containing dinner, or with a fat-containing snack). During the treatment period, ADT and compound (1) / placebo were administered simultaneously; participants assigned duloxetine also took ADT in the morning (twice daily dosing) as part of a split dose for the first 7 days. Participants returned to the study center as outlined in the assessment schedule (Table 1).
[1110] During the treatment period, participants may receive Compound (1) / placebo as long as there are no dose-limiting safety / tolerability issues. Participants who are unable to tolerate Compound (1) / placebo 50 mg receive 40 mg for the remainder of the treatment period. Participants who are unable to tolerate the 40 mg dose of Compound (1) / placebo at the investigator's discretion may discontinue Compound (1) / placebo at the investigator's discretion. If blinded IP is discontinued, ADT may be continued at the investigator's discretion.
[1111] After completion of the study, eligible participants will have the opportunity to enter a long-term open-label study of compound (1).
[1112] qualifications
[1113] Inclusion criteria
[1114] Participants signed the ICF before undergoing any specific study procedures;
[1115] Participants were male or female, aged between 18 and 64 years (inclusive);
[1116] Participants are in good health and have no clinically significant findings on physical examination, 12-lead ECG or clinical laboratory tests as determined by the investigator;
[1117] Participants agree to comply with the research requirements;
[1118] Participants had a diagnosis of MDD as determined by the SCID-5-CT, and symptoms had been present for at least 4 weeks;
[1119] Participants had a HAMD-17 total score ≥ 24 at Screening and Day 1 (pre-dose);
[1120] Participants are willing to postpone the start of any antidepressant (unless prescribed by the protocol), antianxiety medication, anti-insomnia medication, psychostimulant, prescription opioid regimen, or new psychotherapy (including cognitive behavioral therapy for insomnia [CBT-I]) until after study completion. Participants receiving psychotherapy must have been receiving treatment on a regular schedule for at least 60 days prior to Day 1 and intend to maintain that schedule for the duration of the study;
[1121] Female participants agreed to use at least one highly effective method of contraception (see below) during study participation and for 30 days after the last IP dose, unless she was postmenopausal (natural amenorrhea for at least 12 months without other medical reasons and confirmed follicle-stimulating hormone >40 mIU / mL), and / or surgically infertile (bilateral oophorectomy, hysterectomy, and / or bilateral salpingectomy), or not participating in sexual relations with a risk of pregnancy (excluding abstinence);
[1122] Female participants who are breastfeeding at Screening or Day 1 (before administration of Compound (1)) must be willing to temporarily stop giving breast milk to her child from before receiving Compound (1) on Day 1 until 7 days after the last dose of Compound (1) / placebo;
[1123] Male participants agree to use an acceptable and effective method of contraception during the duration of the study and for 5 days after receiving Compound (1), unless the participant is not engaging in sexual relations with a risk of pregnancy;
[1124] Male participants are willing to abstain from sperm donation during treatment and within 5 days after receiving the last dose of compound (1);
[1125] Participants agree to refrain from drug abuse and alcohol use for the duration of the study; and
[1126] Participants were willing, able, and eligible to take at least one of the 5 ADTs specified in the protocol (eligible ADTs were those not taken during the current depressive episode and for which the participant had no contraindications; in addition, participants were not eligible to take citalopram if they were taking escitalopram during the current depressive episode and vice versa).
[1127] Exclusion criteria
[1128] Subjects meeting any of the following criteria were disqualified from participating in the study:
[1129] The participant is at significant risk of suicide or has attempted suicide related to the current episode of MDD, as determined by the investigator;
[1130] Participants had a current depressive episode onset during pregnancy or during the 4 weeks postpartum, or participants were screened during the 6-month postpartum period;
[1131] · Participants have a recent history or clinically active significant manifestations of metabolic, liver, kidney, hematological, pulmonary, cardiovascular, gastrointestinal, musculoskeletal, dermatological, genitourinary, neurological or eye, ear, nose and throat disorders, or any other acute or chronic condition that the investigator believes will limit the participant's ability to complete or participate in this clinical study. Excluded BMI ≤ 18 or ≥ 45 kg / m2; BMI 40 to 44.9 kg / m2 (inclusive) at screening, with a more extensive medical comorbidity assessment as described above;
[1132] Participants have treatment-resistant depression, defined as persistent depressive symptoms despite treatment with adequate doses of 2 antidepressants from different classes (excluding antipsychotics) for at least 4 weeks during the current major depressive episode. The Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH ATRQ) will be used for this purpose;
[1133] Participants had received vagus nerve stimulation, electroconvulsive therapy, or ketamine during their current major depressive episode;
[1134] Participants received cognitive behavioral therapy for insomnia (CBT-I) within 28 days prior to Day 1;
[1135] · Participants have a known allergic reaction to compound (1), allopregnanolone, or related compounds;
[1136] Participants had taken antidepressants within 30 days before Day 1 and / or fluoxetine within 60 days before Day 1;
[1137] Female participants with a positive pregnancy test or confirmed pregnancy;
[1138] Participants with a clinically significant 12-lead ECG at the Screening or Baseline visit (mean QT interval calculated using the Fridericia method (QTcF) >450 ms for males or >470 ms for females will be used as a basis for exclusion from the study);
[1139] The participant has active psychosis according to the investigator's assessment;
[1140] Participants have a medical history of epilepsy;
[1141] Participants have a medical history of bipolar disorder, schizophrenia, and / or schizoaffective disorder;
[1142] Participants had a history of mild, moderate, or severe substance use disorder (including benzodiazepines) diagnosed using DSM-5 criteria within 12 months prior to screening, or participants had a history of mild or moderate substance use disorder that was not in sustained remission for at least 6 months prior to screening;
[1143] Participants have been exposed to another study drug or device within 30 days prior to screening;
[1144] · Participants have previously received brexanolone or participated in clinical trials of compound (1) or SAGE-547 (brexanolone);
[1145] Participants had used any known strong cytochrome P450 (CYP) 3A4 inhibitor within 28 days or five half-lives (whichever was longer) or had consumed grapefruit juice, grapefruit, or Seville oranges, or products containing these substances within 14 days before the first day;
[1146] Participants had used any strong CYP3A inducers, such as rifampicin, carbamazepine, enzalutamide, mitotane, phenytoin, or St John's Wort, within 28 days before Day 1;
[1147] Participants had a positive drug and / or alcohol screen at screening or on day 1 prior to dosing;
[1148] The participant is scheduled to undergo elective surgery before the completion of the Day 42 visit;
[1149] Participants had taken benzodiazepines, barbiturates, or gamma-aminobutyric acid type A (GABAA) modulators (e.g., eszopiclone, zopiclone, zaleplon, and zolpidem) within 28 days before Day 1, or had used these drugs daily or nearly daily (≥4 times per week) for more than 1 year. Participants had taken any benzodiazepines or GABA modulators with a half-life of ≥48 hours (e.g., diazepam) from 60 days before Day 1;
[1150] Participants were taking non-GABA anti-insomnia medications (e.g., prescription medications specifically for insomnia and / or over-the-counter sleep aids), or first- or second-generation (typical / atypical) antipsychotics within 14 days prior to Day 1. Non-sedating antihistamines were allowed;
[1151] The subject has been diagnosed with any type of cancer (excluding basal cell carcinoma and melanoma in situ) and / or received treatment for any type of cancer (excluding basal cell carcinoma and melanoma in situ) in the past year before screening;
[1152] The participant has a history of sleep apnea;
[1153] Participants who have undergone gastric bypass, gastric sleeve or lap band surgery, or any related surgery that interferes with gastrointestinal transit;
[1154] Taking psychostimulants (e.g., methylphenidate, amphetamines) or opioids regularly or as needed in the 28 days before Day 1;
[1155] The participant is a family member of the sponsor, investigator, investigator's deputy, or research site staff;
[1156] The participant is expected to work night shifts during the 14-day treatment period; or
[1157] Participants had detectable hepatitis B surface antigen, anti-hepatitis C virus (HCV) and positive HCV viral load, or human immunodeficiency virus (HIV) antibodies at screening.
[1158] Dosage and administration
[1159] Compound (1) is available as hard gelatin capsules for oral administration; a variety of capsules (30-mg or 20-mg dosage strengths) are provided for a total 50-mg dose, with the option of reducing to 40 mg depending on tolerability.
[1160] Blinded placebo was provided in hard gelatin capsules matching the appearance of Compound (1) for oral administration.
[1161] Sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine were administered according to label prescribing information.
[1162] It is recommended that sertraline be administered as per label prescribing information, starting with 50 mg daily in the evening during week 1, and increasing the dose to 100 mg daily in the evening during week 2.
[1163] It is recommended to administer citalopram according to the label prescribing information, starting with 20 mg / day.
[1164] It is recommended that escitalopram be administered according to the label prescribing information, starting with 10 mg / day.
[1165] It is recommended to administer duloxetine according to the label prescribing information, starting with 40 or 60 mg / day (divided into 20 or 30 mg, respectively, twice daily for the first 7 days).
[1166] It is recommended to use desvenlafaxine according to the label prescribing information, starting with 50 mg / day.
[1167] Duration of treatment
[1168] Blinded compound (1) or placebo was administered once daily for 14 days; open-label ADT was administered according to the label prescribing information for 42 days.
[1169] Dosage Considerations
[1170] Results from a large, multicenter study of compound (1) 20 and 30 mg in MDD (217-MDD-301) support the need for higher steady-state concentrations of compound (1) in order for participants to experience maximal antidepressant and antianxiety benefits. Compound (1) was administered on a 14-day regimen of 50 mg evening doses, reduced to 40 mg as needed based on tolerability. Given the results from previous studies of compound (1) using a 30 mg dose (determined to be the lowest effective dose), it is expected that a 50 mg dose of compound (1) will exhibit a favorable benefit-risk profile. Based on the current safety database of over 2,000 participants exposed to different doses / concentrations, it is expected that compound (1) will maintain an acceptable tolerability profile.
[1171] Sertraline is a marketed SSRI indicated for the treatment of MDD and other psychiatric disorders. As described in the approved US prescribing information (PI), the dosing and administration of sertraline recommends a starting dose of 50 mg per day in patients with MDD, with a dose increase of 25-50 mg per day weekly to a maximum dose of 200 mg per day if there is an inadequate response to the starting dose. In this study, the recommended starting dose was 50 mg per day for 7 days, followed by an increase to 100 mg per day.
[1172] Citalopram and escitalopram are both commercially available SSRIs, and both are indicated for acute and maintenance treatment of MDD. Escitalopram is also indicated for treatment of generalized anxiety disorder. In the USPI, the starting doses for MDD are 20 mg / day for citalopram and 10 mg / day for escitalopram, with maximums of 40 mg / day and 20 mg / day, respectively. In this study, a starting dose of 20 mg / day for citalopram was recommended, and a starting dose of 10 mg / day for escitalopram was recommended for the first 14 days; subsequent dose increases could be considered, except for participants >60 years of age taking citalopram.
[1173] Duloxetine is a marketed SNRI indicated for the treatment of MDD, generalized anxiety disorder, and pain disorders. The starting dose for MDD in the USPI is 40 to 60 mg / day. The maximum dose is 120 mg / day, although there is no evidence that doses above 60 mg / day provide any additional benefit. In this study, the recommended starting dose was 40 or 60 mg / day (divided into 20 or 30 mg, respectively, twice daily for the first 7 days).
[1174] Desvenlafaxine is a commercially available SNRI indicated for the treatment of MDD. The recommended dose in the USPI is 50 mg / day. In this study, the recommended dose was 50 mg / day. There was no evidence that doses exceeding 50 mg / day would provide any additional benefit.
[1175] Treatment allocation
[1176] Participants were assigned to a blinded IP (Compound (1) or placebo) according to the randomization schedule on Day 1. The investigator assigned 1 of 5 ADTs according to clinical standard of care. Participants were assigned an ADT that could not have been taken by the participant before during the current depressive episode. In addition, participants could not be assigned citalopram if they had taken escitalopram during the current depressive episode, and vice versa.
[1177] Randomization was stratified by antidepressant class (SSRI or SNRI).
[1178] Dose adjustment criteria
[1179] During the treatment period, participants were able to receive Compound (1) / placebo as long as there were no dose-limiting safety / tolerability issues. Participants who were unable to tolerate 50 mg (as determined by the investigator) received 40 mg for the remainder of the treatment period.
[1180] Participants who are unable to tolerate the 40 mg dose at any time may discontinue dosing at the investigator's discretion and should be followed up and complete assessments according to the assessment schedule.
[1181] During weeks 3 to 6, ADT dosing may be modified based on individual response, at the investigator's discretion, and according to label prescribing information.
[1182] Prior and concomitant medications and / or supplements
[1183] The start and end dates, route, dose / unit, frequency, and indication of all medications and / or supplements taken within 30 days prior to screening and throughout the study duration were recorded. In addition, psychotropic medications taken within 6 months prior to screening were recorded.
[1184] The Investigator may decide at any time during the study to administer any medications and / or supplements determined to be necessary for the participant's welfare.
[1185] Prohibited drugs
[1186] The following specific categories of drugs are prohibited:
[1187] Starting new psychotropic medications until the Day 42 visit;
[1188] Initiation of new antidepressant therapy during the period from 30 days prior to Day 1 (60 days for fluoxetine) to the Day 42 visit;
[1189] Any use of benzodiazepines, barbiturates, GABAA modulators, or GABA-containing agents from Day -28 to Day 42 (from Day -60 for benzodiazepines or GABA modulators with a half-life ≥ 48 hours);
[1190] Chronic or as-needed psychostimulants (e.g., methylphenidate, amphetamines) or opioids from Day -28 to Day 42 visit;
[1191] First-generation (typical) antipsychotics (e.g., haloperidol, perphenazine) and second-generation (atypical) antipsychotics (e.g., aripiprazole, quetiapine) from visit -14 to day 42;
[1192] Use of any non-GABA anti-insomnia medications (e.g., prescription medications specifically for insomnia and / or over-the-counter sleep aids) from Day -14 to Day 1. Non-sedating antihistamines were permitted;
[1193] Exposure to another study drug or device from 30 days before screening to the Day 42 visit;
[1194] Any known strong CYP3A4 inhibitor from Day -28 or 5 half-lives before Day 1 (whichever is longer) through the treatment period;
[1195] Use of any strong CYP3A inducers, such as rifampin, carbamazepine, enzalutamide, mitotane, phenytoin, or St. John's wort, from Day -28 through the treatment period; or
[1196] Follow label prescribing information for any contraindications to the prescribed SSRI / SNRI.
[1197] Other restrictions
[1198] Any specific restrictions on the prescribed SSRI / SNRI and its concomitant medications based on the label prescribing information were taken into account.
[1199] Do not consume grapefruit juice, grapefruit, or Seville oranges, or products containing these substances, within 14 days prior to Day 1 and throughout the treatment period.
[1200] Alcohol consumption and use of drugs of abuse were discouraged throughout the study period.
[1201] Female participants who are lactating or actively breastfeeding must stop feeding breast milk to their infants from day 1 until 7 days after the last dose of compound (1) / placebo.
[1202] Elective surgical procedures or surgeries were prohibited during the Day 42 visit.
[1203] Participants were not allowed to work night shifts during the treatment period.
[1204] Participants who feel sedated, sleepy, and / or dizzy should refrain from driving or engaging in any activity requiring alertness.
[1205] Participants were allowed to receive psychotherapy on their usual schedule for at least 60 days prior to Day 1 if they intended to continue on this schedule during the follow-up period (Day 42). Initiation of new psychotherapy was prohibited until study completion.
[1206] Randomization and Blinding
[1207] Participants were randomized in a 1:1 ratio to receive compound (1) or matching placebo. Participants, site staff, and sponsors were blinded to treatment assignment. All participants also received open-label ADT. Randomization was performed centrally using an interactive response technology (IRT) system. The randomization schedule was generated by an independent statistician. Allocation of blinded treatment (compound (1) or placebo) was based on the randomization schedule. The randomization schedule was kept strictly confidential and accessible only to authorized personnel until the time of unblinding. The blinding of the study was broken after the database was locked.
[1208] Research Products
[1209] Blind test product
[1210] Compound (1) is available as hard gelatin capsules containing white to off-white powder. In addition to the specified amount of Compound (1) drug substance, the active Compound (1) capsules contain croscarmellose sodium, mannitol, silicified microcrystalline cellulose, colloidal silicon dioxide and sodium stearyl fumarate as excipients. The capsules are available in dosage strengths of 20 mg and 30 mg.
[1211] Blinded placebo was provided in hard gelatin capsules matching the appearance of Compound (1).
[1212] Open-label research products
[1213] Sertraline, escitalopram, citalopram, duloxetine, and desvenlafaxine (packaged and labeled by commercial manufacturers) were supplied by a third-party supplier. Open-label IPs should be stored and administered according to the package insert. Open-label IPs during this study were used only as directed in this protocol.
[1214] Blind Study Product Packaging and Labeling
[1215] Compound (1) and placebo were provided to clinical pharmacists and / or designated site staff who were responsible for dispensing blinded IP into appropriately labeled, sealed unit-dose kits for participants. Each unit dose of the 40 mg and 50 mg dose levels consisted of 2 capsules. Additional information on packaging and labeling was provided in the pharmacy manual.
[1216] The sponsor prepared labeling for compound (1) and placebo that contained all required information and complied with all applicable FDA regulations of federal regulations and good manufacturing practice / good clinical practice guidelines.
[1217] Blind Study Product Storage
[1218] Compound (1) and placebo should be stored safely at room temperature (59 to 86°F; 15 to 30°C) and kept separate from other medications.
[1219] Blind and open study trial product administration
[1220] Blinded IP and open-label ADT were administered orally once daily at approximately 8 PM with a fat-containing meal (e.g., within 1 hour after a fat-containing dinner, or with a fat-containing snack). Examples of fat-containing snacks include nuts, peanut butter, avocado, eggs, and cheese. Participants assigned duloxetine also took duloxetine in the morning (twice daily in divided doses) for the first 7 days.
[1221] If a participant missed a dose of either the blinded IP or the open-label IP, the participant should skip that dose (eg, they should not take that dose in the morning) and take the next scheduled dose the following evening.
[1222] Efficacy and clinical pharmacology evaluation
[1223] Efficacy evaluation
[1224] Hamilton Depression Rating Scale (HAM-D)
[1225] The primary outcome measure was the change from baseline in the 17-item HAM-D total score at Day 3. Every effort was made to have the same assessor perform all HAM-D assessments for each participant. An assessment time frame of the past 7 days (1 week) was used at Screening, and an assessment time frame of “since last visit” was used for all other visits.
[1226] The 17-item HAM-D is used to assess the severity of depression in participants who have been diagnosed with depression. The 17-item HAM-D includes individual assessments related to the following symptoms: depressed mood (sadness, hopelessness, helplessness, worthlessness), guilt, suicidality, insomnia (early, middle, late), work and activities, slowness (slowed thinking and speech; impaired ability to concentrate; decreased motor activity), agitation, anxiety (mental and physical), somatic symptoms (gastrointestinal and systemic), genital symptoms, hypochondriasis, weight loss, and loss of insight. The total HAM-D score is calculated as the sum of the 17 individual item scores.
[1227] In addition to the primary efficacy endpoint of change from baseline in HAM-D total score, several secondary efficacy endpoints of HAM-D were derived. Hamilton Depression Rating Scale subscale scores were calculated as the sum of the items containing each subscale. Hamilton Depression Rating Scale response was defined as a decrease of 50% or more in the HAM-D total score from baseline. Hamilton Depression Rating Scale remission was defined as having a HAM-D total score of ≤7.
[1228] Montgomery-Åsberg Depression Rating Scale (MADRS)
[1229] The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. It was designed as an adjunct to the HAM-D and is more sensitive to changes brought about by antidepressants and other forms of treatment than the Hamilton Rating Scale. Higher MADRS scores indicate more severe depression, and each item produces a score from 0 to 6. The total score ranges from 0 to 60. The MADRS total score is calculated as the sum of the 10 individual item scores.
[1230] Hamilton Anxiety Rating Scale (HAM-A)
[1231] The 14-item HAM-A will be used to assess the severity of anxiety symptoms. Each of the 14 items is defined by a constellation of symptoms and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical discomfort associated with anxiety). The score on the HAM-A is calculated by assigning a score from 0 (absent) to 4 (very severe), with a total score ranging from 0 to 56, where <17 indicates mild severity, 18 to 24 indicates mild to moderate severity, and 25 to 30 indicates moderate to severe severity. The total HAM-A score is calculated as the sum of the 14 individual item scores.
[1232] Clinical Global Impression (CGI)
[1233] The CGI is a validated measure that is frequently used in clinical research to allow clinicians to integrate multiple sources of information into a single rating of a participant's condition. See Joan Busner and Steven D. Targum, "The Clinical Global Impressons Scale", Psychiatry (Edgmont). 2007 Jul; 4(7): 28–37. Typically, the CGI has two components - the CGI-Severity (SGI-S), which assesses illness severity, and the CGI-Improvement (CGI-I), which assesses change from the start of treatment (baseline).
[1234] The CGI-S uses a 7-point Likert scale to rate the severity of the participant's illness at the time of the assessment relative to the clinician's past experience with participants with the same diagnosis. Taking into account total clinical experience, the severity of the participant's mental illness at the time of the assessment was rated as 1 = normal, not at all ill; 2 = borderline mental illness; 3 = mild illness; 4 = moderate illness; 5 = marked illness; 6 = severe illness; 7 = extreme illness.
[1235] The CGI-I uses a 7-point Likert scale to measure the overall improvement in the participant's condition after treatment. Researchers rated the participant's overall improvement, whether or not it was entirely due to medication. Response options included: 0 = not rated, 1 = very much improved, 2 = very much improved, 3 = slightly improved, 4 = no change, 5 = slightly worse, 6 = very much worse, 7 = very much worse. The CGI-I is assessed only at the post-treatment assessment. By definition, all CGI-I assessments are assessed based on baseline conditions. A CGI-I response is defined as having a CGI-I score of "very much improved" or "very much improved."
[1236] SUMMARY-36 VERSION 2
[1237] The Medical Outcomes Study SF-36v2 is a 36-item measure of health status that has been validated in many different disease states. The SF-36v2 covers eight health dimensions, including four physical health status domains (physical functioning, role participation with physical health problems [role-physical], bodily pain, and general health) and four mental health status domains (vitality, social functioning, role participation with emotional health problems [role-emotional], and mental health). In addition, two summary scores, the physical component summary and the mental component summary, are derived by weighted linear combinations of the eight individual domains. The SF-36v2 has two recall periods: a standard recall period of 4 weeks and an acute recall period of 1 week. This study used the acute version, which asks patients to answer questions related to the past week. Higher SF-36v2 scores indicate better health status.
[1238] Patient Health Questionnaire
[1239] The PHQ-9 is a participant-assessed scale for severity of depressive symptoms. To monitor severity over time in newly diagnosed participants or those currently being treated for depression, participants can complete the questionnaire at baseline and at regular intervals thereafter. Scores are based on responses to specific questions as follows: 0 = not at all; 1 = a few days; 2 = more than half the days; 3 = almost every day.
[1240] The PHQ-9 total score will be calculated as the sum of the 9 individual scores. The PHQ-9 total score will be categorized as follows: 1 to 4 = minimal depression, 5 to 9 = mild depression, 10 to 14 = moderate depression, 15 to 19 = moderate to severe depression; 20 to 27 = severe depression.
[1241] Sheehan Disability Scale
[1242] The SDS is a participant-rated assessment that measures the extent to which the symptoms of mental illness impair work / school, social life, and family life or family responsibilities. The SDS total score ranges from a minimum of 0 to a maximum of 30. For the SDS total score, the lower the score, the better the outcome, and the higher the score, the worse the outcome. A negative change relative to the baseline value (a decrease in score) is considered to be the better outcome, and a positive change relative to the baseline value (an increase in score) is considered to be the worse outcome. The SDS contains 3 items; the total score is calculated as the sum of the scores of the 3 items.
[1243] Clinical pharmacology evaluation
[1244] Pharmacokinetic evaluation
[1245] Pharmacokinetic parameters (e.g., clearance) and exposure estimates (e.g., area under the curve, maximum plasma concentration within the dosing interval) were assessed by population PK methods. Data from this study may be combined with data from other studies to support the analysis and may also be reported separately.
[1246] Blood sample collection
[1247] Plasma samples for PK analysis will be collected according to the sampling schedule. The investigator or their designee will arrange for the shipment of plasma samples for bioanalysis as directed.
[1248] Additional PK samples may be collected at any time if clinically indicated and at the investigator's discretion (e.g., for unusual or serious AEs). In the case of dose adjustments, unscheduled PK samples should be collected before dose adjustments if possible.
[1249] Each sample was labeled with a unique identifier, including at least the study number, participant number, and visit date. The date and actual time of blood sample collection was recorded on the case report form.
[1250] Sample analysis
[1251] Plasma samples were bioanalyzed in a qualified laboratory using a validated liquid chromatography-tandem mass spectrometry method to identify compound (1).
[1252] Security Assessment
[1253] Columbia-Suicide Severity Rating Scale (C-SSRS)
[1254] During the study, suicidality was monitored using the C-SSRS. The scale consists of a baseline assessment that assesses the participant's lifetime experience with suicidal thoughts and behaviors and a post-baseline assessment that focuses on suicidality since the last study visit. The C-SSRS includes "yes" or "no" responses to assess suicidal thoughts and behaviors, as well as a numeric rating (from 1 to 5, with 5 being the most severe) of the severity of the thoughts, if present.
[1255] The "Baseline / Screening" C-SSRS form was completed at Screening (Lifetime History and Past 24 Months). The "Since Last Visit" C-SSRS form was completed at all subsequent time points, as summarized in Table 1.
[1256] Physician Withdrawal Checklist
[1257] The University of Pennsylvania Physician Withdrawal Checklist (PWC) consists of 35 items that measure discontinuation symptoms of benzodiazepines and benzodiazepine-like drugs. The PWC-20 is a simplified version of the PWC based on the 20 items that were most discriminatory from placebo in previous trials. The PWC-20 consists of a list of 20 symptoms (e.g., loss of appetite, nausea-vomiting, diarrhea, anxiety-tension, irritability, etc.) that are rated on a scale of 0 (absent) to 3 (severe). The PWC-20 is used to monitor the presence of potential withdrawal symptoms after discontinuation of compound (1).
[1258] Adverse events and serious adverse events
[1259] Adverse event definition
[1260] An AE is any untoward medical event that occurs in a patient or clinical study participant administered a medicinal product and that is not necessarily causally related to that treatment. Thus, an AE may be any unfavorable and unexpected sign (including abnormal laboratory findings), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. In clinical studies, AEs may include adverse medical conditions that occur at any time, including during the baseline or washout period, even when the study treatment is not administered.
[1261] A TEAE was defined as an AE that began after the start of the IP, or an exacerbation of any pre-existing medical condition / AE that began after the start of the IP and throughout the study. The term IP includes any Sage IP, comparator, or placebo administered in a clinical study.
[1262] Laboratory abnormalities and changes in vital signs and ECGs from baseline were considered AEs if they led to discontinuation or interruption of study treatment, required therapeutic medical intervention, met protocol-specific criteria (if applicable), or if the investigator considered them to be clinically significant. Any abnormality that meets SAE criteria should be reported in an expedited manner. Laboratory abnormalities and changes in vital signs and ECGs from baseline that are clearly attributable to another AE do not require discrete reporting (e.g., electrolyte disturbances in the setting of dehydration, chemistry and hematology disturbances in the setting of sepsis).
[1263] All AEs occurring after any participant signs informed consent and throughout the duration of the study, whether or not they are study-related, should be reported to Sage Therapeutics.
[1264] Participants who discontinue the IP due to an AE, regardless of causality as determined by the investigator, will be followed until the event is resolved, deemed stable, or the investigator determines the event is no longer clinically significant. Participants will be followed by the investigator for any AE that is not resolved at the time of the last AE assessment in the study as long as medically indicated, but will not be further documented in the eCRF. The Sponsor or its representative reserves the right to request additional information for any patient with a persistent AE / SAE at the end of the study, if judged necessary.
[1265] Definition of serious adverse events
[1266] SAE is any adverse medical event occurring at any dose:
[1267] Causes death;
[1268] ·Puts the participant at risk of immediate death (life-threatening event); however, this does not include an event that, in its more severe form, would result in death;
[1269] ·Requires hospitalization or prolongation of existing hospitalization;
[1270] · cause persistent or severe disability or incapacity; or
[1271] Cause congenital anomalies or birth defects.
[1272] An SAE may also be any other medically significant event that, in the opinion of the investigator, may have compromised the participant or may have required medical intervention to prevent one of the outcomes listed above (examples of such events include allergic bronchospasm requiring intensive treatment in the emergency department or seizures that occurred at home but did not require hospitalization).
[1273] All SAEs that occur after any participant signs the ICF and throughout the duration of the study, whether or not they are study related, must be recorded on the SAE Reporting Form provided by Sage Therapeutics. When participants complete their last study visit, the investigator will follow any SAEs that are occurring until the event resolves, stabilizes, returns to baseline, or until the participant dies or is lost to follow-up.
[1274] Prescheduled or elective surgeries or routinely scheduled treatments were not considered SAEs, even if the participant was hospitalized. The site recorded all of the following:
[1275] · a pre-scheduled or elective surgery or routinely scheduled treatment that was scheduled (or on a waiting list) before the participant's consent to participate in the study was obtained; and
[1276] The condition requiring scheduled or elective surgery or routinely scheduled treatment was present before the participant was diagnosed with the condition and did not worsen or progress between the time the participant agreed to participate in the study and the time of surgery or treatment.
[1277] Relationship to research products
[1278] The investigator must determine the relationship of each AE to the IP (not related, related). The following definitions should be considered when evaluating the relationship of AEs and SAEs to IPs.
[1279] Unrelated – An AE is considered “unrelated” to the use of an IP if there is no reasonable possibility that the event was caused by the IP. Factors that point to this assessment include, but are not limited to: lack of a temporal relationship between the administration of the IP and the event, an implausible biological relationship between the product and the AE, or the existence of a more likely alternative explanation for the AE
[1280] Related – An AE is considered “related” to the use of an IP if there is a reasonable possibility that the event was caused by the product under investigation. Factors that point to this assessment include, but are not limited to: positive rechallenge, reasonable temporal sequence between drug administration and event, known response pattern of the suspected drug, improvement after discontinuation or dose reduction, a biologically plausible relationship between the drug and the AE, or lack of an alternative explanation for the AE.
[1281] Recording adverse events
[1282] Adverse events reported spontaneously by participants and / or in response to open-ended questions from the investigators, or revealed by observations recorded during the study at the study site. AE terms should be reported in standard medical terms when possible. For each AE, the investigators assessed and reported its onset (date and time), resolution (date and time), intensity, causality, actions taken, outcome and severity (if applicable), and whether it led to the participant discontinuing the IP or withdrawing from the study early.
[1283] Strength is assessed according to the following criteria:
[1284] Mild: Symptoms are barely noticeable or uncomfortable for the participant; do not affect performance or function; and do not usually require prescription medication to relieve symptoms;
[1285] Moderate: Symptoms are severe enough to make the participant uncomfortable; performance of daily activities is impaired; participant is able to continue in the study; treatment for symptoms may be required;
[1286] Severe: Symptoms cause severe discomfort; symptoms cause disability or have a significant impact on the participant's daily life; severity may result in discontinuation of treatment with IP; symptoms may require treatment and / or hospitalization of the participant.
[1287] It is important to distinguish between serious and severe AEs. Severity is a measure of intensity, while severity is defined by the criteria described herein. AEs of serious intensity are not necessarily considered severe.
[1288] Overdose
[1289] Overdoses are considered AEs and are recorded as such on the eCRF, regardless of the presence or absence of associated clinical manifestations (e.g., headache, abnormal laboratory values). Any clinical manifestation of overdoses must also be recorded as an AE on the eCRF. In addition, all overdoses must be documented on the Overdose Form and sent to Sage or designee within 24 hours of the site becoming aware of the overdose.
[1290] Table 1. Assessment schedule
[1291]
[1292]
[1293]
[1294] Abbreviations: AE = adverse event; CGI-I = Clinical Global Impression-Improvement; CGI-S = Clinical Global Impression-Severity; C-SSRS = Columbia-Suicidality Severity Rating Scale; D = day; EOT = end of treatment; ET = early termination; ECG = electrocardiogram; FSH = follicle-stimulating hormone; HAM-A = Hamilton Anxiety Rating Scale; HAM-D = Hamilton Depression Rating Scale, 17 items; HIV = human immunodeficiency virus; IP = investigational product; MADRS = Montgomery–Åsberg Depression Rating Scale; MGH ATRQ = Massachusetts General Hospital Antidepressant Treatment Response Questionnaire; PHQ-9 = 9-item Patient Health Questionnaire; PWC-20 = 20-item Physician Withdrawal Checklist; O = optional; PK = pharmacokinetics; SCID-5-CT = Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Clinical Trial Version; SDS = Sheehan Disability Scale; SF-36v2 = 36-item Short-Form Questionnaire, version 2; V = visit.
[1295] a Participants who discontinue treatment prematurely should return for an end-of-treatment (EOT) visit as soon as possible, preferably on the day following discontinuation of treatment. If necessary, the EOT and ET visits can be conducted on the same day if the participant discontinues IP and discontinues the study during a clinical visit; in this case, all EOT visit assessments should be performed.
[1296] b Participants will be asked to authorize entry of their unique participant identifier into a registry (www.subjectregistry.com) for the purpose of identifying participants who may meet exclusion criteria for participation in another clinical study.
[1297] c Female participants who have not undergone surgical sterilization will have serum FSH measured at screening to confirm whether female participants with ≥12 months of spontaneous amenorrhea meet protocol-defined postmenopausal criteria.
[1298] d Participants will be trained by site personnel on the use of the software applications and equipment needed to conduct the study.
[1299] eA complete physical examination will be performed at Screening and a brief physical examination will be performed thereafter. A complete physical examination includes an assessment of body systems (e.g., head, eyes, ears, nose, and throat; heart; lungs; abdomen; and extremities). A brief physical examination includes a brief medical history followed by a focused physical examination.
[1300] f Safety laboratory testing will include hematology, serum chemistry, coagulation, and urinalysis.
[1301] g Urine toxicology for selected drugs of abuse and breath testing for alcohol.
[1302] h For female participants who were not surgically sterilized and did not meet protocol-defined postmenopausal criteria, a serum pregnancy test was performed at screening and a urine pregnancy test was performed thereafter.
[1303] i With consent, optional blood samples were obtained for exploratory hormone and biochemical testing.
[1304] j With consent, optional genetic samples were used for exploratory biomarker testing.
[1305] k When scheduled vital signs are performed concurrently with the blood draw, vital signs will be obtained first. Vital signs include oral temperature (°C), respiratory rate, heart rate, and blood pressure (supine and standing). Heart rate and blood pressure will be collected in the supine position at all scheduled time points after the participant has rested for 5 minutes and then after approximately 3 minutes in the standing position. Vital sign measurements may be repeated at the investigator's discretion as clinically indicated.
[1306] l The ECG will be collected in triplicate. When the ECG and PK sample collection occur on the same day, the 12-lead ECG will be obtained prior to the PK sample collection.
[1307] m The “Baseline / Screening” C-SSRS form will be completed at Screening. The “Since Last Visit” C-SSRS form will be completed at all subsequent time points.
[1308] n The HAM-D should be completed as early as possible during the visit.
[1309] o The assessment time frame for the HAM-D scale will refer to the past 7 days (1 week) at Screening and "since last visit" for all other visits. The assessment time frame for the HAM-A scale will refer to the past 7 days (1 week) for all visits.
[1310] p Blood samples for PK analysis will be collected at any time during the clinical visit. In the case of dose adjustments, unscheduled PK samples should be collected prior to dose adjustments, if possible. The date and time of sample collection and the date and time of the last dose administration must be recorded. When ECG and PK sample collection occur on the same day, a 12-lead ECG will be performed prior to PK sample collection.
[1311] q IP administration will be monitored via a medication adherence monitoring platform used on a smartphone to confirm IP intake. IP adherence will no longer be recorded after a participant stops taking IP.
[1312] r ADT will be administered according to label prescribing information.
[1313] s AEs will be collected starting at the time of informed consent and throughout the duration of the participant's participation in the study.
[1314] t Prior medications will be collected at screening, and concomitant medications and / or procedures will be collected at each subsequent visit.
[1315] Example 2: Research results of Example 1.
[1316] Summary
[1317] This is a randomized, double-blind, parallel-group, active / placebo-controlled Phase 3 study (NCT04476030) conducted in participants with major depressive disorder (MDD) as described in Example 1. The study evaluated the efficacy and safety of concurrent administration of compound (1) and standard of care (SOC) antidepressants (ADT; SSRI or SNRI). Compound (1) was taken for only 14 days, but ADT was continued until the end of the study (42 days). Figure 1 is a schematic diagram of the clinical study design. Briefly, the study period consisted of a screening period of up to 28 days, followed by a 14-day double-blind treatment course (treatment period), and then a 28-day open-label follow-up period with continuation of SOC ADT treatment.
[1318] The study met its objectives, demonstrating a rapid and statistically significant reduction in depressive symptoms on Day 3 and over the 2-week treatment period, achieving both the primary and key secondary endpoints. This significance was demonstrated at the first measurement time point (Day 3), where Compound (1) 50 mg was co-initiated with open-label standard-of-care antidepressant (ADT), as assessed by the change from baseline on the 17-item Hamilton Depression Rating Scale (HAMD-17). The study also met its key secondary endpoint, where Compound (1) co-initiated with standard-of-care ADT demonstrated a statistically significant improvement in depressive symptoms compared to co-initiation of ADT with placebo, measured using equal weights over the 2-week treatment period.
[1319] Compound (1) was generally well tolerated, and no new safety signals were identified that could be attributed to Compound (1). In achieving its intended objective, this study supports the potential of Compound (1) to promote therapeutic benefit in depression when co-initiated with standard of care, compared to treatment with ADT alone.
[1320] A total of 440 participants were randomized in a 1:1 ratio to the Compound (1) + ADT and Placebo + ADT treatment groups. A total of 430 participants received at least one dose of blinded treatment (safety group) - 212 in the Compound (1) + ADT group and 218 in the Placebo + ADT group.
[1321] Statistical analysis
[1322] The safety set included all patients who received blinded study drug. The full analysis set (FAS) included all randomized patients in the safety set who had a valid baseline and ≥1 postbaseline total score on at least one efficacy assessment (HAMD-17, Hamilton Anxiety Rating Scale [HAM-A], Montgomery-Åsberg Depression Rating Scale, or 9-Item Patient Health Questionnaire) or a valid baseline and ≥1 postbaseline value on the Clinical Global Impression-Improvement score and / or the Clinical Global Impression-Severity score.
[1323] A sample size of 382 evaluable patients was determined to provide 90% power to detect a statistically significant difference in the primary endpoint, using a two-sided alpha level of 0.05, assuming a true difference of 3 points and a standard deviation (SD) of 9 points. Evaluable patients were those who were randomized and received blinded study drug and had a valid baseline and ≥1 post-baseline HAMD-17 assessment.
[1324] Continuous endpoints, including the primary and key secondary endpoints, were analyzed using a mixed-effects model with repeated measures. The key secondary endpoints were adjusted for multiplicity using a fixed sequence strategy. Key secondary endpoints were tested at the same significance level only if the primary endpoint was statistically significant at the two-sided 0.05 level. Efficacy endpoints, other than the primary and key secondary endpoints, were not adjusted for multiplicity, and differences in these endpoints are reported with nominal p values. All efficacy-related endpoints were analyzed using the FAS.
[1325] HAMD-17 response, HAMD-17 remission, and CGI-I response were analyzed with the use of generalized estimating equations. The time to first HAMD-17 response was estimated with the use of the Kaplan–Meier method, with the number and percentage of patients who responded or were censored included in the analysis. Similarly, the time to first HAMD-17 remission was estimated with the use of the Kaplan–Meier method.
[1326] CFB of HAMD-17 total scores at day 3 and over time were also analyzed in patients with MDD with elevated anxiety (defined as HAM-A total score ≥ 20 at baseline, who were pre-specified as a subgroup).
[1327] result
[1328] Participant Disposition, Demographics, and Baseline Clinical Characteristics
[1329] During the treatment period, 430 of the 440 randomized patients received ≥1 dose of study drug (Compound (1) + ADT, n = 212; Placebo + ADT, n = 218; Safety Set) ( Figure 2 ), of which 5 patients (n=2 and n=3, respectively) discontinued the study prematurely after day 1, with no post-baseline efficacy data, leaving a total of 425 patients in the FAS (n=210 and n=215, respectively). A total of 186 (87.7%) patients receiving compound (1) + ADT and 193 (88.5%) patients receiving placebo + ADT completed treatment; 180 (84.9%) and 177 (81.2%) patients completed the study, respectively.
[1330] Among participants dosed with Compound (1) or placebo, 80.9% (348 / 430) completed ADT overall; 80.3% (175 / 218) with placebo+ADT and 81.6% (173 / 212) with Compound (1)+ADT completed ADT.
[1331] Table 2 shows the patient disposition for this study.
[1332] Table 2. Patient disposition
[1333]
[1334] Demographics and Baseline Characteristics
[1335] The demographic and baseline characteristics of the participants entering the study were balanced (comparable) between the treatment groups (Table 3). The majority of patients in the compound (1) + ADT group and the placebo + ADT group were female (60.8% and 64.2%, respectively), white (72.2% and 77.1%), and had a history of antidepressant use (54.2% and 55.0%). The mean age of patients receiving compound (1) + ADT and placebo + ADT was 38.6 years and 37.7 years, respectively. The median time since the first episode of patients receiving compound (1) + ADT and placebo + ADT was 4914 days and 4838 days, respectively, and both groups of p...
Claims
1. A method for treating major depressive disorder (MDD) or postpartum depression (PPD) in a subject in need thereof, comprising: (i) providing a first treatment comprising administering a combination comprising about 40 mg to about 50 mg of compound (1) or a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound, and a therapeutically effective amount of an additional antidepressant; and (ii) providing a second treatment comprising administering a therapeutically effective amount of said additional antidepressant.
2. A method for treating major depressive disorder (MDD) or postpartum depression (PPD) in a subject in need thereof, comprising: (i) providing a first treatment comprising administering a combination comprising a therapeutically effective amount of compound (1) or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an additional antidepressant; and (ii) providing a second treatment comprising administering a therapeutically effective amount of said additional antidepressant, The subjects had not received treatment.
3. The method of claim 1, wherein the subject is treatment naive.
4. The method of any one of claims 1 to 3, wherein a. The subject has not received any antidepressant treatment for at least 30 days before the start of the first treatment; b. the subject has not received treatment with the additional antidepressant within at least 30 days prior to the start of the first treatment; or c. the subject has not been receiving treatment with the additional antidepressant within at least 60 days prior to the start of the first treatment.
5. The method of any one of claims 1-4, wherein the first treatment administers the combination for about 14 days.
6. The method of any one of claims 1-5, wherein the second treatment administers the additional antidepressant for at least 28 days.
7. The method of any one of claims 1 to 6, wherein a. said additional antidepressant is administered at the same dose in said first and second treatments; or b. said additional antidepressant is administered at different doses in said first and second treatments.
8. The method of any one of claims 1-7, wherein compound (1) or a pharmaceutically acceptable salt thereof is not administered to the subject in the second treatment.
9. The method of any one of claims 1 to 8, wherein a. in said first treatment compound (1) or a pharmaceutically acceptable salt thereof and said additional antidepressant are administered in separate dosage forms; and / or b. in said first treatment, compound (1) or a pharmaceutically acceptable salt thereof and said additional antidepressant are administered at the same time; or c. In the first treatment, compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant are administered at different times.
10. The method of any one of claims 1-9, wherein the additional antidepressant administered is a. the dose in the first treatment and the second treatment is the same; or b. The dosage in the first treatment and the second treatment is different.
11. The method of any one of claims 1-10, wherein the additional antidepressant administered in the second treatment is the same as the additional antidepressant administered in the first treatment.
12. A method for treating major depressive disorder (MDD) or postpartum depression (PPD) in a subject in need thereof, comprising administering a combination comprising a therapeutically effective amount of compound (1) or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of another antidepressant, The subjects had not received treatment.
13. A method for treating major depressive disorder (MDD) or postpartum depression (PPD) in a treatment-naive subject in need thereof, comprising co-initiating administration of a combination comprising a therapeutically effective amount of compound (1) or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an additional antidepressant.
14. The method of claim 12 or 13, wherein a. The subject has not received any antidepressant treatment for at least 30 days before treatment; b. the subject has not received treatment with the additional antidepressant within at least 30 days prior to treatment; or c. The subject has not received treatment with the additional antidepressant within at least 60 days prior to treatment.
15. The method of any one of claims 12-14, wherein the combination is administered for about 14 days.
16. The method of any one of claims 12-15, wherein a. Compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant are administered in separate dosage forms; and / or b. Compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant are administered at the same time; or c. Compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant are administered at different times.
17. The method of any one of claims 12-16, wherein the treatment further comprises a second treatment comprising administering a therapeutically effective amount of an additional antidepressant; Optionally, wherein the second treatment administers the additional antidepressant for at least 28 days; Optionally, compound (1) or a pharmaceutically acceptable salt thereof is not administered to the subject in the second treatment.
18. The method of claim 17, wherein a. the additional antidepressant is administered in the second treatment at the same dose as in the combination; b. said additional antidepressant is administered in said second treatment at a different dose than that administered in said combination; Optionally, wherein the additional antidepressant administered in said second treatment is the same as the additional antidepressant administered in said combination.
19. The method of any one of claims 1-18, wherein the subject suffers from MDD; Optionally, wherein the subject suffers from MDD with elevated anxiety; Optionally, wherein the subject is experiencing a major depressive episode; Optionally, wherein the subject has elevated anxiety during most days of the major depressive episode; Optionally, wherein the subject has a HAM-D Anxiety / Somatization subscale score of at least 7 at baseline; and / or Optionally, wherein the subject has a HAM-A total score of at least 17 or at least 20 at baseline.
20. The method of any one of claims 1-18, wherein the subject suffers from PPD; Optionally, wherein the subject suffers from PPD with elevated anxiety; Optionally, wherein the subject is experiencing a major depressive episode with peripartum onset; Optionally, wherein the subject has elevated anxiety during most days of the major depressive episode with peripartum onset; Optionally, wherein the subject has a HAM-D Anxiety / Somatization subscale score of at least 7 at baseline; and / or Optionally, wherein the subject has a HAM-A total score of at least 17 or at least 20 at baseline.
21. The method of any one of claims 1-20, wherein administration of the combination reduces adverse events seen in gastrointestinal treatments; Optionally, the adverse events occurring during the gastrointestinal treatment include nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, increased appetite or dry mouth, or any combination thereof; Optionally, adverse events occurring during the gastrointestinal treatment include nausea and / or diarrhea; and / or Optionally, wherein said gastrointestinal treatment-emergent adverse event is caused by treatment with said additional antidepressant.
22. The method of any one of claims 1 to 21, wherein compound (1) or a pharmaceutically acceptable salt thereof is administered once a day.
23. The method of any one of claims 1-22, wherein compound (1) is administered.
24. The method of any one of claims 2 to 22, wherein the compound (1) administered is a. a dose of about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg or about 50 mg; b. The dose is about 50 mg; c. The dose is about 40 mg; d. A dose of about 50 mg once a day; or e. The dose is about 40 mg, once a day.
25. The method of any one of claims 1-22, wherein a pharmaceutically acceptable salt of compound (1) is administered.
26. The method of any one of claims 2 to 22, wherein the administered compound (1) is a pharmaceutically acceptable salt a. a dose equivalent to about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg or about 50 mg of the free base compound; b. a dose equivalent to about 50 mg of the free base compound; c. a dose equivalent to about 40 mg of the free base compound; d. a dose equivalent to about 50 mg of the free base compound once daily; or e. The dose is equivalent to about 40 mg of the free base compound once daily.
27. The method of any one of claims 1-26, wherein compound (1) or a pharmaceutically acceptable salt thereof is administered orally, parenterally, intradermally, intrathecally, intramuscularly, subcutaneously, vaginally, buccally, sublingually, rectally, topically, as an inhalant, intranasally or transdermally; Optionally, wherein compound (1) or a pharmaceutically acceptable salt thereof is administered orally; Optionally, compound (1) or a pharmaceutically acceptable salt thereof is administered with food; and / or Optionally, compound (1) or a pharmaceutically acceptable salt thereof is administered once a day in the evening.
28. The method of any one of claims 1-11, wherein the combination of compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant is re-administered to the subject in response to a recurrence of depression symptoms; Optionally, wherein there is an interval of at least 6 weeks between the last dose of said first treatment and the first dose of re-administration.
29. The method of any one of claims 12-18, wherein the combination of compound (1) or a pharmaceutically acceptable salt thereof and the additional antidepressant is re-administered to the subject in response to a recurrence of depression symptoms; Optionally, wherein there is an interval of at least 6 weeks between the last dose administered and the first dose re-administered.
30. The method of any one of claims 1-24 or 27-29, wherein a. Compound (1) is in a crystalline form having an XRPD pattern comprising peaks between 9.7 and 10.1 °2θ and inclusive, between 11.6 and 12.0 °2θ and inclusive, between 13.2 and 13.6 °2θ and inclusive, between 14.2 and 14.6 °2θ and inclusive, between 14.6 and 15.0 °2θ and inclusive, between 16.8 and 17.2 °2θ and inclusive, between 20.5 and 20.9 °2θ and inclusive, between 21.3 and 21.7 °2θ and inclusive, between 21.4 and 21.8 °2θ and inclusive, and between 22.4 and 22.8 °2θ and inclusive; b. Compound (1) is in a crystalline form having an XRPD pattern comprising peaks between 9.3 and 9.7 °2θ and inclusive, between 10.6 and 11.0 °2θ and inclusive, between 13.0 and 13.4 °2θ and inclusive, between 14.7 and 15.1 °2θ and inclusive, between 15.8 and 16.2 °2θ and inclusive, between 18.1 and 18.5 °2θ and inclusive, between 18.7 and 19.1 °2θ and inclusive, between 20.9 and 21.3 °2θ and inclusive, between 21.4 and 21.8 °2θ and inclusive, and between 23.3 and 23.7 °2θ and inclusive; c. Compound (1) is in crystalline form having an XRPD pattern comprising peaks between 9.7 and 10.1° 2θ, including end values, between 14.6 and 15.0° 2θ, including end values, between 16.8 and 17.2° 2θ, including end values, between 20.5 and 20.9° 2θ, including end values, and between 21.3 and 21.7° 2θ, including end values; or d. Compound (1) is in a crystalline form having an XRPD pattern comprising peaks between 9.3 and 9.7°2θ, inclusive, between 10.6 and 11.0°2θ, inclusive, between 13.0 and 13.4°2θ, inclusive, between 18.7 and 19.1°2θ, and between 21.4 and 21.8°2θ.
31. The method of any one of claims 1-30, wherein the additional antidepressant is a selective serotonin reuptake inhibitor (SSRI), a serotonin norepinephrine reuptake inhibitor (SNRI), a serotonin modulator and stimulator (SMS), a serotonin antagonist and reuptake inhibitor (SARI), a norepinephrine reuptake inhibitor (NRI), a norepinephrine dopamine reuptake inhibitor (NDRI), a tricyclic antidepressant (TCA), a tetracyclic antidepressant (TCA), or a tetracyclic antidepressant (TCA). ), monoamine oxidase inhibitors (MAOIs), atypical antipsychotics, agomelatine, esketamine, tianeptine, ketamine, alpha-methyltryptamine, ethyltryptamine, ethyltryptamine, indolozine, medixamine, oxaflophen, pitavagine, adenosine methionine, hypericum perforatum, hydroxytryptophan, tryptophan, trifluoperazine, buspirone, lithium, thyroxine, triiodothyronine, amitriptyline and chlordiazepoxide, amitriptyline and perphenazine, flupentixol and melitracen, olanzapine and fluoxetine, or tranylcypromine and trifluoperazine.
32. The method of any one of claims 1-31, wherein the additional antidepressant is a.SSRI; Optionally, wherein the SSRI is sertraline, escitalopram, citalopram, fluvoxamine, paroxetine, fluoxetine, indalpine or zestradiol; Optionally, wherein the SSRI is sertraline; Optionally, wherein the SSRI is escitalopram; Optionally, wherein the SSRI is citalopram; b.SNRI; Optionally, wherein the SNRI is duloxetine, desvenlafaxine, levomilnacipran, milnacipran, or venlafaxine; Optionally, wherein the SNRI is duloxetine; Optionally, wherein the SNRI is desvenlafaxine; c. SMS; optionally, wherein the SMS is vilazodone or vortioxetine; d. SARI; optionally, wherein the SARI is nefazodone, trazodone or etoperidone; e. NRI; optionally, wherein the NRI is reboxetine, tenisazine, viloxazine or atomoxetine; f. NDRI; optionally, wherein the NDRI is bupropion, amphetamine, methylphenidate, modafinil, amineptine or nomifensine; g. TCA; optionally, wherein the TCA is amitriptyline, amitriptyline oxy, clomipramine, desipramine, dibenzepine, dimetholine, dosluepin, doxepin, imipramine, lofepramine, melitracen, nitrazepam, nortriptyline, noxetylline, opipramol, pipofiazine, protriptyline, trimipramine, butriptyline, demetriptyline, fluocinol, oxymipramine, iprapindole, metapramine, propazepine, quinupramine, thiozepine or tolfenacin; h. TeCA; optionally, wherein the TeCA is amoxapine, maprotiline, mianserin, mirtazapine or setiline; i. MAOI; optionally, wherein the MAOI is isocarboxazid, phenelzine, tranylcypromine, phenmosin, iproclorazepam, iproniazid, mebanazine, nyalamide, octamoxin, pheniprazine, phenoxyprorazine, pivalazine, safrazine, selegiline, caroxadone, metralindole, moclobemide, pyrindole, iprelinide, bendamorph, toloxatone or difemelane; i. MAOI; optionally, wherein the MAOI is isocarboxazid, phenelzine, tranylcypromine, benmosin, iproclorazepam, iproniazid, mebanazine, nyalamide, octamoxine, pheniprazine, phenoxyprorazine, pivalazine, safrazine, selegiline, caroxadone, metralindole, moclobem j. an atypical antipsychotic; optionally, wherein the atypical antipsychotic is amisulpride, lumepirone, lurasidone, quetiapine, aripiprazole, epiriprazole, lumepirone, lurasidone, olanzapine, quetiapine or risperidone; k. agomelatine, esketamine, tianeptine, ketamine, alpha-methyltryptamine, ethyltryptamine, ethyltryptamine, indolozine, medixamine, oxafluxane, pitavagine, adenosine methionine, hypericum perforatum, hydroxytryptophan, tryptophan, trifluoperazine, buspirone, lithium, thyroxine, triiodothyronine, amitriptyline and chlordiazepoxide, amitriptyline and perphenazine, flupentixol and melitracen, olanzapine and fluoxetine, or tranylcypromine and trifluoperazine; or l.4-Chlorokynurenine (AV-101), Apimostinel (NRX-1074), L-ketamine (PCN-101, HR-071603), Dextromethadone (REL-1017), MIJ-821, Rislenemdaz (CERC-301, MK-0657), TAK-653 (NBI-1065845), OPC-64005, PDC-1421 (BLI-1005), Ludivenlafaxine, hydroxypiperidone (YL-0919), TGBA01AD (FKB01MD), vortioxetine, lisdexamfetamine dimesylate, methylenedioxymethamphetamine, (R)-amisulpride / (S)-amisulpride (85:15 ratio) (SEP-4199), gepirone, pramipexole, psilocybin, brilaroxazine, cariprazine, lumepirone, lurasidone, pimavanserin, adenosine methionine, 3β-methoxypregnenolone (MAP -4343), PH-10–vomeropherine, Aticaprant, BTRX-335140 (BTRX-140), buprenorphine / samidorphine, BTRX-246040 (LY-2940094), scopolamine (DPI-386), JNJ-39393406, botulinum toxin type A, JNJ-61393215, Seltorexant, BI-1358894, Crisd esalazine, Erteberel, JNJ-54175446, NSI-189, NV-5138, SNG-12, TS-121, WIP-DF17, tramadol, bupropion / dextromethorphan (AXS-05), carbidopa / hydroxytryptophan (EVX-101), cycloserine / lurasidone (NRX-101; Cyclurad), or deuterated dextromethorphan / quinidine (AVP-786, CTP-786); Optionally, wherein the additional antidepressant is administered according to the prescribing information of its label.
33. A method for treating major depressive disorder (MDD) or postpartum depression (PPD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with about 40 mg to about 50 mg of compound (1): wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment, The antidepressant is continued to be administered after the 14th day of treatment.
34. A method for treating major depressive disorder (MDD) or postpartum depression (PPD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound: wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment, The antidepressant is continued to be administered after the 14th day of treatment.
35. A method for treating major depressive disorder with increased anxiety (MDD) or postpartum depression with increased anxiety (PPD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with about 40 mg to about 50 mg of compound (1): wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment, The antidepressant is continued to be administered after the 14th day of treatment.
36. A method for treating major depressive disorder with increased anxiety (MDD) or postpartum depression with increased anxiety (PPD) in a subject in need thereof, comprising co-administering a therapeutically effective amount of an antidepressant with a pharmaceutically acceptable salt of compound (1) at a dose equivalent to about 40 mg to about 50 mg of the free base compound: wherein the co-administration occurs on about day 1 of the treatment to about day 14 of the treatment, The antidepressant is continued to be administered after the 14th day of treatment. E 37. The method of any one of E 33-36, wherein the subject is treatment naive.
Citation Information
Patent Citations
Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid
US11236121B2
Compositions and methods for treating CNS disorders
US20220098231A1
Formulations of 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
US20230057130A1
19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US9512165B2
A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
WO2018039378A1
